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Abstract 
 
Mutations affecting the p62 signalling adapter protein are commonly found in 
SDWLHQWVZLWKWKHVNHOHWDOGLVRUGHU3DJHW¶VGLVHDVHRIERQH3'%:HKave 
extended previous in vitro functional analyses of PDB-mutant p62 proteins 
(Cavey et al., 2006) to study the effects of several uncharacterised PDB-
associated mutations on the ubiquitin-binding properties of p62. These include 
mutations which affect regions of p62 outside of the ubiquitin-binding UBA 
domain (A381V, D335E and a mutant equivalent to a predicted product of the 
G1205C splice-site mutation which lacks amino acids 351-388), as well as a 
double mutation involving the P392L and S399P changes on the same allele. 
In accordance with previous findings, both of the non-UBA domain mutations 
$9¨-388) showed deleterious effects on ubiquitin-binding by p62 in 
pull-down assays, further emphasising the important role of non-UBA domain 
sequences in mediating ubiquitin-recognition, as well as in PDB aetiology. The 
D335E mutant retained its ubiquitin-binding function in vitro. The 
P392L/S399P double mutant showed a more severe effect on ubiquitin-
binding than either of the single P392L or S399P missense mutations alone; 
as this double mutation is associated with a particularly severe phenotype, 
our findings are supportive of the proposal that disease severity in PDB with 
p62 mutations may be directly related to the effects of the mutations on the 
ubiquitin-binding function of the p62 protein. 
 
Since the in vitro pull-down assays are semi-quantitative at best, we sought 
to investigate if a more quantitative biophysical approach, two dimensional 
Heteronuclear Single Quantum Coherence (2D-HSQC) protein NMR, might be 
applied to investigate the effects of PDB-associated mutations on protein 
(ubiquitin-binding) function. Our results showed that protein NMR was not 
optimal to quantitatively assess the effects of the mutations on the interaction 
between p62 and ubiquitin in vitro. 
 
Using confocal microscopy, co-transfection of U20S cells showed that the 
selected PDB-associated p62 mutants (A381V, P392L, G425R) co-localised 
with ubiquitin with a cellular phenotype indistinguishable from wild type, as 
each PDB mutant formed cytoplasmic bodies with an area ranging from the 
GHWHFWLRQOLPLWRIWKHPLFURVFRSHWRǋP2 or higher; in contrast the E396X 
truncating mutant did not form cytoplasmic bodies nor co-localise with 
ubiquitin. 
 xii 
In addition to interacting with ubiquitin, p62 also interacts with the LC3 (an 
autophagic marker) through its LC3 interacting region (LIR) to mediate the 
formation of autophagosomes. By co-transfecting p62 constructs with LC3 We 
found that some of the p62-positive cytoplasmic bodies were 
autophagosomes, and that the D335E mutation of p62 (which lies within the 
LIR) did not appear to affect the formation of autophagosomes.  
 
The effects of the wild type and PDB-mutant p62 proteins on NF-ǉ%signalling 
were assessed in HEK293 cells co-transfected with an NF-ǉ% luciferase 
reporter construct. A381V mutant p62 produced a level of activation of NF-ǉ%
signalling greater than wildtype and similar to that of UBA domain mutants, 
indicating that non-UBA and UBA domain mutations may exert their effects 
through a common mechanism involving dysregulated NF-ǉ% signalling. To 
further examine the function of p62 in the regulation of NF-ǉ%VLJQDOOLQJZH
went on to determine possible effects of PDB-associated mutations on p62-
CYLD (a DUB enzyme) interactions. Unexpectedly we found that CYLD 
expression appears to abrogate the formation of the p62 cytoplasmic bodies 
previously shown to be ubiquitin-positive. 
 
Finally, we went on to study the interaction of p62 (and its PDB mutants) with 
another important regulator of NF-ǉ%VLJQDOOLQJ,..Ǆ1(02:HFRQFOXGHG
that wild type and PDB-mutant p62 proteins are capable of recruiting NEMO to 
cytoplasmic bodies which may represent autophagosomes, but do not appear 
to accelerate its degradation.
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1.1 Introduction  
 
3DJHW¶VGLVHDVHRIERQHPDB) is the second most common metabolic bone 
disease in the UK after osteoporosis. The disease is asymptomatic in the 
majority of patients, however about 30% of those affected may show 
symptoms (Cooper et al., 1999), with bone pain being the most common. In 
addition, bone deformity, increased bone vascularity and other variable signs 
and complications might accompany PDB depending on the stage of the 
disease (Kanis et al., 1992).  
 
PDB has an interesting prevalence, as it is common in Europe, America, New 
Zealand and Australia, and not found or very rare in Asia, and Africa (Figure 
1.1). Intriguingly, the incidence of PDB appears to be declining in Europe over 
the last few years (Poor et al., 2006), suggesting environmental factors such 
as diet and viruses (which themselves might be in decline) might contribute to 
the disease development, although there might be other declining unknown 
factors might contribute to the decline in PDB. However, increasing evidence 
supports the important contribution of genetic factors to the disease aetiology. 
To date seven susceptibility loci have been identified (although not all 
confirmed) in PDB patients. The most common genetic mutations found in PDB 
affect the SQSTM1 gene (encodes the p62 protein), which is located on 
chromosome 5 at the PDB3 locus (Watts et al., 2004) with the P392L missense 
mutation being the most common p62 mutation (Laurin et al., 2002). 
 
At the cellular level, ongoing research shows that disruption of the osteoclast 
RANK-NF-ȒB signalling pathway contributes to the development of PDB and 
related syndromes (Layfield et al., 2007; Duran et al., 2004). For example, 
mutations in the RANK (5HFHSWRU$FWLYDWRUIRU1XFOHDU)DFWRUǉ%gene which 
encodes the receptor in this pathway have been found in several Pagetic-like 
3 
 
syndromes such as familial expansile osteolysis (FEO), expansile skeletal 
hyperphosphatasia (ESH) and early±onset familiar PDB. Also, mutations 
affecting the osteoprotegerin (OPG) protein (a decoy receptor in the pathway) 
which inhibits binding of Receptor $FWLYDWRUIRU1XFOHDU)DFWRUǉB Ligand 
(RANK-L) to RANK (Figure 1.8) have been associated with juvenile PDB.  
 
NF-ȒB signalling is regulated through complicated pathways composed of 
different proteins, and a considerable number of these proteins require 
ubiquitylation (post-translational modification with ubiquitin) at different 
stages of the pathway (Chen et al., 2005, Layfield et al., 2007). Many adaptor 
proteins in the NF-ȒB pathways contain ubiquitin-binding domains; these 
adaptors interact with other ubiquitylated signalling proteins noncovalently 
and function as scaffolds to mediate signal induced interactions between the 
two new proteins (Layfield et al., 2007) (Figure 1.8). For example, the adaptor 
proteins TAB2-TAB3 through their ubiquitin-binding regions recognize the 
Lys63-linked polyubiquitin chain assembled on TRAF6 following receptor 
activation. This step facilities phosphorylation and activation of another 
complex which includes IKKß; the latter activated complex finally causes 
phosphorylation and subsequent degradation of I-Ȓ%ZKLFKQRUPDOO\
sequesters NF-ȒB in the cytoplasm), releasing NF-ȒB to the nucleus to activate 
gene expression. 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Prevalence of PDB worldwide 
PDB is common in the USA, Canada, Australia and most of Europe 
(indicated by ticks), but is rare in Africa, India, and Asia (crosses). 
 
.  
 
 
 
 
 
 
 
 
 
 
Reproduced from Leach et al., 2004 
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The p62 protein (encoded by the SQSTM1 gene) is a further example of a 
scaffold protein which regulates a variety of NF-ȒB signalling pathways, 
including RANK-L-NF-ȒB signalling in osteoclasts (Layfield et al. 2007). In 
particular, p62 through its ubiquitin-associated (UBA) domain interacts with 
ubiquitin and is proposed to facilitate the autoubiquitylation of TRAF6 in 
response to activation of the signalling pathway. This ubiquitylation step 
ultimately leads to further activation of other signalling complexes in the 
pathway with subsequent activation of NF-ȒB (Layfield et al., 2004a) (Figure 
1.8). 
 
Interestingly, all the PDB-associated SQSTM1 mutations studied prior to this 
study commencing affected the ubiquitin-binding UBA domain of p62. 
Obviously therefore, investigating the ubiquitin-binding properties of p62 is 
important to understand the (dys) regulation of the NF-ȒB pathway in PDB. In 
2005, Cavey et al. proposed that all PDB-associated p62 mutations impair 
ubiquitin-binding in vitro, subsequently leading to a proposal that SQSTM1 
mutations predispose to PDB by a unifying mechanism which involves this loss 
of function of the p62 protein (Cavey et al., 2005; Cavey et al., 2006).  
 
These findings were the starting point of our project, as we wanted to further 
extend these studies and investigate the ubiquitin-binding properties of 
several recently discovered p62 mutations, of note several of which were 
located outside the UBA domain of p62 (Figure 1.2). Prior to this study, the 
ubiquitin-binding properties of p62 had been only studied through semi-
quantitative techniques (in vitro protein pull-down assays), and it was deemed 
desirable to investigate the interaction between p62 and ubiquitin using more 
quantitative protein interaction methods. 
In addition, several other experimental approaches have been used in recent 
years to investigate the role of p62 and the effects of its mutation on NF-ȒB 
6 
 
signalling and bone cell function. For example, the functional roles of p62 and 
effects of selected PDB-associated mutants (e.g. P392L, K378X and E396X) in 
NF-Ȓ% signalling have been investigated using luciferase reporter assays. 
These mutations were found to cause an increase in NF-ȒB activation relative 
to empty vector controls (Rea et al., 2006). 
 
Further to the functional role of p62, the subcellular localisation of wild type 
p62 and several PDB mutants was previously investigated using confocal 
microscopy (Leach et al., 2006; Biørkøy et al., 2005). Transfected wild type 
p62 was found to form vesicle-like cytoplasmic bodies in a wide variety of cell 
lines, and interestingly p62 truncating mutants, which lack the UBA domain, 
showed a distinct diffused cytoplasmic pattern which could be easily 
distinguished from wild type p62. The subcellular localisation of two other 
PDB-associated p62 missense mutants (P392L, P387L) was also investigated 
and it was concluded that these changes were associated with larger 
cytoplasmic bodies than wild type p62 (Leach et al., 2006). These 
observations can potentially be used as a diagnostic tool to study the impact 
of the PDB-associated mutations on cellular functions of p62, although further 
research is needed to draw absolute conclusions and it should be noted that 
the functional characterisation of p62 cytoplasmic bodies is incomplete.  
 
Another group showed that wild type p62 formed cytoplasmic bodies also 
contain ubiquitin when co-transfected in HeLa cells, and later it was shown 
that these cytoplasmic bodies were autophagosomes (Biørkøy et al., 2005). An 
alternative way to degrade proteins other than via the ubiquitin-proteasome 
system (UPS) is through autophagy, in which ubiquitylated proteins (through 
p62 binding) are directed for degradation in the lysosome, although the exact 
mechanism for the degradation is still unknown. In general autophagy is 
thought of as a bulk degradation mechanism during cell starvation and cellular 
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stress (Pankiv et al., 2007; Komatsu et al., 2007), although recently it has 
been shown that p62 regulates the selective degradation of proteins by 
autophagy and is selectively degraded itself as part of the process (Ichimura 
et al., 2008). Therefore it will be particularly interesting to examine the role of 
autophagy in PDB and the implications of p62 dysfunction in autophagy and 
PDB development. 
 
Interaction of p62 with other proteins in the RANK-L-NF-ȒB signalling pathway 
may be relevant to understanding the molecular mechanisms by which p62 
controls osteoclastogenesis and bone remodelling, and how PDB-associated 
mutations exert their effects. p62 interacts with several proteins downstream 
of TRAF6 upon stimulation of RANK (Xu et al., 2008). For example, p62 
interacts ZLWK1(02,..ǄDQGUHJXODWHs its ubiquitylation through TRAF6. 
NEMO is a regulatory subunit of the IKK complex (Scheidereit et al., 2006); 
this complex is activated following activation of the RANK receptor by RANK-L, 
and activation of the complex leads further to NF-ȒB activation (Layfield et al., 
2007).  
 
As noted earlier, p62 through its ubiquitylation of TRAF6 appears to positively 
regulate NF-ȒB activity; however it has also been shown that NF-ȒB is 
negatively regulated by a deubiquitylating enzyme CYLD (Kovalenco et al., 
7KURXJKLQWHUDFWLRQRI&</'ZLWK,..Ǆ&</'QHJDWLYHO\UHJXODWHVNF-
ȒB signalling by controlling deubiquitylation of TRAF6 (Jin et al., 2008). 
Interestingly, p62 facilitates this interaction between CYLD and TRAF6, 
suggesting that p62 also might negatively regulate NF-ȒB signalling. 
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Figure 1.2: Schematic representation of the domain structure of p62 
LQGLFDWLQJVLWHVRIµQHZ¶3'%PXWDWLRQVDQDO\VHGLQWKLV study 
  
The PDB mutations analysed in this study can be classified into those within 
the UBA domain (double mutation P392L/S399P) and those outside the UBA 
GRPDLQ'($9DQG¨-388). A381V is located within a linker region 
between the UBA domain and second PEST sequence; D335E is located at N-
WHUPLQDORIWKHVHFRQG3(67VHTXHQFHDQG¨-388 results in a p62 protein 
that lacks almost the entire second PEST sequence. The double mutation 
(P392L/S399P) is located within the UBA domain. p62 binds to ubiquitylated 
protein substrates through non-covalent interactions involving its UBA domain 
and to LC3 through its LIR (see 1.7.2). Numbering relates to the position 
within the 440 amino acid sequence of the human p62 protein. 
 
UBA, ubiquitin-associated domain; PEST sequence is rich in Proline (P), 
Glutamic acid (E), Serine (S), and Threonine (T); PB1 (Phox and Bem1) allows 
polymerisation of p62 with itself and other proteins containing PB1 domain; ZZ 
(zinc finger motif) mediates binding with RIP (receptor-interacting protein), 
which is necessary for NF-Ȓ%DFWLYDWLRQ75$)6±b is the TRAF6-binding 
domain. 
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1.2 Bone 
 
1.2.1 Bone structure and cell types 
Bone is a specialised tissue with multiple functions; it serves as a 
mechanical support, protects other softer organs such as the brain, and 
functions as a reservoir for minerals such as calcium. Bone marrow is 
responsible for producing red blood cells, certain white blood cells and 
blood platelets. 
 
Bone is mainly composed of an extra-cellular matrix, which comprises a 
non-mineral matrix composed of collagen and glycosaminoglycans 
(osteoid), inorganic mineral salts deposited within the matrix, and a 
variety of cell types. Bone cells include osteoprogenitor cells, resorbing 
cells (osteoclasts), bone forming cells (osteoblasts) and support cells 
(osteocytes). The components of the extra-cellular matrix and bone cells 
are discussed in more detail below (5XELQ¶VPathology 5th Ed). 
 
The osteoid is the organic part of bone tissue and is synthesised by 
osteoblasts. Osteoid is mainly composed of type I collagen embedded in a 
glycosaminoglycan gel. Osteoprogenitor cells are precursors of osteoblasts 
which give rise to osteoblasts; these are essentially derived from the 
mesenchymal lineage which can synthesize and secrete osteoid collagen 
and other organic components to bone matrix, then mineralise it by 
depositing calcium and phosphate hydroxides (hydroxyapatite)(5XELQ¶V
Pathology 5th Ed). 
Osteoblasts are active when there is need for osteoid deposition, and when 
they are inactive they can be found lying on the bone surface (bone lining 
cells). Osteocytes are mature osteoblasts that have been trapped in the 
mineralised bone (5XELQ¶VPathology 5th Ed). 
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In contrast, osteoclasts are large cells with multiple nuclei (usually 3 to 5), and 
are originated from monocyte-marcophage lineage (Layfield et al., 2007). 
Osteoclasts are highly mobile cells which have the ability to erode mineralised 
bone. At the end of the resorption process osteoclasts undergo apoptosis 
(Hughes et al., 1996). Osteoclasts are distinguished by the presence of 
extended Golgi complexes around each nucleus, and also have large number of 
mitochondria and transport vesicles and lysosomes (Mundy et al., 1999). 
Osteoclasts are characterised by a folded plasma membrane at a location 
facing bone matrix termed the ruffled border. Through this border osteoclasts 
secrete digestive enzymes and pump hydrogen ions to dissolve bone matrix; 
the area between the ruffled border of the osteoclasts and bone matrix is 
WHUPHG+RZVKLS¶VODFXQDZKLFKLVWKHFDYLW\ZKHUHERQHUHVRUSWLRQRFFXUs 
(5XELQ¶VPathology 5th Ed).  
 
1.2.2 Osteoclasts in PDB 
Osteoclasts in PDB are characterised by increased numbers of nuclei (up to 
100), are larger in their size compared to normal counterparts (Reddy et al., 
1999). In addition, osteoclasts in PDB are hyperactive, being hyperresponsive 
to 1,25(OH)2D3, RANK-L and TNF-Į, and also showing increased expression of 
TAF(11)-17 (Kurihara et al., 2000) and SQSTM1 (Collet et al., 2007). 
Frequently, nuclear (and sometimes cytoplasmic) inclusions that resemble 
paramyxovirus nucleocapsids are found in Pagetic osteoclasts. 
Notably, PDB osteoblasts have similar morphology to normal osteoblasts, 
implying that the condition is principally a disease of the osteoclasts. 
Although osteoblasts cultured form Pagetic bone lesions showed increased 
expression of IL-1, IL-6 and DKK1 and alkaline phosphatase (Naot et al., 
2007), the role of osteoblasts in PDB has not been investigated extensively 
and more research is needed to draw definitive conclusions about their 
contributions (Layfield et al., 2007).  
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1.2.3 Signalling in osteoclasts 
Osteoclasts originate from haematopoietic stem cells (HSC), and through a 
series of steps they differentiate to preosteoclasts before maturing to active 
osteoclasts. Osteoclastogenesis is a complicated process which is regulated 
negatively and positively by at least 24 genes (Boyle et al., 2003). Several 
signalling pathways and transcription factors regulate each step of 
osteoclastogenesis. Each of these genes functions at different stages of 
osteoclastogenesis. For example, some genes such as PU.1 and op/CSF-1 are 
responsible for formation and or survival of the osteoclast precursor cells, 
whilst other genes such as RANK, NF-ȒB1/NF-ȒB2 rel and fos help in the 
differentiation of the precursor cells. Genes such as src, oc/Tcirg and CATK 
mediate the adherence and lytic function of mature osteoclasts (Boyle et al., 
2003).  
 
Together colony stimulating factor (CSF)-1 and RANK-L are required to induce 
expression of osteoclast specific genes, such as a lytic enzyme tartrate-
resistant acid phosphatase (TRAP), osteoclast specific protease cathepsin K 
(CATK), calcitonin receptor and b3-integrin. The latter proteins are secreted to 
the reVRUSWLRQSLWRIWKHRVWHRFODVWV+RZVKLS¶VODFXQDHLQZKLFKWKH
osteoclasts resorb the underlying bones (Boyle et al., 2003). Upon interaction 
of RANK-L with RANK at least five signalling pathways are activated, which are 
mediated by protein kinases, such as inhibitor of NF-ȒB kinase (IKK), c-Jun N-
terminal kinase (JNK), p38, extracellular signal-regulated kinase (ERK) and Src 
pathways (Figure 1.3). The osteoclastogenic pathways activated by RANK-L 
are also activated by other cytokines such as TNF-Į and IL-1, which both play 
important roles in osteoclast differentiation and function (Pfeilschifter et al., 
1989; Roodman et al., 2005). However, RANK-L is considered the main 
cytokine in osteoclastogenesis and other cytokines are not as central as RANK-
L in regulating osteoclastogenesis. The marginal role of these two cytokines 
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was proven by generating mice with disrupted receptors of TNF-Į and IL-1, 
which had minimal bone phenotypes compared to RANK or RANK-L knockout 
mice (Erickson et al., 1994; Roodman et al., 2005). 
 
The most important regulator of osteoclastogenesis is the regulatory axis 
known as RANK-L/RANK/OPG signalling axis. The amount of bone resorption 
depends on the balance between RANK-L and OPG; as RANK-L increases bone 
resorption increases and if OPG increases bone resorption decreases. RANK-L 
is a cytokine expressed by preosteoblastic cells and interacts with RANK on the 
surface of osteoclasts (Khosla et al., 2001). RANK-L is the key cytokine 
required for differentiation, activation and survival of osteoclastic cells (Khosla 
et al., 2001). This is evidenced by analysis of RANK-L knockout mice, which 
show severe osetpetrosis, defective tooth formation, and impaired 
osteoclastogenesis causing complete deficiency of osteoclasts (Kong et al., 
1999).  
 
OPG is a soluble decoy receptor expressed by osteoblasts which prevents 
RANK-L from interacting with RANK, thereby deactivating the RANK-L-NF-ȒB 
signalling (Figure 1.3). OPG over-expression inhibits osteoclast formation and 
causes ostepetrosis in mice. On the other hand, OPG deletion causes enhanced 
remodelling of bone and osteoporosis (Boyle et al., 2003). 
 
There are other regulators which are important in osteoclasts, such as c-fos 
and c-src. Knockout mouse models of these two genes developed 
osteopetrosis, which is believed to result from impaired osteoclast function in 
c-src knockout mice and the inability of c-fos mice to form osteoclasts 
(Roodman et al., 2005). 
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Figure 1.3: RANK signalling in osteoclasts 
RANK-L interaction with RANK triggers several signalling cascades. The most 
important cascade in osteoclast includes the RANKL/OPG/NF-ȒB proteins. NF-
ȒB causes activation of osteoclast specific genes such as TRAP, calcitonin 
receptor, CATK and other effector genes. 
 
 
 
 
 
 
 
 
 
Reproduced from Boyle et al., 2003 
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1.2.4 Role of the NF-ȒB transcription factor in osteoclasts  
NF-ȒB is a transcription factor that functions in all eukaryotic cell types and 
regulates various genes. NF-ȒB activity is activated by cytokines, bacterial and 
viral factors and various other inducers (Karin et al., 2005). Interestingly, 
defective NF-ȒB signalling is correlated with several diseases including those 
with osteolytic conditions such as PDB, arthritis and periodontitis (Xu et al., 
2008). Recent studies show that NF-ȒB activates osteoclast-specific genes, 
and in particular NF-ȒB¶V role lies within the differentiation and survival of 
osteoclasts, with defective NF-ȒB activation in osteoclasts causing excessive 
osteoclastic activity (Xu et al., 2008).  
 
The important role of NF-ȒB in osteoclasts was demonstrated by generating 
double knockout mice of NF-ȒB p50/p52 (p50 and p52 are class I NF-ȒB 
member proteins formed after processing of their larger inactive precursors 
p105 and p100 respectively); these mice had defective osteoclast 
differentiation, which caused them to develop osteopetrosis (Iotsova et al., 
1997; Xu et al., 2008). As noted earlier, NF-ȒB signalling pathways are 
specifically regulated by several cytokines, such as TNF-Į and IL1 (Xu et al., 
2008). 
 
In osteoclasts, NF-ȒB activation is regulated by the signalling axis composed of 
RANK-L, OPG and RANK (Wada et al., 2006) with important downstream 
molecules in this axis include TRAF6, aPKC, p62 and the deubiquitylating 
enzyme CYLD. Not surprisingly mouse models with gene knock out of several 
of these proteins show defective NF-ȒB signalling and various pathological 
bone phenotypes. For example, TRAF6 knockout mice exhibit ostepetrosis, 
which is due to defective NF-ȒB signalling (Wada et al., 2006).  
 
 
15 
 
1.2.5 Bone remodelling  
In adult vertebrates about 10% of bone is regenerated every year through 
a process called bone remodelling, which is a coupled process, in which 
osteoblast formation will be triggered when osteoclasts first digest old 
bone (Roodman et al., 1996). In healthy bones, bone remodelling is 
maintained at a homeostatic state (Figure 1.4) but, in PDB the rate of 
osteoclastogenesis increases focally, causing a disorganized secondary 
increase in osteoblast formation. This secondary increase in osteoblast 
activity produces denser bones, which are weaker than normal bone, and 
susceptible to fractures and mechanical deformities.  
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Figure 1.4: Bone remodelling 
 
The first cartoon image shows the skeleton in balance, in which the rate of 
bone deposition is equivalent to the rate of bone resorption. The second image 
shows the state of bone remodelling during osteoporosis, in which the rate of 
bone resorbed is more than bone deposited, resulting from increased 
osteoclastic activity or osteoclastogenesis. The third image shows the state of 
bone remodelling in PDB, in which the rate of bone deposition is equivalent to 
bone resorption however, bone remodelling increases causing increased 
osteoclastic activity and/or osteoclastogenesis at focal regions of bone, leading 
to secondary increase in osteoblast activity. 
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3DJHW¶VGLVHDVHRIERQH3'%  
PDB is a common skeletal disorder, which is characterised by focal 
abnormalities and increased bone turnover affecting one or more sites 
throught the skeleton (Ralston et al., 2008a).  
It is thought that PDB is resulting from abnormal bone remodelling, in 
which excess osteoblasts (bone-forming cells) are produced to compensate 
for increased osteoclast (bone-resorbing cells) activity, which lead to the 
formation of disordered (Pagetic) bone that is fragile and susceptible to 
fractures (Layfield et al., 2007). 
 
The disease is characterised by defomred bone formation in various parts 
of the skeleton with various frequencies, often affecting the pelvis, 
vertebral bodies, skull, femur and tibia (Kanis et al., 1992) (Figure 1.5). 
PDB is asymptomatic in the majority of patients, however about 30% of 
those affected may show features such as: bone pain; increase in bone 
vascularity; expanding lytic lesions; and bowing which leads to restriction 
in bone movement (Van Staa et al., 2002). Bone fractures often occur at 
later stages of the disease, and PDB can develop to osteosarcoma in rare 
cases (less than 1%) (Huvos et al., 1983). In addition, although it is rare, 
cardiovascular complications occasionally accompany PDB, in particular if 
the patient is suffering from high frequencies (15-35%) of bone 
deformities (Harrison, 16th Ed.). With respect to clinical investigation of 
PDB, the disease is often diagnosed through investigations for other 
diseases (since the disease is asymptomatic in majority of the cases) but it 
is known to be accompanied by increased level of serum alkaline 
phosphatase ALP (Harinck et al., 1986); in addition, radiograms can be 
used to uncover enlarged bone formation in various parts of the skeleton.  
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Figure 1.5:  Drawings of Sir -DPHV3DJHW¶VILUVWSDWLHQWSXEOLVKHG
in his original paper (1877) 
 
1) Curvature of the spine; 2) tibial thickening and bowing; 3) bowing of 
the femur and tibia in the leg; 4) increase in hat size indicative of skull 
enlargement.  
 
Source: www.surgeongeneral.gov/library/bonehealth/chapter_3.html 
 
Paget J, On a form of chronic inflammation of bones (osteitis deformans), 
Trans Med-Chir Soc, 1877, 60, 37:63. 
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PDB is more common in people over 55 years old of age, and occurs more 
frequently in males (2.5%) than females (1.6%) (Cooper et al., 1999). 
PDB is most common in Caucasian populations with a prevalence of about 
3% (PDB is found in France, Germany, and within English speaking 
countries such as USA, Australia, New Zealand, with Great Britain having 
the highest prevalence up to 1,000,000 of the population (Van Staa et al.,  
2002;  source: [www.paget.org.co.uk]). However, PDB is uncommon in 
Scandinavia, Switzerland and Asia, indicating a genetic background 
(Barker et al., 1984; Takata 2006; Joshi et al., 2006).  
 
Although there are some theories suggesting a role for viruses in PDB 
pathogenesis, the precise cause(s) of the disease is still unknown.  
As noted earlier, p62 mutations are commonly found in PDB patients and 
interestingly, all of the PDB-associated p62 mutations identified prior to 
this study directly affect the UBA domain or sequences very close to it 
(Cavey et al., 2006). Since p62 is a scaffold protein in the RANK-TRAF6-
NF-Ȓ%VLJQDOOLQJSDWKZD\LQRVWHRFODVWVLWLVOLNHO\WKDWWKH3'%PXWDWLRQV
cause altered function of p62 within this signalling axis (Cavey et al., 
2006). 
In these cases (presumably as in the sporadic cases) the increase in 
osteoclast activity is believed to result from hyper-activation or hyper-
responsiveness of the osteoclast-specific signalling pathway stimulated by 
RANK-L, which leads to activation of NF-Ȓ% (Duran et al., 2004).  
 
Clinical treatments of the disease are still relatively ineffective, and several 
treatments (including surgical) have been used to treat the disease. Drug 
treatments include bisphosphonates (such as Etidronate, Tiludronate, 
Pamidronate) or calcitonin, although these do not allow complete recovery 
from the disease, and Pamidronate was the only bisphosphonates 
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approved for treatment of PDB (Miller et al., 1999; Reid et al., 2005, 
Ralston et al., 2008a).  
Another study showed that Zoledronate (another type of bisphosphonates) 
is the most effective treatement for PDB (Hosking et al., 2007), as in 90% 
of the pateints treated with Zoledronate total ALP levels remained in the 
normal range, in addition the quality of life of the patients were also 
improved. 
Previous observations suggested treatment of asymptomatic patients with 
bisphosphonates might help in preventing further progression of PDB or 
even suppressing the disease, however a recent clinical trial showed that 
although bisphosphonates help in maintaining low levels of ALP, they are 
ineffective in preventing the disease complications or improving quality of 
life of patients who were treated with bisphosphonates irrespective of their 
symptoms (Langston et al., 2009). 
  
1.3.1 Diagnostic metabolic markers for PDB  
PDB is largely asymptomatic in the majority of patients. Although bone 
pain is regarded as the most common symptom of PDB, generally patients 
are diagnosed with PDB when they are referred for investigation for other 
possible diseases. Currently, a combination of biochemical markers and 
radiographic imaging are used to confirm the diagnosis of PDB. Focal 
disruption in the balance of bone remodelling in PDB i.e. acceleration in 
the rate bone resorption and formation and osteoblasts formation, 
increases respective bone markers in blood and urine (Fukunaga et al., 
2001).  
 
ALP is a hydrolase enzyme, which dephosphorylates several targets and it 
reaches its optimum activity at alkaline pH (Harris et al., 1990). There are 
several isoenzymes of ALP and the skeletal isoform of ALP is a glycoprotein 
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(Harris et al., 1990). ALP is used as a marker for osteoblastic activity 
(Leunge et al., 1993), as this enzyme is required for mineralization of bone 
matrix in osteoblasts (Whyte, 3rd Ed.). Since bone remodelling is coupled, 
the amount of ALP produced from osteoblasts can be used as indirect 
measurement of osteoclastic activity. 
ALP usually is elevated in active PDB, and patients with PDB should be 
refrerred to test for their ALP levels regularly to monitor disease extent 
(Schneider et al., 2002). ALP can be used as a good marker to observe the 
metabolic state of bone turnover, also to monitor the response to 
antiresorptive therapy (Shankar et al., 2006).  
 
As ALP measurements have some limitations, for example interfering 
results from hepatic ALP may affect the assessment of PDB severity, 
measurement of bone specific ALP was developed to avoid false results 
(Farley et al., 1994).  
 
1.3.2 Genetics of PDB  
Several observations suggested a genetic predisposition to PDB. For 
example, 15-40% of PDB patients have a positive family history (Morales-
Piga et al., 1995; Sofaer et al., 1983; Siris et al., 1991) and PDB relatives 
also have 7-10 times higher risks of developing PDB than control patients 
(Sofaer et al.,1983; Siris et al.,1991). Notably, relatives of PDB patients 
have severe disease phenotypes, earlier age of onset with bone deformity 
and polyostotic involvement (Daroszewska et al., 2005).  
 
A number of other observations support the genetic predisposition to PDB. 
For example, PDB prevalence varies between countries, as it is most 
common in Caucasian populations and rare in Asia and Africa, although 
there is evidence for involvement of environmental factors in PDB 
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development as well (Gardner et al., 1978; Daroszewska et al., 2005) (see 
section 1.9).  
Although SQSTM1 is the only gene identified which predisposes to classical 
PDB, recent research confirmed the importance of several susceptibility 
loci for PDB, including the PDB1 locus on chromosome 6 (Fotino et al., 
1977); the PDB2 locus on chromosome 18q21 (Hughes  et al.,1994; Cody 
et al., 1997; Haslam et al., 1998;); the PDB3 locus on chromosome 5q35 
(contains the SQSTM1 gene, see section 1.4) (Hocking et al., 2001; Laurin 
et al., 2001); the PDB4 locus on chromosome 5q31 (Laurin  et al., 2001); 
the PDB5 locus on chromosome 2q36 (Hocking et al., 2001); the PDB6 
locus on chromosome 10p13 (Hocking et al., 2001); and the PDB7 locus 
on chromosome 18q23 (Good  et al., 2002); although some of these 
candidate loci have been reported as being false positives, such as  PDB1 
(Ralston et al., 2008).Given the role of p62 in the RANK-L-NF-Ȓ% pathway, 
it will be interesting to find if the specified new genes at these loci encode 
proteins which function in this same signalling pathway. 
 
Another association of the genetic predisposition to PDB originates from 
the notion that several PDB-like syndromes are all caused by genetic 
defect. Notably, mutated genes are all located in the signalling pathway 
downstream of RANK-L (Layfield et al., 2007). PDB-like syndromes share 
several features with classical PDB such as high concentrations of serum 
ALP, but these syndromes are distinguished from classical PDB by having 
earlier age of onset, often accompanied with deafness and premature 
tooth loss rather than bone lesions (Ralston et al., 2008b). 
 
Common PDB-like syndromes include Familial expansile osteolysis (FEO), 
Expansile skeletal hyperphosphatasia (ESH) and early-onset familial PDB, 
which are all caused by different mutations in the TNFRSF11A gene, which 
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encodes the RANK receptor. All three diseases are caused by insertion 
mutations between 15-27 bp in exon 1 of TNFRSF11A gene, affecting the 
signal peptide and causing abnormal localisation of RANK in cells (Crockett 
et al., 2007; Hughes et al., 2000). Interestingly, similar to classical PDB, 
FEO, ESH and early-onset familial Paget's disease is inherited in an 
autosomal dominant manner (Ralston et al., 2008b). 
 
Juvenile Paget disease (also known as juvenile hyperphosphatasia) is 
caused by mutations affecting the TNFRSF11B gene encoding OPG. OPG is 
a protein secreted by osteoblasts and acts as decoy receptor for RANK-L 
(Simonet et al., 1997). OPG negatively regulates RANK-mediated 
signalling (Menna et al., 2000) therefore, inactivating mutations in OPG 
are believed to increase levels of free RANK-L and hence increase NF-ȒB 
activation. 
 
A further condition also associated with a PDB phenotype, inclusion body  
myopathy associated with PDB and frontotemporal dementia (IBMPFD) is 
caused by variations in VCP gene (also known as p97). VCP is a member of 
type II AAA (ATPases Associated with a variety of Activities) proteins, which 
serves as basic molecular chaperone in the UPS (Daroszewska et al., 2005; Li 
et al., 2002). VCP, like p62, is an ubiquitin-binding protein, and one of its roles 
is believed to involve to delivery of polyubiquitylated I-ȒB for degradation by 
the 26S proteasome (Dai et al., 1998). 
 
The majority of classical PDB patients carry heterozygous mutations, in 
which one of the alleles is a variant form of SQSTM1 (Helfrich et al., 
2008). Some researchers (including our own group) have proposed that 
the severity of PDB phenotype may correlate with the ability of the mutant 
form of the p62 protein to bind ubiquitin (Hocking et al., 2004; Layfield et 
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al., 2006). Further, on comparison of SQSTM1 and VCP mutations, both 
mutations appear to affect the ubiquitin-binding region of the respective 
proteins (Layfield et al., 2007), implying that disruption of ubiquitin-
binding function may play a critical role in the development of these 
diseases (Layfield et al., 2001).  
Some of the mutant genes associated with PDB-like syndromes were 
investigated as possible candidates for classical PDB and investigations 
showed that TNFRSF11A, TNFRSF11B and VCP mutations did not cause 
classical late onset PDB (Wuyts et al., 2001; Lucas et al., 2006). However, 
it was suggested that a genetic polymorphism found in TNFRSF11A and 
TNFRSF11B genes might predispose to PDB development (Daroszewska et 
al., 2005). For example, single-nucleotide polymorphism (SNP) variation at 
exon 1 of TNFRSF11B (G1181C) predisposed to both sporadic and familial 
PDB. This SNP is a common variant causing a change of lysine to 
aspargine at codon 3 of OPG; although the exact role for this variation is 
not clear, it might subtly alter OPG functions (Daroszewska et al., 2004; 
Daroszewska et al., 2005).  
 
PDB phenotypes vary in severity, and several genetic effects or a 
combination of genetic and environmental factors might account for this 
spectrum; alternatively, the spectrum of phenotypes might originate from 
genetic mutations affecting different interacting proteins in the RANK-NF-
ȒB signalling pathway (Johnson-Pais et al., 2003). For example, the 
contribution from a polymorphism of the TNFRSF11B gene, which is found 
in association with PDB, may cause moderate additional effects on PDB 
phenotypes (Daroszewska et al., 2004; Helfrich et al., 2008). 
Interestingly, these effects appear to be entirely gender specific, as it was 
associated significantly with females (Beyens et al., 2007). Although the 
exact reason for this gender difference is unclear, the difference in gender 
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prevalence might occur because of protective effects (such as estrogen 
hormones) in females (Helfrich et al., 2008).  
 
Genetic heterogeneity is a common feature of many diseases, and is a 
feature of PDB as well, as heterogeneity was found between different 
families and within the same families. For example, members (with PDB) 
of the same families carried SQSTM1 mutation, whilst other members were 
not carriers (Good et al., 2004). Offspring who inherited SQSTM1 
mutations had milder PDB phenotypes (Bolland et al., 2007), which might 
be because combinations of factors are necessary to cause the disease 
(Bolland et al., 2007). Genetic variation, or/and any environmental 
factors, or all of the above factors might account for the variation in the 
disease phenotypes between affected PDB patients (Helfrich et al., 2008). 
 
Finally, the overlap between major susceptibility loci within families affected 
with PDB suggetsts the possiblity that two seprate genetic variants might be 
necessary tRFRUVVVRPH³WKHUHVKROG´UDWHWRFDXVH3'%SKHQRW\SHV+HOIULFK
et al., 2008). For example in a large family with PDB some individuals had 
linkage to locus (PDB7) on choromsome 18q23 also had mutations is SQSTM1 
(although not all family members had SQSTM1 mutations) (Helfrich et al., 
2008). Of note, those patients with the PDB7 linkage had earlier onset of 
disease phenotype, indicating that this locus might have the necessary factors 
to cause the occurrence of PDB phenotypes at an earlier age (Good et al., 
2002).    
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1.4 SQSTM1 and PDB  
 
The SQSTM1 gene, encoding the p62 protein, is located on chromosome 5q35, 
the PDB3 locus (Laurin et al., 2004) and the disease has as high as an 80% 
penetrance for SQSTM1 mutations carriers (Morissette et al., 2006). SQSTM1 
mutations are found in PDB to a varying extent between different populations 
ranging from 5-30% in sporadic cases and 10-50% of familial PDB (Collet et 
al., 2007; Eekhoff et al., 2004; Hocking et al., 2004; Laurin et al., 2002; 
Rhodes et al., 2008). In addition to PDB, SQSTM1 has been associated with 
RWKHUGLVHDVHVVXFKDV$O]KHLPHU¶VGLVHDVH$'3DUNLQVRQ¶VGLVHDVHDQG
+XQWLQJWRQ¶VGLVHDVH.XXVLVWRet al., 2001 & 2002; Zatloukal et al., 2002; 
Nagaoka et al., 2004). p62 knockout mice have a greater susceptibility to late 
onset obesity accompanied by diabetic phenotypes such as insulin resistance 
(Rodriguez et al., 2006).  Interestingly p62 knockout mice and wild type mice 
had similar bone phenotypes, however upon challenge with osteoclastogenic 
stimuli such as the calciotropic hormone parathyroid hormone-related protein 
(PTHrP), p62 knockout mice showed different bone phenotypes to the wild type 
mice (see section 1.10.3). The p62 protein is also found to be over-expressed 
in some cancers, such as prostate (Kitamura et al., 2006) and breast cancer 
(Thompson et al., 2003) and p62 is also necessary for asthma development 
(Martin et al., 2006). 
 
The C-terminus of the p62 protein contains the UBA domain which 
harbours most of the mutations linked to PDB, and as noted earlier these 
mutations result in loss or impairment of ubiquitin-binding function and 
defective NF-ȒB signalling (Cavey et al., 2006). In addition being the most 
common PDB-associated SQSTM1 mutation (first recognized by Laurin et 
al., 2004) in French Canadian families, P392L is also the most common 
PDB-associated mutation in Great Britain, New Zealand and Australia and 
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haplotype analysis indicated that P392L is a founder mutation (Lucas et 
al., 2005) although in the French-Canadian population two founder effects 
are proposed and founder effects were not detected for other common PDB 
mutations (Helfrich et al., 2008). In total more than 20 different SQSTM1 
mutations have now been identified in PDB patients (Table 1.1). 
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No. of 
p62-PDB 
associated References 
mutation mutations 
  
1 P392L                  Laurin et al., 2002 
2 S399P                   Eekhoff et al., 2004 
3 G425E                   Falchetti et al.,2009 
4 A426V E.Corral Moro et al., 2005 
5 E396X                   Hocking et al., 2002 
6 K378X                   Rea et al., 2006 
7 P392L/S399P        Eekhoff et al., 2004 
8 ¨-388 Beyens et al., 2006 
9 A381V                  Falchetti et al., 2009 
10 D335E                  Falchetti et al., 2009 
11 P364S                   Rea et al., 2009 
12 P387L                  Johanson-pais et al., 2003 
13 G411S                  Hocking et al., 2004 
14 M404V          Eekhoff et al., 2004; Falchetti et al., 2004  
15 A390X                  Hocking et al., 2002 
16 Y383X                          Falchetti et al., 2009 
17 D423X                          Falchetti et al., 2009 
18 S397A                           Falchetti et al., 2009 
19 M404T                  Eekhoff et al., 2004 
20 A381V/P392L         Collet  et al., 2007 
21 L413F                   Collet  et al., 2007 
22 A390X/P392L        Collet  et al., 2007 
23 G425R                  Eekhoff et al., 2004; Falchetti et al., 2004;  
    Hocking et al., 2004 
24 L394X                  Good et al., 2004; Hocking et al., 2004;    
    Johanson pais et al., 2003 
 
 
 
 Table 1.1: p62-PDB associated mutations identified todate 
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1.4.1 Structure of the p62 protein 
In humans the SQSTM1 gene encodes the 440 amino acid p62 protein. 
This gene consists of eight exons which range in size from 81bp to 872bp, 
and seven introns ranging in size from 8kb to 200kb (Vadlamudi et al., 
1998). The p62 protein has several homologs with approximately 90% 
conserved amino acid sequences, such as zeta atypical protein kinase 
(aPKC-ǅ-interacting protein (ZIP) (Puls et al., 1997), the murine homologs 
A170 (Ishii et al., 1996) and signal transduction and adaptor protein 
(STAP) (Okazaki et al., 1999). 
 
The p62 protein has several domains (see Figure 1.2), with the N-terminal 
region of the protein containing a PB1 domain, through which it can 
interact with other p62 monomers producing polymers structured in a 
µEDFNWRIURQW¶PDQQHU:LOVRQet al., 2003). The C-terminal region 
contains a UBA domain between residues 387-440; through this domain 
p62 is able to bind to monoubiquitin or polyubiquitin chains (linked either 
through Lys48, -63 or -29 of ubiquitin) (Vadlamudi et al., 1998; Shin et 
al., 1998). ZZ, TRAF6-binding and two PEST domains are located between 
the N and C termini of p62, allowing p62 to interact with various other 
proteins mediating intracellular signalling. These domains are discussed in 
more detail below. 
 
1.4.1.1 The ZZ domain 
The ZZ domain is a domain that is found in diverse cellular proteins: in 
p62 the ZZ domain mediates binding with RIP, which is necessary for the 
activation of certain NF-ȒB signalling pathways (Sanz et al., 1999). 
Because of the presence of the ZZ domain, p62 has been classified as 
member of zinc finger proteins (ZZ & TAZ; zinc finger proteins are 
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composed of putative finger structure which cluster around a Zn2+ ion 
which is tetrahedrically coordinated by cysteine and histidines residues, 
stabilising the folded structure of zinc finger peptide (Ponting et al., 1996). 
1.4.1.2 TRAF6-binding domain 
This region of p62 mediates interactions with a range of proteins (including 
TRAF6) which, in general leads to the phosphorylation of IKK and the 
subsequent release of NF-ȒB to the nucleus (Sanz et al., 2000). Through 
these pathways TRAF6 is stimulated by various signals for example when 
cells are stimulated by IL-1, TRAF6 binds with IRAK protein (Geetha et al., 
2002); upon activation of the RANK receptor by RANK-L in osteoclasts, 
TRAF6 directly binds to RANK stimulating the Lys63-linked 
autoubiquitylation of TRAF6 (Layfield et al., 2004a). 
 
1.4.1.3 PEST sequences 
PEST is the abbreviation of Proline (P), Glutamic acid (E), Serine (S), and 
Threonine (T). Two regions of p62 contain sequences rich in these amino 
acids; proteins containing PEST domains are often degraded by the 
ubiquitin-dependent proteolysis pathway (Rechsteiner et al., 1996). 
                                                                                                                                    
1.4.1.4 The UBA domain 
The UBA domain is a small domain located at the C-terminus of the p62 
protein. NMR studies showed that the p62 UBA domain has a stable 
hydrophobic three helix structure (Ciani et al., 2003), through which it 
binds to ubiquitin by non-covalent hydrophobic interactions (Long et al., 
2008). The UBA domain is thought to play important roles in the functions 
of p62, including in the control of protein degradation (Chau et al., 1989; 
Thrower al., 2000), endocytosis (Galan et al., 1997; Haglund et al., 2003), 
and NF-ȒB signalling (Deng et al., 2000; Wang et al., 2001; Layfield et al., 
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2004a). Binding of the UBA domain to monoubiquitin is apparently weaker 
to that observed for polyubiquitin, and its precise functional role (in 
particular in osteoclasts) requires further investigation.  
 
 
1.4.1.4.1 Ubiquitin 
Ubiquitin is a small protein which has a pear-drop like structure (Doherty 
et al., 2002), that it is composed of 76 amino acids (Schlesinger et al., 
1975). In man ubiquitin is composed of 19 polar (CNQSTY) amino acids, 
24 hydrophobic (AILFWV) amino acids, 11 acidic (DE) amino acids, 11 
basic (KR) amino acids, in addition these amino acids include 24 charged 
amino acids (DEHKR8ELTXLWLQ¶VPROHFXODUZHLJKWLQWRWDO is ~8.5kDa 
(Schlesinger et al., 1975) and its primary sequence being highly conserved 
between species (Schlesinger et al., 1975). For example, the human 
ubiquitin sequence (Figure 1.6) only differs from yeast ubiquitin by three 
amino acids.  
 
 
(1)MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRT
DYNIQKESTLHLVLRLRGG (76) 
 
Figure 1.6: Primary sequence of human ubiquitin 
 
Ubiquitin is a highly stable protein, due to presence of stabilizing residues 
(A,C,G,M,P,S,V,T) with a half life (t1/2)>20 hours; it is not denatured by 
temperature, pH (Lenkinski et al., 1977) or proteases (Schlesinger et al., 
1975), although often ubiquitin loses its C-terminal glycine residues during 
proteolysis upon purification. The general stability of ubiquitin is attributed 
to the prevalence of extensive hydrogen bonding in its structure.  
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Ubiquitin serves as a tag for non-lysosomal degradation, by recruiting 
damaged proteins (or normal short-lived proteins destined for 
degradation) to the 26S proteasome; in this case an isopeptide bond is 
formed between glycine residue (Gly-76) at the C-terminus of ubiquitin 
and VSHFLILFİ-amino groups in lysine residues of the target protein 
(Hershko et al., 1998). Ubiquitin itself contains seven lysine residues, and 
multiple ubiquitins can be linked together through all seven of these 
lysines to form polyubiquitin chains (Haglund et al., 2005). Depending on 
the lysine residues used in these chains, the ubiquitylated proteins have 
differing fates. For example, polyubiquitin chains linked via Lys48 (or 
Lys29) generally target the protein for degradation by the 26S proteasome 
complex (Thrower et al., 2000; as is the case for I-ȒB). Polyubiquitin 
chains linked via Lys63 have important non-degradative roles in processes 
such as DNA repair, apoptosis, and activation of NF-ȒB signalling pathways 
(Chan et al., 2001) as is the case for TRAF6. Monoubiquitylation regulates 
processes such as endocytosis (Haglund et al., 2003). 
 
Ubiquitin is first activated by an ubiquitin-activating enzyme (E1), through 
the formation of a thioester bond between Gly76 of ubiquitin and a 
cysteine residue of E1, in an ATP-dependent reaction, releasing AMP and 
the E1-ubiquitin complex. The E1-ubiquitin complex is then recognised by 
another group of enzymes called ubiquitin conjugating enzymes (E2s) 
replacing E1 by E2, through the formation of another thioester bond with a 
cysteine residue of E2, producing a new complex E2-ubiquitin. The last 
step in the ubiquitylation cascade is mediated by E3 (ubiquitin ligase) 
enzymes which can bind to both of the substrate and the E2-ubiquitin 
complex, producing a bridge between the two, hence recruiting ubiquitin 
for its conjugation to the substrate (Hershko et al., 1998; Doherty et al., 
2002). After degradation of the substrates, ubiquitin is detached from the 
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complex by Deubiquitylating enzymes (DUBs) (Figure 1.7) which also play 
important regulatory roles in other ubiquitin-mediated processes. 
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Figure 1.7: Outline of the ubiquitylation pathway 
 
Ubiquitin-activating enzyme (E1) binds to ubiquitin, then activated 
ubiquitin is transferred to an ubiquitin conjugating enzyme (E2). Finally, 
the substrate protein is transferred to the E2-ubiquitin complex by an E3 
enzyme. Substrate can either be monoubiquitylated or polyubiquitylated.  
DUBs detach ubiquitin from the complex, after degradation or to reverse 
the modification. 
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1.5 Relationship between PDB severity and ubiquitin-binding 
properties of p62 
 
The exact role of SQSTM1 mutations in PDB is still unclear, but recent research 
highlights a possible correlation between impaired protein function of p62 
mutants and PDB (Layfield et al., 2007). For example, individuals who have 
SQSTM1 mutations are on average diagnosed 10 years younger than those 
without SQSTM1 mutations (Hocking et al., 2004) and PDB patients (not 
healthy controls) are the only carriers of SQSTM1 mutations. Also, SQSTM1 
mutation effects on the ubiquitin-binding function of p62 proteins were found 
to be variable depending on the type of mutation (Cavey et al., 2005; Cavey 
et al., 2006), and the severity of PDB may be directly correlated to effects on 
ubiquitin-binding function of p62. For example, patient carriers of truncating 
mutations have more severe disease phenotype than those with missense 
mutations (Hocking et al., 2004) and interestingly these truncating mutations 
have the most severe effect on the ubiquitin-binding function of the p62 
protein (Cavey et al., 2006).  
 
 
1.6 S¶V role in RANK-L-NF-ȒB signalling  
 
p62 is an important protein in multiple signalling pathways that control 
osteoclastogenesis (Figure 1.8) (Roodman et al., 2005). For example, as noted 
earlier p62 functions as a scaffold protein that regulates NF-ȒB signalling 
downstream of the RANK receptor (Moscat et al., 2002). 
 
In RANKL-NF-ȒB signalling, RANK-L interacts with RANK and the cytoplasmic 
tail of RANK binds to TRAF6 (Galibert et al., 1998). Notably, p62 binds through 
its UBA domain to ubiquitin and mediate Lys63-linked polyubiquitylation of 
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TRAF6, and also p62 acts as a scaffold in bridging aPKC and forming a 
complex with TRAF6. Ultimately this complex leads to phosphorylation and 
degradation of I-Ȓ%E\WKHUPS; I-Ȓ%GHJUDGDWLRQLVIROORZHGE\WKHUHOHDVHRI
NF-ȒB transcription factor and its translocation to the nucleus, in which NF-ȒB 
induces appropriate gene expression (Layfield et al., 2007). 
 
The important role of p62 in NF-ȒB signalling and osteoclastogenesis has been 
investigated by several groups. For example, to elucidate the role of p62 in 
bone remodelling, Duran et al. conducted an investigation on p62 knockout 
mice. Although, wild type mice and p62 knockout mice had similar 
phenotypes, which implies that basal osteoclastogenesis was unaffected, 
osteoclastic stimuli uncovered different results; p62 knockout mice showed 
impaired osteoclastogenesis upon stimulation with both RANK-L in vitro and 
PTHrP in vivo indicating a requirement of p62 in induced osteoclastogenesis 
(Duran et al., 2004). 
 
The importance of p62 in NF-ȒB signalling is also illustrated by luciferase 
reporter assays, in which PDB-associated mutants were found to be associated 
with increased NF-ȒB activation and osteoclast activity in vitro (Yip et al., 
2006; Rea et al., 2006).  
 
Further, a PDB-associated p62 mutant (P392L) resulted in an increase in 
osteoclast activity in a mouse model with progressive bone loss, but without 
affecting osteoblast numbers (Kurihara et al., 2007), possibly by increasing 
RANK signalling and increased NF-ȒB activation. The exact role of p62 in 
osteoclastogenesis is still not clear but, it was suggested by earlier 
investigators that it could involve ubiquitin-dependent proteolysis (Roodman et 
al., 2005). 
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Furthermore, osteoclasts expressing a p62 UBA domain deletion mutant 
showed increased osteoclastogenesis. The osteoclasts had higher number of 
nuclei than control osteoclasts, and the osteoclasts were larger, similar to the 
phenotypes of pagetic osteoclasts. This observation leads to a hypothesis that 
p62 may normally serve to negatively regulate osteoclastogenesis, and that 
UBA domain is an important factor in this negative regulation (Yip et al., 2006; 
Rea et al., 2006).  
p62 also regulates NF-ȒB pathways through its interaction with other equally 
important regulators of the pathway, such as NF-ȒB Essential Modulator 
(NEMO) and the DUB enzyme CYLD (see sections 1.6.1 and 1.6.2). 
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      Figure 1.8: The RANK-L-NF-ȒB signalling pathway 
Upon interaction of RANK-L with RANK, TRAF6 directly interacts with RANK 
and undergoes autoubiquitylation by its intrinsic ubiquitin ligase activity. 
Also, TRAF6 interacts with SQSTM1 (p62) through its TF6-b, and it is 
believed that p62 facilitates the K63-linked polyubiquitylation of TRAF6. 
p62 recruits aPKC to the signalling complex, and polyubiquitylation of 
TRAF6 leads to activation of TAK1, which in turn leads to phosphorylation 
and activation of the IKK complex (IKKĮ,..ǃ,..Ǆ; the activated IKK 
complex ultimately leads to phosphorylation of I-ȒB and its degradation by 
the 26S proteasome, followed by the release of NF-ȒB to the nucleus.   
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1.6.1 ,..Ǆ1(02 
 
1.6.1.1 Characteristics of IK.Ǆ   
,..ǄVRPHWLPHVknown as NEMO (NF-ȒB essential modulator), is a 48kDa 
protein, composed of 419 amino acids and located on chromosome Xq28 
(Jin et al., 7KH,..ǄSURWHLQLVDFLGLFS,DQG unusually rich 
LQJOXWDPLFDFLGDQGJOXWDPLQHHDFK,..ǄLVFRPSRVHGRIDWZR
coiled-coil regions (CC1 and CC2), a leucine zipper, a zing finger C-
terminal structure and a CC1 region N-terminal, which interacts with the 
C-terminal tails of IKK kinase (Rushi et al., 2008; Ghosh et al., 2002; 
Leonardi et al., 2000). 
 
,..ǄLVWKHUHJXODWRU\VXEXQLWRI,..FRPSOH[ZKLFKLVFRPSRVHGRIWZR
other catalytic subunits IKKĮ anG,..ǃ6FKHLGHUHLWet al,..Ǆ
interacts with IKKĮ DQG,..ǃWKURXJKDVKRUWVHTXHQFHDWWKHH[WUHPH&-
terminal of these two subunits (May et al., 2000). IKKǄLQWHUDFWVPDLQO\
ZLWK,..ǃWKrough the N-WHUPLQDORI,..ǄPrajapati et al., 2002), but I..Ǆ
has a weaker interaction with IKKĮ(Yamaoka et al., 1999).  
 
,..ǄSKRVSKRU\ODWLRQLVPHGLDWHGE\,..ǃPrajapati et al., 2002). 
Interestingly, p62 is involved in phosphorylation of the IKK complex and 
SUREDEO\IDYRXUVWKHSKRVSKRU\ODWLRQRI,..ǃWKURXJh interaction with the 
aPKCs (Lallena et al., 1999). Previously, it was shown that ,..ǄELQGVWR
Lys63-linked polyubiquitin chains, but not Lys48-linked polyubiquitin 
chains (Wu et al., 2006) cRQVLVWHQWZLWKWKHQRWLRQWKDW,..ǄXELTXLW\ODWLRQ
is not for its degradation (Zhou et al., 2004). Interestingly, recent studies 
showed that NEMO also binds selectively to linear polyubiquitin chains and 
this interaction is required for NF-ȒB activation; studies showed that the 
UBAN (ubiquitin binding in ABIN and NEMO) motif of NEMO binds stronger 
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to linear diubiquitin chains than both Lys63 and Lys48 linked polyubiquitin 
chains (Rahighi et al., 2009). 
 
1.6.15ROHRI,..ǄLQ5$1.-L-NF-ȒB signalling   
,..ǄLVUHTXLUHGIRUWKHDFWLYDWLRQRIWKH,..FRPSOH[LQWKHFDQRQLFDO1)-
ǉ%VLJQalling pathway (Bonizzi et al., 2004). IKK activation leads to 
phoshphorylation of I-ȒB and its degradation by the proteasome, thereby 
releasing NF-ȒB from the cytoplasm to the nucleus (Zhang et al., 2005). 
Activation of IKK is mediated by formation of a complex between TRAF6, 
p62 and aPKC, the formation of this complex is stimulated by IL-1, RANK-L 
and other signals (Zhang et al., 2005). 
 
p62 interacts with TRAF6 and regulates Lys63-linked polyubiquitylation  of 
TRAF6 (Wooten et al., 2005) and TRAF6 in turn acts as an ubiquitin ligase 
E3 by attaching Lys63-linked polyubiquitin chains to IKK; this 
ubiquitylation is important for IKK activation (Ruefli-Brasse et al, 2003; 
Ruland et al, 2003; Sun et al, 2004; Zhou et al, 2004). Specifically, p62 
LQGXFHV75$)WRXELTXLW\ODWH,..ǄDVZLWKRXW75$)SZDVXQDEOHWR
XELTXLW\ODWH,..Ǆ0DUWLQet al., 2006).     
  
1.6.2 CYLD 
 
1.6.2.1 Characteristics of CYLD  
CYLD is a deubiquitylating enzyme (one of ~70 or so in man) which 
deubiquitylates Lys63-linked polyubiquitylated substrates, but not Lys48-
linked targets. CYLD deubiquitylates several proteins associated with NF-
ȒB signalling, such as NEMO, TRAF6 and TRAF2 (Kovalenco et al., 2003). 
CYLD also functions as a tumour suppresor gene (Courtois et al., 2008). At 
the sequence level CYLD is an approximately 120 kDa protein, composed 
41 
 
of 956 amino acids and its gene is located on chromosome 16q12±13 
(Courtois et al., 2008). 
CYLD was first discovered in a genetic analysis of a rare cancer, 
cylindromatosis (turban tumour syndrome); the tumours of this disease 
are benign and called cylndromas, occurring mostly in the scalp or other 
skin appendages (Bignell et al., 2000). In addition to its tumour 
suppression activity, CYLD has diverse roles in other cellular activities, 
such as apoptosis, cell proliferation (Jono et al., 2004), and is involved in 
immunity, infection and tumorigenesis (Courtois et al., 2008). 
 
CYLD functions in a cell type specific manner, for example it is inactive in 
macrophages but, on the other hand CYLD negatively regulates 
lymphocytes and preosteoclasts (Jin et al., 2008). 
 
1.6.2.2 Role of CYLD in RANK-L-NF-ȒB signalling   
In addition to the positive role of p62 in NF-ȒB signalling, p62 also has a 
negative role in regulating signalling; although this regulation is poorly 
understood it is likely to involve interaction of p62 with the negative 
regulators of NF-ȒB activity (Jin et al., 2008). 
 
Recently, it has been shown that p62 mediates the interaction between 
CYLD and TRAF6 (this interaction requires the C-terminal of p62). Notably, 
the interaction between p62 and TRAF6 is unaffected by expression levels 
of CYLD. CYLD mediates deubiquitylation of Lys63-linked polyubiquitin 
chains from TRAF6, thereby deactivating NF-ȒB signalling (Trompouki et 
al., 2003). On the other hand CYLD itself seems also to be induced by NF-
ȒB (Jono et al., 2004). CYLD was defined as the first DUB enzyme that has 
a negative role in osteoclastogenesis (Jin et al., 2008). This negative 
regulation is believed to be through its interactions with TRAF6 and TRAF2 
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and ,..Ǆ(Kovalenco et al., 2003). When CYLD interacts with NEMO 
(Kovalenco et al., 2003), NEMO facilitates the phosphorylation of CYLD but 
the exact reason for this phosphorylation is not obvious (Courtois et al., 
2008). Interestingly, as CYLD prefers Lys63-linked polyubiquitylated 
substrates, in addition to TRAF6 it is also able to dHXELTXLW\ODWH,..Ǆ
(Kovalenco et al., 2003; Sebban-Benin et al., 2007).  
 
Using mouse models, in vitro studies showed CYLD specifically acts as a 
negative regulator for osteoclast development through suppression of 
RANK signalling. The expression of CYLD is induced specifically by RANK-L 
although, the mechanism is still unknown (Jin et al., 2008). Further, CYLD 
knockout mice had increased activation of osteoclastogenesis and had 
large and multinucleated osteoclasts, although osteoblast activities were 
not affected considerably (Jin et al., 2008). 
 
 
1.7 Emerging functions of p62  
 
The role of p62 in autophagy will be described. Although there is no direct 
evidence for the role of autophagy in PDB development, emerging 
research point to the direction of an important role of p62 and autophagy 
in PDB pathogenesis. 
 
1.7.1 General overview of autophagy 
Autophagy is a process by which a FHOO¶VORQJOLYHGSURWHLQs and organelles 
are degraded in the lysosomes. Autophagy was first recognised by 
Christian de Duve in 1963, when he was observing cytoplasmic structures 
using electron microscopy (Cecconi et al., 2008).  
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Defective autophagy has many complications. For example, impairment of 
autophagy is linked to cancer development (Gozuacik et al., 2004), 
neurodegenerative diseases, cardiomyopathies and several other diseases 
(Cuervo et al., 2004). In addition, autophagy is involved in tissue 
remodelling, cellular differentiation and removal of bacterial infections 
(Biørkøy et al., 2005).    
 
Generally, autophagy is thought to be a non-selective degradation process, 
but recent studies highlight the possible selective degradation of individual 
proteins through autophagy in an ubiquitin-dependent manner, including 
selective degradation of organelles by autophagy such as pexophagy (Bellu 
et al., 2001) and mitophagy (Lemasters et al., 2005), which represent 
selective degradation of peroxisomes and mitochondria, respectively. More 
evidence of selective degradation is emerging, for example the IKK 
complex is selectively degraded by autophagy (Li et al., 2006), and most 
recently p62-associated ubiquitylated protein aggregates were shown to 
be selectively degraded by autophagy (Ichimura et al., 2008).  
 
During inhibition of the UPS, autophagy serves as an alternative 
mechanism to degrade ubiquitylated proteins and aggregates.This 
coordination between the UPS and autophagy requires further research to 
understand these molecular processes completely (Ding et al., 2007). 
 
Autophagy occurs in all eukaryotes (Komatsu et al., 2007) and it has two 
basic physiological roles. Firstly, autophagy functions as basic survival 
process in eukaryotes, as it supplies amino acids by degrading cell 
constituents; this process is defined as adaptive autophagy. In contrast, 
basal or constitutive autophagy is a process which is activated irrespective 
of cells nutritional conditions, as basal autophagy is responsible for the 
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degradation of long lived proteins (Iwata et al., 2006), damaged and non-
functional organelles (Elmore et al., 2001) and toxic aggregated proteins 
(Komatsu et al., 2007). 
 
In addition, autophagy serves as a substitute to apoptosis when cell death 
through apoptosis is dysfunctional (Levine al., 2005); as a result 
autophagy was classified as type II cell death (Levine al., 2005). Despite 
the ongoing extensive research in autophagy, the paradoxical function of 
autophagy in cell survival and cell death is not clearly understood. 
 
Autophagy can be classified into three basic types based on the way 
cytoplasmic materials are shuttled to the lysosomes: macroautophagy, 
microautophagy and chaperone-mediated autophagy (Pankiv et al., 2007). 
Macroautophagy (commonly denoted as autophagy) is a multi-step 
process, which is initiated by the formation of a separation membrane 
around the materials which need to be degraded, sequestering the 
materials inside a structure called phagophore or isolation membrane 
(Kroemer et al., 2005); this structure is a flat organelle like Golgi cisterna 
(Mizushima et al., 2007) (Figure1.9). The phagophore then elongates to 
enclose the cytoplasmic materials completely, forming autophagosomes. 
Autophagosomes fuse with endosomes to produce amphisomes; this step 
is followed by further fusion step with the lysosome, in which the 
structures will be called autolysosomes. These autophagic structures are 
classified based on their function not their morphology, and are difficult to 
recognise under electron microscopy (Mizushima et al., 2007). 
 
The second type of autophagy is microautophagy, which is characterised 
by sequestration of cytoplasmic materials by lysosomal membrane 
directly. 
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The third type of autophagy, chaperone mediated autophagy (CMA), as the 
name implies requires specific set of molecular chaperones, which 
recognise peptide sequences in the proteins which needed to be degraded. 
In this process a complex will form between the unwanted proteins and 
the molecular chaperones, the complex is then imported to the lysosomes 
(Kroemer et al., 2005).  
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Figure 1.9: Autophagy 
 
Macroautophagy is a multi step process which starts with the enclosure of the 
cytoplasmic materials by phagophore (isolating membrane) and a cisterna. 
The next step is the formation of autophagosomes, in which the cyotplasmic 
materials will be sequestered. Autophagosomes are double membrane 
structures and p62 is required for their formation. The final step of autophagy 
is characterised by fusion of the autophagosomes with endosomes and/or 
lysosomes, thereby forming autolysosomes (also known as 
autophagolysosomes), in which the inner membrane together with the luminal 
content of the autophagosomes will be degraded by the active lysosomal 
enzymes in the acidic environment of the autolysosomes. 
 
Microautophagy is similar to macroautophagy, as microautophagy starts with 
sequestration of cytoplasmic materials, but the lysosomal membrane itself 
engulf the cytoplasmic materials to be degraded. CMA is characterised by 
cytosolic chaperones which interact with soluble cytosolic proteins, forming a 
complex that will be engulfed to the lysosomal lumen through interaction of 
the complex with a receptor on the membrane of lysosomes. 
 
 
 
 
 
 
Reproduced from Kroemer et al., 2005 
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Each step in autophagy is controlled by specific autophagy-related genes. 
To date 27 autophagy genes (Atg) have been identified (Ding et al., 
2007). One of the important genes in autophagy is Atg8-
phosphatidylethanolamine (PE), which mediates the formation of 
autophagosomes. LC3 (light chain3) is the best characterised mammalian 
Atg8 homologue, and LC3 is used commonly as an autophagic marker 
(Mizushima et al., 2004). 
 
LC3 is classified into two types, depending on its structure, LC3I and LC3-
II. LC3I is the cytoplasmic form, which is the backbone structure for 
formation of LC3-II. A series of steps convert LC3I to LC3-II: Atg4B 
cleaves pro-LC3 and exposes its C-terminal glycine residue, then LC3-II 
will form by conjugation of phosphatidylethanolamine (PE) to the exposed 
glycine residue of LC3I and the association of LC3-II to the 
autophagosomal membrane (Pankiv et al., 2007). LC3-II is PE conjugated 
and it is localised in the inner and outer membrane of autophagosomes; 
LC3-II in the inner membrane is degraded together with the materials 
inside the autophagosomes after the fusion step of the autophagosomes 
with the lysosomes (Kabeya et al., 2000).    
 
 
1.7.2 Role of p62 in autophagy 
Recent studies highlighted the important role of p62 in autophagy. LC3 
interacts with p62 through a region of p62 known as LC3 interacting region 
(LIR), which is encoded by amino acids 321-342 of human p62 (Pankiv et 
al., 2007). 
 
The role of p62 in autophagy is evident by the notion that large portion of 
cellular p62-containing ubiquitylated aggregates are degraded by 
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autophagy (Biørkøy et al., 2005). Interestingly, autophagic degradation of 
p62 is present in a wide range of cell types, such as HEK293 cells, HeLa 
cells and mouse embryonic fibroblasts (Biørkøy et al., 2005). 
 
Furthermore, other studies showed the importance of p62 in autophagy. 
p62 is required for LC3 accumulation in HeLa cells, as when HeLa cells 
were depleted of endogenous p62 and starved of amino acids, LC3 did not 
accumulate in HeLa cells. Further, LC3 did not accumulate in cells 
expressing mutant forms of p62 (Biørkøy et al., 2005). 
 
To test the role of p62 in autophagy in a more physiological environment, 
autophagy deficient mice models were generated. When hepatocytes of mice 
were depleted of two important genes in autophagy (Atg7 and Atg5), p62 
accumulated in hepatocytes of the autophagy-deficient livers; in addition p62 
accumulated in the neurons of autophagy deficient neurons. p62 accumulation 
formed inclusion bodies which co-localised with ubiquitin (Komatsu et al., 
2007). These results are indicative that p62-ubiquitin positive inclusion bodies 
are degraded by autophagy. 
 
In addition, in contrast to single Atg7 knockout mice, ubiquitin-positive 
inclusion bodies were absent in hepatocytes of a double knockout mice 
(Atg7 and p62), showing the importance of p62 in the formation of the 
ubiquitin inclusion bodies (Komatsu et al., 2007). 
 
Recent studies suggest that p62 is regulated by autophagy in osteoclasts 
and more research is ongoing to establish the regulation mechanism 
(Helfrich et al., 2008). Preliminary results showed that Autophagy-Linked 
FYVE-domain containing protein (ALFY) co-localised with p62 in osteoclasts 
(unpublished data by Hocking et al). Interestingly, inhibition of autophagy 
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leads to accumulation of aggregates containing p62, ubiquitylated proteins 
and ALFY (Filimonenko, et al., 2007), consistent with the inclusion bodies 
in the hepatocytes and neurons of autophagy-deficient mice. 
 
 
1.8 Role of viral factors in PDB pathogenesis  
 
Some thirty years ago a viral aetiology was proposed for PDB, as inclusion 
bodies similar in structure, morphology, and size to nucleocapsid of 
paramyxovirus were observed in pagetic osteoclasts (Mills et al., 1976; 
Harvey et al., 1982). These inclusion bodies were commonly located in the 
nucleus and occasionally in the cytoplasm of osteoclasts, without any 
appearance in any other types of bone cells (Helfrich et al., 2000). 
Nevertheless, detection of viruses in PDB gave contradicting results 
(Ralston et al., 2007), and since the first proposal of viral aetiology in PDB 
extensive research is ongoing to determine the viral contribution to PDB 
pathogenesis. 
  
In support of the role of viruses in PDB, several groups attempted to test 
the viral hypothesis using common detection techniques. As a result, 
measles virus nucleocapsid (MVNP) sequence was detected in pagetic 
osteoclasts using reverse transcriptase PCR (RT-PCR) (Reddy et al., 
1999a; Friedrichs et al., 2002). Another study showed that expression of 
the MVNP gene in normal OCL precursors stimulated OCL formation and 
induced the formation of OCLs with pagetic phenotypes (Kurihara et al., 
2000). 
 
50 
 
In addition, transgenic mouse models were made by targeting MVNP to the 
osteoclast lineage. The mice developed pagetic phenotypes and sometimes 
pagetic lesions (Kurihara et al., 2006).  
Another virus, Canine distemper virus (CDV) has also been linked with 
PDB. In support of this notion, studies in Spain and Italy suggest that 
there is higher risk of PDB development in rural areas, which might be 
because of zoonotic origins (Gennari et al., 2006; Lopez-Abente et al., 
2003) and dog owners were reported to have a higher prevalence of PDB 
(O'Driscoll et al., 1985). Osteoclasts infected with CDV showed high 
expression levels of p62 and ubiquitin (Selby et al., 2006), implying that 
the virus might disturb RANK±NF-ȒB signalling (Layfield et al., 2007).  
 
Previous techniques to robustly detect viral transcripts in pagetic 
osteoclasts may not have been sensitive enough to be conclusive and the 
role of virus in PDB is still subject to conflicting views. In an attempt to 
resolve this issue, a comparison study between several groups in UK was 
conducted by Ralston et al. in 2007, which found a 1000-fold difference in 
the sensitivity of RT-PCR for detection of measles virus, emphasising the 
unreliability of the techniques used. Several experimental variables were 
suggested to explain the variability of the results.  One of these 
explanations was lab contamination, as one of the groups has been 
working with this virus for a long time and all of the transcripts were from 
the same strain without detection of other common measles virus strains. 
However, Ralston et al. argued that the difference arising between the 
laboratories cannot simply be explained by sensitivity of the techniques or 
experimental errors; therefore, research is still ongoing to clarify the role 
of viruses in PDB (Ralston et al., 2007). 
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Despite the notion that viruses might have a role in PDB development, 
several pieces of evidence oppose the viral aetiology of PDB, and these 
can be summarised as follows: 
- Using more sensitive assays such as in situ hybridization (ISH), one  
group showed that samples of peripheral blood from PDB patients were 
positive for measles virus (Reddy et al., 1999a), whilst other groups failed 
to detect the same virus using ISH-RT-PCR or ISH in bone samples 
(Helfrich et al., 2000)  
- The prevalence of these viruses is fairly equal worldwide and they infect 
humans at a young age, which does not explain the geographic differences 
in PDB prevalence (Cooper et al., 2006). 
- The inclusion bodies are not exclusive for PDB, for example similar 
inclusions are found in FEO (Wallace et al., 1989). 
- The characteristics of osteoclasts in PDB accompanied by IBMPFD have 
high similarity with classical PDB; and it should be noted that this type of 
syndrome results from mutations in VCP rather than SQSTM1 and without  
contribution of virological factors (Hübbers, et al., 2007; Watts et al., 
2007; Bersano et al., 2007; Helfrich et al., 2008) 
 - Some viruses can highjack microtubule routes used by autophagy 
machinery to deliver aggregates for degradation, by mimicking the normal 
functions of dynein (Helfrich et al., 2008; Wileman et al., 2007) 
- Importantly, these structures µYLUDO¶LQFOXVLRQVmight be simply 
aggregates of proteins which have not been degraded by normal cellular 
degradation mechanisms, such as the proteasome system and autophagy 
(Ralston et al., 2008).   
- Some patients showed viral antigens without detection of inclusion 
bodies (Mills et al., 1988). 
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- The location of these inclusions in the nucleus is also intriguing, since 
usually virus replication and transcription occur in the cytoplasm rather 
than in the nucleus (Helfrich et al., 2000). 
- No intact virus has yet been fully isolated from Pagetic osteoclasts. 
- Finally, the most recent research (Ralston et al., 2007; Matthews et al., 
2008) showed no evidence of paramyxovirus protein or nucleic acids in 
Pagetic bone samples or peripheral blood using a wide range of 
techniques, including nested RT/PCR, immunohistochemistry, and ISH. 
 
 
1.9 Role of environmental factors in PDB pathogenesis 
 
In the last 30 years, strong evidence for a decline in PDB was noted in 
some countries such as Great Britain, New Zealand and Spain. In support 
of this decline, offspring who inherit the SQSTM1 mutation have less 
extensive phenotypes than their parents, being diagnosed at later age and 
with reduced penetrance (Bolland et al., 2007).   
 
Interestingly, PDB decline is so rapid that it negates the possibility of 
genetic dilution (Cundy et al., 2006); therefore it is proposed that 
environmental factors are causing this decline (Van Staa et al., 2002; 
Cundy et al., 1997; Morales-Piga et al., 2002). However, the specific 
environmental factors are still unknown and several suggestions have been 
made to explain the possible causes of PDB decline including changes in 
diet, physical activity, oral bacteria, zoonotic infections and viruses (Cundy 
et al., 2006).  
 
An interesting study in Lancashire linked arsenic, which was used in the 
cotton mill industry, to PDB development. Lancashire historically had a 
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high rate of PDB in Britain (Lever et al., 2002) and in vitro studies showed 
osteoblasts treated with arsenic had high levels of p62 expression and 
ubiquitylation (Aono et al., 2003).    
  
Moreover, studies in Italy and Spain showed that people living in rural 
areas were more susceptible to develop PDB, supporting the role of 
zoonotic factors, also in some studies ownership of dogs and cats are 
linked to PDB (Gennari et al., 2006; Lopez-Abente et al., 2003). 
Nevertheless, it should be noted that vaccines developed against canine 
distemper virus (~1955) and measles virus (~1970) precede the decline in 
PDB in New Zealand (Cundy et al., 2006), therefore these observations 
might indicate that vaccine introduction did not cause PDB decline. 
 
Obviously, it is difficult to prove which factor(s) might be a possible trigger 
of PDB and further research is still needed in this area.   
 
 
1.10 PDB mouse models 
 
Several PDB mouse models (involving p62 mutation) have been generated 
by different groups in recent years, in an attempt to understand the role of 
p62 in bone physiology in vivo and in vitro. The phenotypes of the models 
are discussed in detail below 
 
1.10.1 P392L knock-in mice   
P392L knockin mice were generated by targeting cells of the osteoclast 
lineage (Kurihara et al., 2007). P392L mice did not exhibit full 
development of pagetic phenotypes, which strengthens the idea that other 
factors are necessary for full PDB development. Although the mice did not 
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develop full pagetic phenotypes, they did however show progressive bone 
loss, increased number of osteoclasts, but without parallel increase in 
osteoblast activity (Kurihara et al., 2007). Osteoclast precursors from 
P392L transgenic mice had some phenotypic similarity to pagetic cells, 
such as hyper-responsivity to RANK-L, TNF-Į and increased NF-ȒB 
signalling. Nevertheless, the cells were not hyper-responsive to 1,25-
(OH)2D3, GLGQ¶WKDYHLQFUHDVHGH[SUHVVLRQRI TAF(II)-17, and did not show 
increased numbers of nuclei (Kurihara et al., 2007).  
 
1.10.2 S409X mouse model  
A truncating p62 mutant mouse model (S409X), which is a mutation that 
has not been found in humans, was generated (Rojas et al., 2007). 
In contrast to the P392L mice, S409X animals developed focal osteolytic 
lesions and other features of pagetic phenotype. This difference in the 
mice phenotypes between the two mutations might be due to the fact that 
the truncating mutations S409X inhibit normal functions of p62 more 
effectively than the missense P392L mutation. Another reason for the 
difference might lie in the cell lines which the mutations were introduced 
to, as P392L was introduced to mature osteoclasts, whilst S409X was germ 
line, more closely resembling the origin of the mutations in humans 
(Ralston et al., 2008).  
   
1.10.3 p62 knockout mice  
Although p62 knockout mice have a similar phenotype properties to wild 
type mice (Duran et al., 2004) and do not show signs of osteopetrosis, the 
animals do show impaired osteoclastogenesis upon stimulation with both 
RANK-L in vitro and PTHrP in vivo (Duran et al., 2004). p62 knockout mice 
also have greater susceptibility for late onset obesity, accompanied by 
diabetic phenotypes, such as insulin resistance (Rodriguez et al., 2006). 
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p62 knockout mice had normal liver and neurons, the mice neither 
developed nurodegeneration nor formed inclusion bodies in neurons 
(Komatsu et al., 2007). In p62 knockout mice basal osteoclastogenesis 
was unaffected, while stimulated osteoclastogenesis was defective, in 
which bone cells were challenged by PTHrP, which makes the osteoclasts 
hyper-responsive to PTHrP in vivo (Li et al., 2000). The mice induced with 
PTHrP had larger bone volume and some other phenotypic differences 
when compared to wild type mice (Duran et al., 2004). Upon stimulation 
with PTHrP, IL-6 expression was shown to be decreased in p62 knockout 
mice, although RANK-L expression was not affected by PTHrP stimulation, 
consistent with increased IL-6 expression in pagetic patients (Roodman et 
al., 1996). p62 knockout mice showed impaired autophagy, as the mice 
suppressed inclusion bodies in hepatocytes and neurons (Komatsu et al., 
2007). 
 
1.10.4 MVNP mouse models  
Two different MVNP genes [one of the sequences was from the Edmonston 
strain (E-MVNP), the second one isolated from a PDB patient (P-MVNP)] 
were targeted independently to OCL lineage of mice, using the TRACP 
promoter, which is highly expressed in OCLs and OCL precursors (Kurihara 
et al., 2006). OCL precursors from the two variants had common 
characteristics of Pagetic OCL precursors, which can be summarized as: 
increased levels of OCL formation; large OCL size; multinucleation; and 
hyper-responsivity to 1,25(OH)2D3. Noticeably, the OCLs were not hyper 
responsive to RANK-L, suggesting that other factors might contribute to 
the response of Pagetic OCLs toward RANK-L. 
 
The OCL from the P-MVNP animals also expressed high levels of IL-6, 
consistent with Pagetic bone phenotypes. The mice had increased bone 
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volume and thickened trabeculae and these phenotypes developed in older 
mice, which might indicate that slow development of PDB may result from 
virus infection. In addition, bones from the two strains had bone lesions 
similar to Pagetic bone lesions, some monostotic in their nature. The fact 
that the two strains were associated with similar phenotypes was taken to 
imply that MVNP is directly linked to PDB (Kurihara et al., 2006). 
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1.11 Aims and objectives 
 
To further test the hypothesis that all PDB-associated p62 mutations cause 
impaired or loss of ubiquitin-binding (Cavey et al., 2005; Cavey et al., 2006), 
this study investigated in detail several newly-identified p62 mutations found 
in PDB patients. Different approaches were used to examine the ubiquitin-
binding properties of the new PDB-associated mutants. The initial 
investigations were extended to examine the role of p62 in autophagy, as well 
as the functional roles of wild type p62 and PDB-associated mutant p62 in NF-
ȒB signalling. 
 
The µQHZ¶PXWDWLRQVanalysed in the study are summarised below (Figure 1.2): 
x a double missense mutation located within the UBA domain 
(P392L/S399P) (Eekhoff et al., 2004) 
x two missense mutations located outside of the UBA domain (D335E, 
A381V) 
x a predicted product of G1205C splice-site mutation, which produces a 
p62 sequence lacking amino acids 351-388 (¨351-388) (Beyens et al., 
2006); this region is also outside the UBA domain and includes the site 
of the non-UBA domain A381V mutation. 
 
Specific aims: 
1) Effects of PDB mutations on the ubiquitin-binding properties of p62: 
x to determine the effects of each of the mutations on ubiquitin-binding 
by p62 using in vitro protein pull-down assays at 37oC. To further 
examine the correlation between the ubiquitin-binding properties of 
p62 mutants and PDB disease severity, from analysis of the 
P392L/S399P double mutation (since patients with individual mutants 
58 
 
were reported to show a milder phenotype than those with the double 
mutations). 
x to assess the ubiquitin-binding function of p62 using two dimensional 
Heteronuclear Single Quantum Coherence (2D-HSQC) protein NMR, a 
biophysical method that allows quantitative measurements of the 
association constant (Ka) between two proteins to be determined. 
x to study the interaction of p62 and certain PDB mutants in a cellular 
context using confocal microscopy analysis of transfected U2OS cells. 
 
2) Role of p62 in autophagy and effects of PDB-associated mutations 
x to investigate the interaction properities of wild type p62 with LC3 (an 
autophagic marker) using confocal microscopy analysis of co-
transfected U2OS cells. 
x to determine the role of p62 in autophagosome formation; since 
autophagosome formation requires both p62 and LC3 (Biørkøy et al., 
2005; Pankiv et al., 2007) and the PDB-associated D335E mutant of 
p62 is located within the LC3-binding region of p62 (Pankiv et al., 
2007), we also investigated the effect of this missense mutation on the 
autophagosome formation using confocal microscopy. 
 
3) Functional roles of wild type p62 and PDB-associated mutants on NF-ȒB 
signalling 
x initially, to use luciferase reporter assays to assess the effect of wild 
type and mutant p62 on signalling in HEK293 cells co-transfected with 
an NF-ȒB luciferase reporter construct. 
x to determine the interaction properties of wild type p62 and PDB-
associated p62 mutations with CYLD using confocal microscopy analysis 
of co-transfected U2OS cells. 
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x to investigate of the interaction properties of wild type p62 and PDB-
associated p62 mutants with NEMO using confocal microscopy analysis 
of transfected U2OS cells. 
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2 Materials and methods  
 
2.1 DNA techniques  
 
2.1.1 Plasmids  
[Note: for vector maps see appendix] 
A starting point for this study was the provision of plasmids pGEX-4T1-WT-p62 
and pcDNA3.1-WT-p62, previously produced in the lab, which allow the 
expression of wild type sequence human p62 (440 residues) in prokaryotic and 
eukaryotic host cells, respectively. pGEX-4T1-WT-p62 encodes a GST-p62 fusion 
protein and pcDNA3.1-WT-p62 a polyHis-FLAG-p62 fusion protein. Both were 
provided as frozen (15% glycerol) stocks, stored at -80oC.  
 
- The pcDNA3.1 construct for expression of LC3 as a fusion with tdTomato 
(tdTomato-LC3), a red fluorescent protein (Biørkøy et al., 2005), was kindly 
provided by T. Johansen, University of Tromsø, Norway. 
 
- The pcDNA3.1 construct for expression of CYLD as a fusion with a HA tag, 
was kindly provided by Dr. S.C. Sun, University of Houston. 
 
- The NF-ǉ% reporter construct was provided by Dr. Thilo Hagen, Wolfson 
Digestive Diseases Centre, University of Nottingham. 
 
- The pcDNA3.1 construct for expression of ubiquitin as a fusion with a HA tag, 
was also kindly provided by Dr. Thilo Hagen. 
 
2.1.2 Plasmid DNA preparation  
[Note: for buffers and reagents see 2.7.5] 
The method is based on alkaline lysis of bacteria, followed by adsorption of DNA 
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on a silica gel membrane in the presence of high salt (www.biocompare.com). 
Bacteria were grown overnight in 10ml of LB/ampicillin (see 2.7.1) and cell 
pellets were collected by centrifugation. After removing the supernatant, the 
pellets were re-suspended using 250µl of buffer P1, then the suspension was 
transferred to a microcentrifuge tube (at this step no cell clumps should be 
visible). The suspension was lysed using 250µl of P2 with the tube being inverted 
six times, resulting in a viscous and slightly clear solution. After a maximum of 
five minutes, 350µl of neutralization buffer (N3) was added, followed by mixing 
immediately by inverting the tube 10 times until the solution become cloudy (to 
avoid localized precipitation). Following centrifugation for 10 minutes at 13,000 
RPM the supernatants were transferred to QIAprep spin columns, which were 
centrifuged for 60 seconds at 13,000 RPM. The flow through was discarded and 
the column was washed using 500µl PB buffer, followed by centrifugation for a 
further 60 seconds. The flow through was again discarded, and columns were 
washed using 750µl of buffer PE with centrifugation for 60 seconds. The flow 
through was discarded and a final 60 second centrifugation was performed to 
remove residual wash buffer. The last step to collect the DNA involved placing 
the QIAprep spin columns in clean 1.5ml microcentrifuge tubes, followed by 
addition of 50µl of nuclease-free deionised water. After 1 minute, centrifugation 
of the columns for 1 minute was carried out and the eluant which contains the 
purified plasmid DNA was collected, and stored at -20oC. 
 
2.1.3 DNA electrophoresis  
1% (agarose in TAE) gels were prepared by melting the agarose using a 
microwave for approximately two minutes. After cooling and mixing, 1µl of 
ethidium bromide (which binds DNA and emits light upon UV excitation) was 
added to the mixture, followed by pouring the gel in horizontal gel tank, with the 
insertion of an appropriate comb and leaving to set for at least 20 minutes. After 
loading the samples, the tank was filled with TAE buffer and electrophoresed at a 
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constant voltage of 150V (for approximately one hour). Bands were visualised on 
a UV Transilluminator.  
 
2.1.4 Measurement of DNA concentration  
DNA concentration was measured using a NanoDrop (ND-1000) 
spectrophotometer (NanoDrop Technologies). The spectrophotometer is blanked 
twice using 1 µl sterile deionised water, then 1 µl sample is introduced directly 
without dilution to the spectrophotometer. The purity of the sample is monitored 
by observing the numerical outcome of A260/280 ratio on the spectrophotometer 
(A260/280 LQGLFDWHVSXUH'1$$260/280 LQGLFDWHVSUHVHQFHRILPSXULWLHV
such as proteins and aromatic compounds (for example, phenol), while A260/280 
LQGLFDWHVSRVVLEOH51$LPSXULWLHV 
 
2.1.5 Storage of plasmid DNA 
DNA samples prepared using the Qiagen miniprep purification kit (see 2.1.2), 
were kept at -20oC. 
 
2.1.6 DNA Sequencing  
All DNA sequencing was performed by the Biopolymer Synthesis and Analysis 
Unit (BSAU), School of Biomedical Sciences, D95, D floor, Medical School, The 
University of Nottingham. The sequencing was performed with the use of an ABI 
PRISM® 3130 Genetic Analyzer, using dye terminator chemistry (Big Dye 
version 3.1). The sequences were analysed using the ebi.ac.uk/clustalw 
alignment tool, and ChromasLite software (version 2.01) was used for 
chromatogram analysis.  
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2.2 Mammalian cell culture methods  
 
2.2.1 Cell handling 
U2OS or HEK293 cells (obtained from ATCC) were grown in DMEM growth 
medium (see 2.7.1), which contains the nutrients necessary for cell culture. The 
cells were kept humidified in 75 cm2 Corning cell culture flasks in a 5% CO2 37
oC 
incubator. The cells were split every 48hours or when they reached 
approximately 90% confluency, with regular inspection for contamination.  
 
2.2.2 Passaging cells 
When the cells reached ~90% confluency they were subcultured. Prior to 
splitting, EDTA-Trypsin enzyme (see 2.7.1) and the DMEM media were 
equilibrated to room temperature. After discarding the old DMEM media, the cells 
were washed with 5ml DPBS (see 2.7.3), followed by introducing 3ml of Trypsin 
solution for 10-15 minutes to cells in the humidified 5% CO2 37
oC  incubator, 
then the detached cells were diluted at a ratio 1:20 with DMEM growth media, 
and kept humidified in the 5% CO2 37
oC  incubator.  
 
2.2.3 Thawing cells 
Frozen cells stored in liquid nitrogen were thawed in a 37oC water bath, and 
transferred to 10ml of DMEM growth medium followed by centrifugation at 1000 
RPM for 5 minutes. The pellets were re-suspended in a fresh 5 ml of DMEM 
growth medium and grown as usual in the humidified 5% CO2 37
oC incubator.  
 
2.2.4 Cell freezing and storage  
Cells were subcultured as above (2.2.2) then centrifuged at 1000 RPM for 5 
minutes. After decanting the supernatant, the pellets were re-suspended in 1ml 
cell freezing media (see 2.7.1), which helps maintain the cells in a cryopreserved 
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state. Before storing them in liquid nitrogen, the cells were first stored at -80oC 
for one or two days.  
 
2.2.5 Counting cells with a haemocytometer  
Prior to performing this procedure, the cover slip and the counting chamber were 
cleaned carefully with ethanol and properly dried. The cells were washed with 
DPBS, then were detached from the flask using trypsin enzyme and diluted with 
DMEM to an appropriate dilution volume to avoid overloading the chambers. 
Then the cover slip was placed on the haemocytometer followed by introducing 
5µl of the suspension carefully to both chambers of the haemocytometer, the 
rest of the suspension were left to cover the whole chamber through capillary 
force. Average numbers of cells were counted using a light microscope as 
indicated below. 
The haemocytometer is divided to several squares; since each square is equal to 
a volume of 0.1mm3 (10-4cm3), and 1ml is equal to 1cm3, hence the total cell 
number per 1ml solution was determined according to the following equation: 
Cells/ml= (Average count) x 104 (chamber conversion factor) 
Total cells= (cells/ml) x (original volume of solution) 
 
2.2.6 Transient co-transfection based on non lipid based transfection 
reagent  
~60% confluent cells (U2OS) were split and left to grow on 19mm cover slips 
(VWR International) in 12 well plates. 1ml DMEM growth medium was added to 
the wells. The cells were left to grow at least for 24 hours before performing 
transient co-transfection of the exogenous plasmids. This was achieved by 
mixing 0.25µg of each of the plasmids in separate eppendorfs; then a mixture of 
50µl serum free medium (Opti-MEM; see 2.7.1) and 1.5µl transfection reagent, 
GeneJuice (Novagen; composed of non-toxic cellular protein and a small amount 
of novel polyamine), was incubated at room temperature for five minutes, 
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followed by introducing the plasmids to the latter mixture with gentle mixing and 
incubating for 20-30 minutes at room temperature. To avoid sudden pH 
changes, the final mixture was added drop wise to the U2OS cells and the cells 
were incubated in the humidified 5% CO2 37
oC incubator for ~ 48hours.  
 
 
2.3 Indirect immunofluorescence confocal microscopy  
 
Before starting the procedure, PBS buffer (see 2.7.3) was sterilised in an 
autoclave, left to equilibrate to room temperature and kept at 4oC.  
DMEM media was discarded from cells and the cover slips were washed 3X with 
PBS. The cells were fixed by incubating with 1ml of fresh cold 4% formaldehyde 
for five minutes at room temperature, and then the cells were washed with 3X 
PBS and quenched for 5 minutes with 3X 100mM glycine. Later the cells were 
washed 3X for 5 minutes with PBS, followed by permeabilising with 0.2% (v/v) 
Triton-X100 for 10 minutes at room temperature. Blocking of non-specific sites 
was performed by incubating the cells with a PBS solution containing 0.5% (w/v) 
fish skin gelatin and 0.2% (w/v) BSA (99.9% purity; Sigma-Aldrich) at room 
temperature, for 1 hour.  
After the blocking step, primary and secondary antibodies were introduced to the 
cells as follows: 
- the cells were washed 3X with PBS and the primary antibody mixture (mouse 
anti-p62 and rabbit anti-HA; see 2.7.2) were introduced to the cells with a 
dilution ratio of 1:500 in PBS and incubated for one hour at room temperature.  
- cells were washed with PBS 3X, and the secondary antibody mixture 
(AlexaFluor488 anti-mouse and AlexaFluor 568 anti-rabbit; see 2.7.2) was 
diluted in PBS (1:1000) and incubated for 1 hour at room temperature.  
- 1 ml Hoechst 33258 (1:20,000) in PBS was used to stain the nuclei for five 
minutes and cells were washed 3X with PBS; 50µl mounting media 
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(Glycerol/PBS) was applied to the cover slips, followed by sealing the cover slips 
to microscopic slides with toluene and formaldehyde free nail polish.  
- finally, slides were kept at 4oC in the dark until visualized with a Leica TCS SPII 
confocal microscope.  
 
2.3.1 Confocal microscopy  
All images were collected using a Leica TCS SPII confocal microscope, with a 63X 
objective lens, with 20 averaged sequential scanning images collected. The 
images were analysed and processed using LCS Lite software. 
 
 
2.4 NF-ǉ%reporter assays 
2.4.1 Preparation of NF-NB reporter construct   
An NF-ǉ%OXFLIHUDVHUHSRUWHUFRQVWUXFWZDVJHQHUDWHGE\'U7KLOR+DJHQ7KH
reporter gene is composed of a fusion in which an IL-8 promoter (with an NF-ǉ%
consensus sequence) is ligated in to a luciferase pGL2 vector (Promega). The 
expression of the luciferase enzyme is under control of the IL-8 promoter (which 
has the NF-ǉ%response element), therefore the amount of luciferase enzyme 
activity is proportional to the activity of the promoter in the fused gene.  
 
2.4.2 Transient co-transfection of p62 and NF-ǉ%UHSRUWHUFRQVWUXFWV
using polyamine based (non lipid based) transfection reagent  
This assay is based on transiently co-transfecting the polyHis-FLAG-p62 
constructs with the NF-ǉ%UHSRUWHULQ+(.FHOOVIROORZHGE\PHDVXULQJWKH
NF-ǉ%activity through the amount of the light detected from the luciferase 
enzyme using a luminometer; the assay was performed with the Steady Glo kit 
from Promega. 
 
Before starting the transfection procedure, HEK293 cells were grown in 12 well 
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plates, in DMEM growth media, in a humidified 5% CO2 37
oC incubator until they 
reached 70% confluency. Cells were transfected as follows: 0.3 µg of NF-ǉ%
reporter construct was mixed with 0.2 µg of wild type or mutant polyHis-FLAG-
p62 pcDNA3.1 (or empty pcDNA3 vector for the control) at room temperature, 
then a mixture of 100µl of serum free medium (Opti-MEM) and 2.1µl of 
genejuice transfection reagent (Novagen) was prepared and incubated at room 
temperature for five minutes, followed by addition of the two plasmids to the 
transfection mixture and incubating for 15 minutes at room temperature. The 
final mixture was added drop wise to the 70% confluent HEK293 cells. After 24 
hours, the cells were equilibrated to room temperature, then the old media was 
discarded and 80µl of the luciferase reagent (prepared by mixing one bottle of 
Steady Glo buffer with one bottle of Steady Glo substrate, provided with the kit) 
was added to each well, and the cells were incubated for 5 minutes at room 
temperature with rocking. Then the cells were re-suspended, and the lysates 
were added to a luminometer tube; the amount of the light emitted were 
measured quickly. Each measurement was performed in duplicate, and each 
assay was performed in triplicates, with the mean values of the results analysed 
statistically using PRISM4 software.  
 
2.5 Western blotting and immunodetection techniques 
 
2.5.1 Sodium dodecyl sulphate polyacrylamide-gel electrophoresis (SDS 
PAGE)  
A mixture of 5% (10ml) acrylamide resolving gel and 20% (10ml) acrylamide 
resolving gel, with the addition of 100µl AMPS and 10µl TEMED (added at the last 
step; since they are the catalysers of gel polymerization) was poured using 
gradient caster to generate a 5-20% gradient gel. Water-saturated butanol was 
immediately over-layed on to the gel, which was left for at least 30 minutes until 
polymerisation had taken place. The butanol was then removed using deionised 
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water. The stacking gel was poured (5ml stacking gel buffer, and 1ml of 30% 
acrylamide, with the addition of 100µl AMPS and 10µl TEMED), and a correct 
sized comb was inserted to form the loading wells. The gel was left for at least 
20 minutes to polymerize, followed by the careful removal of the comb. The gel 
was then transferred to an ATTO electrophoresis unit (GRI), in which SDS-PAGE 
running buffer is poured, and used to wash the lanes of the gel to remove any 
debris. After setting up the electrophoresis unit appropriately and loading the 
samples, gels were run at a constant current of 40mA until the bromophenol 
blue dye reached the bottom of the gel.  
 
2.5.2 Coomassie blue staining of SDS-PAGE gels  
When protein staining was required, the SDS-PAGE gel was shaken carefully for 
one hour in Coomassie blue staining solution (see 2.7.1), then to remove 
background staining the gel was de-stained by incubation overnight with de-
staining solution (see 2.7.1). 
 
2.5.3 Western blotting  
When required, proteins resolved by SDS-PAGE were transferred to nitrocellulose 
membrane (Hybond-C extra, GE Healthcare), by laying the gel on to the 
nitrocellulose membrane and layering between two western buffer-soaked filter 
papers. After elimination of the bubbles produced during the sandwiching of gel, 
the nitrocellulose membrane was directed to the positive anode of the western 
blotting unit (Fisher Scientific) then the sandwich was left over night to be 
transferred using a constant current of 40mA. The proteins on the membrane 
were reversibly visualized with Ponceau staining (see 2.5.4). 
 
2.5.4 Ponceau S staining of nitrocellulose membranes  
The proteins on the nitrocellulose membrane were visualized by shaking the 
membrane slowly in Ponceau S (see 2.7.1) solution for approximately two 
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minutes, followed by washing the membrane in deionised water, to eliminate 
background staining. For complete de-staining, the membrane washed several 
times with TBS (see 2.7.3).  
 
2.5.5 Immunodetection  
[For ubiquitin-Sepharose binding assays (anti-p62 immunodetection)]  
The nitrocellulose membrane was blocked in blocking buffer for one hour, in 
order to block non-specific binding sites. After incubation of the nitrocellulose 
membrane in the primary antibody (anti-p62), the membrane was washed at 
least four times in TBS for approximately 30 minutes to eliminate non-specific 
binding, then the membrane was incubated with the secondary antibody 
(Peroxidase-Conjugated Rabbit Anti-Guinea Pig immunoglobulins (PRAG) for one 
hour, and washed again in TBS for 4X. Immunoreactive bands were visualised 
using high performance chemiluminescence film (HyperfilmTM, GE Healthcare), 
and the film developed by an automatic developing system (Curix 60 processor, 
Agfa Gevaaert Ltd.). Before exposure to the films, the nitrocellulose membrane 
was agitated gently for one minute in Enhanced Chemiluminescence Reagent 
(Western lightning TM, PerkinElmer Life Sciences) and sealed in cling-film. The 
emitted light from the membrane was left to react with the film for one minute 
or more depending on the sensitivity of the antibodies.  
 
 
[For anti-ubiquitin immunodetection]  
Before blocking the nitrocellulose membrane it was first autoclaved; this was 
done by sandwiching the membrane between two filter papers soaked in TBS, 
then holding them between two glass plates, followed by autoclaving the plate 
for approximately one hour. This step is to increase the sensitivity of the 
ubiquitin antibodies. The rest of the method is identical to that for detecting p62, 
with the use of appropriate anti-ubiquitin primary and PSAR secondary 
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antibodies (see 2.7.2). The same protocol was applied to detect other proteins 
through out the thesis, but simply changing the antibodies as appropriate (see 
2.7.2). 
 
2.5.6 Detection of expression levels of overexpressed plasmids in cells 
using immunoblotting 
The transfected cells were introduced to 1ml gel application buffer (GAB; see 
2.7.3) and incubated for 5 minutes at room temperature. Then 50µl of the 
lysates were subjected to SDS-PAGE (see 2.5.1) and further immunodetection 
(see 2.5.5) using mouse anti-p62 diluted 1:1000 (or other antibodies depending 
on the experiment) as a primary antibody, and peroxidase-conjugated swine 
anti-mouse (PSAR) immunoglobulins diluted 1:2000 as secondary antibody (see 
2.7.2). To detect the amount of expressed HA-ubiquitin, the blot was stripped 
using 10ml stripping reagent for 15 minutes, then the same steps for 
immunodetection were repeated to detect the bound proteins with the use of 
1:1000 rabbit anti-HA antibody and 1:2000  peroxidase-conjugated swine anti-
rabbit (PSAR) immunoglobulins (see 2.7.2). 
 
 
2.6 General laboratory methods 
 
2.6.1 Preparation of chemically competent bacterial cells 
XL10-Gold E. coli bacterial cells were treated with (CaCl2) to make them 
competent for plasmid transformation. 300 ml of autoclaved LB was inoculated 
with 10ml overnight cultures of XL10-Gold cells (obtained originally from 
Stratagene) and incubated at 37oC in a shaking incubator until the OD600 of the 
culture reached 0.4-0.5 (this range is critical to obtain high quality competent 
cells), then the cells were cooled on ice for 20 minutes (it is necessary to keep all 
the solutions at 4oC and on ice during mixing steps). The culture was 
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centrifuged, using a Beckman Avanti J-25 centrifuge, at 4000 RPM for 20 
minutes at 4oC and the supernatant was discarded, while the pellets were 
suspended with cold sterile MgCl2 (0.1M). The suspension was centrifuged again 
at 4000 RPM for 20 minutes at 4oC, followed by discarding the filtrate and 
incubating the cells with cold sterile CaCl2 (0.1M) at 4
oC 
 
for 20 minutes. The 
cells were harvested by centrifugation at 4000RPM, 4oC for 20 minutes. Finally, 
the cells were stored in 400µl aliquots in a mixture of 86% cold CaCl2 and 14% 
glycerol at -80oC.  
 
2.6.2 Oligonucleotide mutagenic primer preparation 
Mutagenic primers were synthesised by the BSAU, School of Biomedical 
Sciences, D95, D Floor, Medical School, The University of Nottingham using an 
Applied Biosystems model 394 DNA Synthesizer; the preparation is based on 
solid phase synthesis methodology.  
 
2.6.3 Site-directed mutagenesis  
The procedure follows the instructions in the QuikChange® Site-Directed 
Mutagenesis Kit (Stratagene). For every mutation created a control reaction were 
carried out in which the same protocol were performed, but without the addition 
of PfuTurbo DNA polymerase to the reaction mixture. A mixture of the following 
solutions was prepared in a thin-walled PCR tube, giviQJDILQDOYROXPHRIǋO 
For full-length p62 and 341-440 constructs: 
ǋOî3IXUHDFWLRQEXIIHU 
ǋOILQDOFRQFHQWUDWLRQQJORIWKHWHPSODWHSODVPLG 
ǋOILQDOFRQFHQWUDWLRQQJORIROLJRQXFOHRWLGHIRUZDUGSULPHU 
ǋOILQDOFRQFHQWUDtion 125 ng/µl) of oligonucleotide reverse primer  
ǋO'062 
ǋOP0RIG173PL[WXUH 
33.5µl Autoclaved sterile dH2O to a final volume of 50µl  
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0.5 ǋl PfuTurbo DNA polymerase (2.5 U/ǋl)  
The mixture (without polymerase) was placed in a thermocycler and the lid 
heated until it reached 95oC, then the reaction mixture were left to cool for two 
minutes on ice, prior to introducing the DNA polymerase (quickly with gentle 
mixing). After this time the PCR mutagenesis program was continued according 
to the following cycling programme:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At the end of the last cycle, 1µl of the restriction enzyme Dpn1 was added to the 
mixture on ice, followed by incubation at 37oC for one hour, to allow the 
complete digestion of the non-mutated template. Finally, the mutated plasmid 
was transformed in to XL10-Gold bacterial cells (see 2.6.4).  
 
 
Segment Cycles 
 
Temperature Time 
 
1 
 
1 
 
95oC (initial denaturation 
step) 
 
30sec 
2 18 95oC (denaturation step) 
 
30sec 
 
55oC  (annealing step) 1min 
 
68oC (extension step) 7min 
3 cooling 
reaction 
4oC - 
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2.6.4 Transformation of Plasmid DNA to XL10-Gold® competent cells  
200µl of XL10-Gold competent cells were mixed with 5µl of the digested plasmid 
and left on ice for 30 minutes, followed by heat shocking the mixture at 42oC, for 
30 seconds and incubating on ice again for five minutes. The cells were 
inoculated into 800µl sterile LB, and incubated at 37oC in a shaking incubator for 
one hour. The culture was spun down at 5000 RPM for two minutes, and the 
pellets were re-suspended in 50 µl of LB. Suspension were plated out on agar/LB 
plates (see 2.7.1) and spread with a sterile spreader over the plate, followed by 
incubation overnight at 37oC. 
 
 2.6.5 GST-fusion protein expression   
The pGEX-4T1 plasmid allows expression of the cloned protein (in this case p62) 
fused with GST in E. coli and confers ampicillin-resistance to the host cells 
(allows the replication only of the bacteria that contain the plasmid). Cells were 
grown overnight with shaking at 37oC in 10ml of LB, with the addition of 
ampicillin (see 2.7.1) (1:1000). The next day, cells were diluted (1/50) in 
ampicillin/LB and grown for three hours at 37oC (1:1000); to induce recombinant 
gene expression IPTG (see 2.7.1) to a final concentration of 200µM was added, 
then the bacterial cells were grown for a further four hours at 37 oC. The pellets 
were collected by centrifugation and stored at -20 oC. 
 
2.6.6 Bacterial storage  
500µl of 10 ml overnight cultures were made up to 500µl with filter sterilised 
glycerol (Sigma) and stored in a cryovial tube at -80oC.  
 
2.6.7 Preparation of ubiquitin-Sepharose  
[Note: Control Sepharose was prepared in parallel without the addition of 
ubiquitin]. 
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Cyanogen bromide-activated-Sepharose 4B (Sigma) was swollen for 15 minutes 
in 0.1M HCl solution, transferred to a polyprep column (BioRad) and washed 
further in HCl. The Sepharose was then washed with 5 bed volumes of coupling 
buffer (see 2.7.4). The polyprep column was capped and the Sepharose 
incubated on a rotary mixer for 2 hours at 4oC
 
in a solution of ubiquitin (10 mg of 
purified bovine ubiquitin (Sigma) per 1 ml of Sepharose) in coupling buffer. The 
Sepharose was washed extensively with coupling buffer and then incubated in 
ethanolamine solution on a rotary mixer overnight at 4oC. The Sepharose was 
then washed alternatively (4 times with 10 bed volumes) with acetate and Tris 
buffer (see 2.7.4) and then in column storage buffer (see 2.7.4). The Sepharose 
was stored at 4oC as 50% slurry in column storage buffer. 
 
2.6.8 Measurement of protein concentration using the Bradford assay  
This assay was first described by Bradford et al., 1976. Its basic principle 
depends on the binding between Coomassie brilliant blue dye G-250 with arginyl 
and lysyl residues of proteins. 8 diluted standards (0, 5, 10, 20, 25, 30, 40 and 
50µg), which were prepared from a stock solution (1 mg/ml of BSA in H2O or a 
buffer used to prepare the protein under study) were used to generate a 
calibration curve. The final volume of each of the standards was 50µl. The 
unknown proteins were diluted to a final volume of 50µl, and the assay was 
performed by mixing 150µl of Bradford reagent (see 2.7.1) to both of the 
standards and the unknowns, followed by incubation for 2 minutes at room 
temperature. The standards and the unknowns were measured in duplicate by 
introducing the samples to a microplate spectrophotometer (SpectraMax 
340PC384) in 96 well plates (Falcon) and reading the absorbance at a 
wavelength of 630nm.  
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2.6.9 Ubiquitin-Sepharose binding assay  
50µl aliquots of glutathione-Sepharose (GE healthcare), control-Sepharose and 
ubiquitin-Sepharose beads (see 2.6.7) were washed once in 1ml TBSTr (see 
%DFWHULDOVXSHUQDWDQWVǋOGHULYHGE\VRQLFDWLQJDPOFXOWXUH
prepared as in section 2.6.5 in 1ml TBSTr, and centrifugation at 13,000 RPM in a 
microfuge) containing the wild type and mutant GST-p62 proteins were 
incubated for 30 minutes at 37oC with the three types of beads, with mixing 
every few minutes to ensure complete binding. To eliminate unbound and non-
specific binding proteins the beads were washed three times in TBSTr (1ml) and 
the bound protein were eluted using GAB, by heating at 95oC for five minutes. 
The eluted proteins were analyzed using SDS-PAGE (see 2.5.1), and the bound 
GST-p62 was detected by immunodetection (see 2.5.5) with anti-p62 antibodies 
(see 2.7.2). 
 
2.6.10 Large scale protein purification  
20 ml overnight cultures of XL10 Gold cells transformed with the GST-p62 
plasmid (residues 341-440 including the P392L change) were inoculated to 
1000ml sterile medium (Amp/LB 1:1000µl) and left to grow for three hours at 
37oC in a shaking incubator. Recombinant protein was expressed by the addition 
of 2ml IPTG (1:500) followed by incubation for 10 hours at 30oC in a shaking 
incubator, then the cells were collected in 1 litre centrifuge tubes and were 
centrifuged at 4000 RPM, 4oC, for 10 minutes. The pellets were washed in TBS 
(10ml/4oC), and the suspension were transferred to 50ml Falcon tubes and re-
centrifuged at 4000 RPM, 4oC, for 10 minutes. The pellets were stored at -80oC. 
The next day, the pellets were re-suspended in a mixture of 10ml TBS and 10µl 
of Benzonase® Nuclease (Novagen) and sonicated on ice at 6 microns for 
5x30seconds, with 30 second breaks to allow cooling of the mixture. 10µl of 
protease inhibitor (Sigma-Aldrich) was added to the mixture and the sonication 
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step was repeated as before. The mixture was centrifuged using a Beckman 
Avanti J-25 at 4oC, 17010 RPM (35000g) for 35 minutes.  
If the filtrate had visible impurities, the filtrate was transferred to a new set of 
centrifuge tubes and the centrifugation step was repeated with the same 
conditions. Then the supernatant was bound for 6 hours at 4oC on a mixing 
rotator to 0.5ml of glutathione-Sepharose beads, which has been previously 
introduced to a poly prep chromatography column (Biorad) and washed twice in 
TBS, then glutathione-Sepharose beads were washed extensively with TBS (6X) 
and 1X TCB (see 2.7.3). At this stage 20µl of the beads were kept for further 
analysis using SDS-PAGE and Coomassie blue staining to check the purification 
of the fusion proteins. 10 µl (5 units/ml) of thrombin enzyme (Sigma-Aldrich) 
was introduced to the beads in a final volume of 1ml TCB and rotated overnight 
at 10oC. The 1ml digested protein was eluted and kept on ice, then the beads 
were washed with 3x 0.5ml TCB, and the eluted washes were pooled with the 
previous 1ml eluted protein, giving a final volume of 2.5ml. Finally, 20 µl EDTA 
(1M; pH 8) was added to the proteins, in order to stabilise the proteins. Since 
Ca+2 is necessary for enzymatic activities, EDTA is added to chelate the Ca+2. The 
protein was kept at -20oC. 20µl of the cleaved proteins were subjected to SDS-
PAGE analysis for Coomassie blue staining (see 2.5.2). Protein concentration was 
calculated using the Bradford assay (see 2.6.8). Thomas Garner in the School of 
Chemistry performed protein gel filtration as a final preparation step prior to 
protein NMR analysis. 
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2.7 Buffers and reagents 
 
 
2.7.1 Reagents: 
 
IPTG solution (Melford): (200mM, filter sterilised) 
 
LB: Luria broth (25g/L) 
 
Ampicillin (Fischer): (100µg/ml, filter sterilised) 
 
Coomassie blue stain: 
50% (v/v) methanol 
20% (v/v) glacial acetic acid 
0.12% (w/v) Coomassie Brilliant Blue R-250 
 
Coomassie blue destain: 
10% (v/v) methanol 
10% (v/v) glacial acetic acid 
 
Ponceau S staining solution: 
0.1% (w/v) Ponceau S 
5% (v/v) acetic acid 
 
Bradford reagent (10X): 
0.05% (w/v) Coomassie brilliant blue G250 
50% (v/v) perchloric acid (HClO4) 
25% (v/v) Ethanol 
25% H2O 
79 
 
DMEM growth medum: 
'XOEHFFR¶V0RGLILHG(DJOHPHGLXP'0(0 
10% (v/v) FCS 
1% (v/v) penicillin/streptomycin 
 
Trypsin:  
0.5 g porcine trypsin (Sigma-Aldrich) 
0.2 g EDTA·4Na per litre of +DQNV¶%DODQFHG6DOW Solution, plus phenol red  
 
Opti-0(0*,%&2 
Reduced-VHUXPPHGLXP;OLTXLG,QYLWURJHQFRQWDLQV$*OXWD0$;-I 
medium. This includes the dipeptide L-alanyl-L-glutamine substituted on a 
molar equivalent basis for L-glutamine 
 
Cell freezing medum: 
90% (v/v) FCS 
10% (v/v) DMSO 
 
Agar/ampicillin plates:  
(1.5% agar in LB (W/v)ǋJPODPSLFLOOLQ 
 
Glutathione Sepharose beads 4B:  
purchased from GE Healthcare. 
 
 
2.7.2 Antibodies  
 
- rabbit anti-ubiquitin antibody was prepared in house in the School of 
Biomedical Sciences, University of Nottingham. 
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- mouse anti-,..ǄZDVSXUFKDVHGIURP$EFDP/UK.  
- mouse anti-p62 was purchased from BD-Biosciences/UK. 
- rabbit anti-HA was purchased from Sigma-Aldrich/UK. 
- peroxidase-conjugated swine anti-mouse (PSAR) immunoglobulins was      
purchased from DAKO/UK. 
- peroxidase-conjugated swine anti-rabbit (PSAR) immunoglobulins were 
purchased from DAKO/UK. 
- Alexaflour488 anti-mouse and AlexaFluor 568 anti-rabbit were purchased 
from Invitrogen/UK. 
- mouse anti-ǃ-actin was purchased from Abcam/UK. 
- mouse anti-FLAG was purchased from Sigma-Aldrich/UK. 
 
 
2.7.3 Buffers 
 
TAE (Tris acetic acid EDTA) buffer: 
40 mM Tris (hydroxymethyl) methylamine 
1 mM EDTA 
pH 8 with 1.14ml glacial acetic acid 
 
Blocking buffer: 
5% (w/v) Marvel milk powder in TBS 
 
TCB (Thrombin cleavage buffer): 
50mm Tris (hydroxymethyl) methylamine 
150mm Sodium Chloride 
2mm Calcium Chloride 
pH 8.3 with HCl 
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Ammonium acetate buffer: 
25 mM Ammonium acetate 
pH 7 with acetic acid 
 
TBS (Tris buffered saline):  
10mM Tris (hydroxymethyl) methylamine 
150mM NaCl 
pH7.5 with HCl 
 
TBSTr:   
0.1% (v/v) Triton X-100 in TBS 
 
GAB (Gel application buffer): 
150mM Tris (hydroxymethyl) methylamine 
8 M urea 
2.5% (w/v) SDS 
20% (v/v) glycerol 
10% (v/v) 2- ǃPHUFDSWRHWKDQRO 
3% (w/v) DTT (dithiothreitol) 
0.1% (w/v) bromophenol blue 
pH 6.8 with HCl 
 
5% acrylamide resolving gel mixture: 
5% (v/v) acrylamide 
367mM Tris (hydroxymethyl) methylamine 
0.13% (w/v) SDS 
pH 8.8 with HCl 
20% acrylamide resolving gel mixture: 
20% (v/v) acrylamide 
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367mM Tris (hydroxymethyl) methylamine 
0.13% (w/v) SDS 
10% (v/v) glycerol 
pH 8.8 with HCl 
 
Stacking gel buffer: 
0.14M Tris (hydroxymethyl) methylamine 
0.1% (w/v) SDS 
pH 6.8 with HCl 
 
SDS-PAGE running buffer: 
25mM Tris (hydroxymethyl) methylamine 
0.1% (w/v) SDS 
186mM glycine 
 
Western transfer buffer: 
25mM Tris (hydroxymethyl) methylamine 
129mM glycine 
20% (v/v) methanol 
 
PBS:  Phosphate buffered saline (Dulbecco A) Oxid, each tablet was dissolved in 
100ml d H2O, autoclaved and left to cool down. The solution has a pH of 7.3 at 
25o&(DFKWDEOHW¶VW\SLFDOIRUPXODLV 
Component                                                                       (g/L) 
NaCl                                                                                    8 
KCl                                                                                      0.2 
Na2HPO4                                                                              1.15 
KH2PO4                                                                                    0.2 
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DPBS'XOEHFFR¶V3KRVSKDWHEXIIHUHGVDOLQH6LJPDOLTXLGVWHULOH-filtered, cell 
culture tested. It has additional CaCl2.2H2O, and MgCl2.6H22WKHVROXWLRQ¶V
typical formula is: 
Component                                                                        (g/L) 
CaCl2.2H2O                                                                          0.113 
MgCl2.6H2O                                                                          0.1 
NaCl                                                                                    8 
KCl                                                                                      0.2 
Na2HPO4                                                                              1.15 
KH2PO4                                                                                    0.2 
 
2.7.4 Buffers used in preparation of ubiquitin-Sepharose beads 
 
Coupling buffer: 
100mM Sodium bicarbonate 
500mM Sodium chloride, pH 8.3 with HCl 
1M Ethanolamine, pH 8 with HCl 
 
Acetate buffer: 
100mM Sodium Acetate 
500mM NaCl 
pH 4 with acetic acid 
Tris buffer:  
100mM Tris (hydroxymethyl) methylamine 
pH8 with HCl 
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Column storage buffer: 
25 mM Tris (hydroxymethyl) methylamine 
1mM sodium azide 
pH 7.4 with HCl 
 
2.7.5 Plasmid DNA purification solutions: 
P1: re-suspension buffer (Tris-EDTA, RNAase added at the time of the 
experiment) 
P2: sodium hydroxide (should be closed immediately after use, to prevent 
reaction with CO2 in the air, which leads to pH change) 
PE: guanidine hydrochloride/isopropanol (ethanol added at the time of the 
experiment) 
N3: neutralization buffer, guanidine hydrochloride/acetic acid 
PB: wash buffer (ethanol added at the time of the experiment) 
 
2.8 List of software: 
x Igor Pro 5.0.5.7: scientific graphing, data analysis, image processing and 
programming software tool from WaveMetrics. 
x Clustlaw2: is a general purpose multiple sequence alignement 
programme for DNA from European bioinformatics institute (EBI). 
x PRISM 4: is a combination of basic biostatistical, curve fitting and 
scientific graphing software from GraphPad. 
x Leica confocal software II: is an imaing software from Leica. 
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CHAPTER 3 
 
 
Interaction of PDB mutant p62 proteins with 
ubiquitin in vitro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86 
 
Chapter 3: Interaction of PDB mutant p62 proteins with ubiquitin in 
vitro 
 
3.1 Introduction 
 
PDB has been linked to numerous mutations affecting the SQSTM1 gene, to 
date several of which have been investigated at the level of protein function. 
The majority of these mutations are located within exon 8 of the SQSTM1 gene 
and affect the UBA domain (residues 387-440) of the p62 protein.  Since this 
region of p62 mediates its ubiquitin-binding properties, the functional effects 
of a number of PDB mutations were previously analysed using in vitro 
ubiquitin-binding (pull-down) assays. In summary the mutations were 
classified into those which showed complete loss of ubiquitin-binding in these 
assays, and those which showed reduced ubiquitin-binding, under the 
µSK\VLRORJLFDO¶FRQGLWLRQVXVHGLHDWS+DQGoC (Cavey et al., 2005; 
Cavey et al., 2006). These observations led to the proposal of a unifying 
hypothesis that all PDB-associated mutations of p62 cause loss or impairment 
of ubiquitin-binding, and this altered function is related to disease aetiology 
(Cavey et al., 2006). 
 
6XEVHTXHQWWRWKHVHLQLWLDODQDO\VHVVHYHUDOµQHZ¶PXWDWLRQVKDYHEHHQ
identified in patients with PDB, including some outside of the UBA domain 
(located within exon 7 of the SQSTM1 gene). In order to further test the above 
hypothesis, and in particular to determine if non-UBA domain mutations exert 
their effects via WKHVDPHPHFKDQLVPDV8%$GRPDLQPXWDWLRQVIRXUµQHZ¶
PDB-associated PDB mutations (Figure 3.1) were selected, including three 
outside the UBA region, and initially analysed in the same in vitro ubiquitin-
binding assays.  
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&OLQLFDOIHDWXUHVDVVRFLDWHGZLWKWKHµQHZ¶3'%-associated p62 
mutations 
 
Two of the new mutations are non-UBA domain missense mutations, D335E 
and A381V, both of Italian origin that were first presented by our collaborators 
(Dr. ML Brandi and co-workers, University of Florence) at the International 
6\PSRVLXPRQ3DJHW¶V'LVHDVH-9th July 2005, Oxford UK, and subsequent to 
this work being completed published in a full paper (Falchetti et al., 2009). 
The A381V mutation was identified in an Italian patient in 2000; the patient 
was diagnosed by scintigraphy with a positive scan in the sacrum and bilateral 
iliac regions. Alkaline phosphatase (ALP) levels were already increased in 1999 
(577 I.U.) and sequencing of DNA samples showed the patient (and her son) 
harboured a heterozygous C to T transversion at position 1182 of exon 7, 
resulting in an alanine to valine substitution at codon 381. In the same 
individual exon 8 of the SQSTM1 gene was sequenced to confirm the absence 
of any other associated p62 mutations. Whilst this work was in progress, the 
A381V mutation was also described by another group but only in combination 
with the P392L mutation (Collet et al., 2007). 
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Figure 3.1: Schematic representation of the domain structure of p62 
indicating sitHVRIµQHZ¶3'%PXWDWLRQVDQDO\VHGLQWKLVVWXG\ 
 
The PDB mutations analysed in this study can be classified into those within 
the UBA domain (double mutation P392L/S399P) and those outside the UBA 
GRPDLQ'($9DQG¨-388). A381V is located within a linker region 
between the UBA domain and second PEST sequence; D335E is located at N-
WHUPLQDORIWKHVHFRQG3(67VHTXHQFHDQG¨-388 results in a p62 protein 
that lacks almost the entire second PEST sequence. The double mutation 
(P392L/S399P) is located within the UBA domain. p62 binds to ubiquitylated 
protein substrates through non-covalent interactions involving its UBA domain 
and to LC3 through its LIR. Numbering relates to the position within the 440 
amino acid sequence of the human p62 protein. 
 
UBA, ubiquitin-associated domain; PEST sequence is rich in Proline (P), 
Glutamic acid (E), Serine (S), and Threonine (T); PB1 (Phox and Bem1) allows 
polymerisation of p62 with itself and other proteins containing PB1 domain; ZZ 
(zinc finger motif) mediates binding with RIP (receptor-interacting protein), 
which is necessary for NF-Ȓ%DFWLYDWLRQ75$)±b is the TRAF6-binding domain; 
LIR is the LC3-interacting region. 
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The D335E mutation was identified in an Italian patient in 1992 with no family 
history of PDB; the patient was diagnosed by scintigraphy with a positive scan 
exhibiting a monostotic lesion in the left femur. ALP levels were 129 I.U. 
before therapy and sequencing of DNA samples showed the patient harboured 
a heterozygous transversion of T to A at position 1047 of exon 7 (Falchetti et 
al., 2004), resulting in an aspartate to glutamate substitution at codon 335. 
Again, exon 8 of the SQSTM1 gene was sequenced to confirm the absence of 
any other associated p62 mutations. 
 
The final non-UBA domain mutant analysed is equivalent to a predicted 
product of a splice donor site mutation, which lacks amino acids 351-388 of 
p62, found in American family (Beyens et al., 2006). This results from a 
G1205C intron 7 mutation that gives rise to two abnormal mRNA transcripts, 
translation of which would result in the formation of a truncated p62 protein 
lacking most of the UBA domain (390X) as well as the p62 sequence analysed 
in this VWXG\¨-388). Patients carrying this mutation were reported to 
have a severe phenotype, with a very early age of onset and high levels of 
ALP, but the disease symptoms varied from none to hearing loss and cranial 
nerve palsies due to compression of nerves (Beyens et al., 2006). 
 
,QDGGLWLRQZHDOVRDQDO\VHGDµGRXEOH¶8%$GRPDLQPXWDWLRQ3/63
which involves two changes on the same allele, identified in a PDB patient 
from a Dutch colony in Suriname (Eekhoff et al., 2004). Since previous work 
has proposed that there may be a relationship between the magnitude of the 
effects of different mutations on the ubiquitin-binding function of p62 and 
disease severity, and the carrier of the P392L/S399P double mutation had a 
more severe phenotype than individuals with the single missense mutations 
(nearly all of the skeleton was reported to be affected with pronounced 
deformities of the extremities, spine and skull), we used this double mutation 
90 
 
to further examine the correlation between the ubiquitin-binding properties of 
p62 mutants and PDB disease severity. Specifically, we wished to assess 
whether this double mutation had an additive negative effect on the ubiquitin-
binding function of p62, compared to the effects exerted by individual 
missense mutations P392L and S399P. 
 
3.3 Generation of prokaryotic expression constructs for PDB mutant 
p62 proteins 
 
Previously in the lab, a construct which allows wild type human p62 to be 
expressed as a GST-fusion protein in E. coli was generated by introducing a 
p62 cDNA into the multiple cloning site of the pGEX-4T-1 plasmid (Cavey et 
al.7KH'($9DQG¨-388 mutations were each separately 
introduced into this wild type GST-p62 sequence by site directed mutagenesis 
following the instructions of QuikChange® Site-Directed Mutagenesis kit 
(Stratagene).  The same protocol was used to generate a GST-p62 
(P392L/S399P) double mutant, by introducing the P392L change in to a GST-
p62 (S399P) construct generated in a previous study (Cavey et al., 2006); a 
separate GST-p62 (P392L) mutant, as well as a GST-p62 (G425R) mutant, 
was also available in the lab (from (Cavey et al., 2005)). Each mutant plasmid 
was analysed by DNA sequencing and resulting chromatograms were viewed 
using ChromasLite2 software (Figure 3.2). The presence of the mutations was 
confirmed by sequence alignment with the wild type p62 sequence using 
ClustalW2. 
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Figure 3.2: DNA sequencing of GST-p62 PDB mutants: D335E, A381V, P392L/S399P and 
¨-388. All the mutations were introduced to the wild type GST-p62 sequence by site directed 
mutagenesis. Arrows indicate the sites of each mutation.  
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3.4 Investigation of the relative expression levels of GST tagged wild 
type and PDB mutant p62 proteins 
 
,QRUGHUWRILUVWFRQILUPWKDWWKHµQHZ¶3'%PXWDWLRQVGLGQRWDGYHUVHO\DIIHFW
expression levels of GST-p62 in E. coli, protein expression was induced in 
bacterial cultures of equal volume (10ml) grown in parallel, and recombinant 
proteins were purified by affinity chromatography using glutathione-Sepharose 
beads. Briefly, cells were pelleted, lysed by sonication, and centrifuged, then 
samples of supernatant (equivalent to 1/200th the volume of the original 
culture) containing soluble proteins were incubated with an excess of 
glutathione-Sepharose beads with continuous mixing for 30 minutes at room 
temperature. Non-specific protein binding was removed by washing the beads 
with TBST (TBS containing Triton X-100), then with TBSA (TBS containing 
albumin). Proteins bound to glutathione-Sepharose were eluted with gel 
loading buffer and the eluted proteins were analysed by SDS PAGE and 
visualised with Coomassie staining. Analysis of the gel indicated comparable 
expression levels of GST-p62 (wild type), GST-p62 (D335E), GST-p62 
(A381V), GST-p62 (P392L/S399P) and GST-S¨-388) proteins (Figure 
3.3). Note the GST-S¨-388) protein migrated with a lower denatured 
molecular weight than the other fusion proteins, consistent with the internal 
deletion of 38 amino acids. 
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Figure 3.3: Investigation of the relative expression levels of GST 
tagged wild type and PDB mutant p62 proteins 
 
GST tagged wild type and PDB mutant p62 proteins (as indicated) were 
expressed in E. coli. GST-tagged proteins (or GST control) were purified from 
bacterial supernatants by incubation at room temperature with glutathione-
Sepharose beads. Beads were washed with TBST (TBS containing Triton X-
100), then with TBSA (TBS containing albumin). Proteins bound to 
glutathione-Sepharose were eluted with gel loading buffer and the eluted 
proteins were analysed by SDS PAGE and visualisation with Coomassie 
staining. Residual BSA is highlighted. 
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(IIHFWVRIµQHZ¶ PDB mutations on ubiquitin-binding function of 
p62 
 
7KHHIIHFWVRIWKHµQHZ¶3'%-associated mutations on the interaction of p62 
with monoubiquitin were assessed using in vitro pull-down assays (Cavey et 
al., 2005). In this assay, the GST-tagged p62 proteins are expressed in E. coli 
(10ml cultures), then bacterial supernatants (equivalent to 1/20th the volume 
of the original culture) containing the recombinant proteins are precipitated 
with an excess of three types of beads: glutathione-Sepharose; 
monoubiquitin-Sepharose; or control-Sepharose (Figure 3.4). The 
monoubiquitin-Sepharose beads have purified bovine ubiquitin (10 mg/ml) 
covalently attached, and the control-Sepharose beads are prepared in parallel 
without the addition of protein. 
 
Binding to glutathione-Sepharose (via GST) indicates the total GST-p62 
protein available, and to ubiquitin-Sepharose the fraction of GST-p62 protein 
able to bind ubiquitin via its UBA domain. Non-specific binding is controlled for 
using the control-Sepharose beads. Bound proteins are eluted with gel loading 
buffer and detected by SDS-PAGE followed by western blotting (anti-p62). 
Loss of ubiquitin-binding function associated with any of the PDB mutants is 
indicated by a reduced immunoreactivity to GST-p62 proteins precipitated by 
the ubiquitin-Sepharose, relative to wild type. 
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Figure 3.4: Schematic representation of monoubiquitin-binding assay 
for GST-p62 fusion proteins 
 
The affinity of the p62-ubiquitin interaction depends on the non-covalent 
interaction of the UBA domain of p62 for the covalently immobilised ubiquitin. 
When glutathione-Sepharose beads are used, the GST-tag binds non-
covalently with immobilised glutathione. Control-Sepharose is used to control 
for non-specific binding to the beads. Bound GST-p62 protein is detected by 
western blotting (anti-p62). 
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The assay was first performed at pH7.5 (and subsequently at pH6.5) and 
throughout the experiment, all the reagents (including beads, binding and 
washing buffers) were maintained at the required temperature (37oC or 21oC). 
The assays were independently repeated several times for each of the 
mutations. 
 
 
3.5.1 Effects of the PDB-associated A381V mutation on the ubiquitin-
binding function of p62 
 
The ubiquitin-binding properties of GST-p62 (A381V) compared to GST-p62 
(wild type) and GST-p62 (G425R) was first assessed at 37oC and pH7.5; the 
latter PDB mutation acts as a control as it has previously been shown to be 
associated with complete loss of ubiquitin-binding under these conditions 
(Cavey et al., 2005). In these experiments, the A381V mutant was initially 
found to show a comparable level of binding to ubiquitin as wild type p62, 
whereas the control mutation G425R showed loss of ubiquitin-binding (for a 
representative example see Figure 3.5). 
 
The binding assay was repeated under several experimental conditions, 
including at different temperatures and with variations in the time used to lyse 
the GST-p62-expressing E. coli  by sonication; none of these changes affected 
the binding of GST-p62 (A381V) to ubiquitin, relative to wild type GST-p62 
(not shown). However, on mild acidification of the binding buffer (pH6.5), we 
noted a small but reproducible reduction in the amount of GST-p62 (A381V) 
mutant p62 binding to ubiquitin-Sepharose, relative to the wild type sequence 
(Figure 3.5). Again, under these conditions GST-p62 (G425R) showed 
complete loss of ubiquitin-binding. 
 
 
97 
 
 
 
 
 
Figure 3.5: Effects of the PDB-associated A381V p62 mutation on 
ubiquitin-binding in vitro; at two different pHs (pH7.5, pH6.5) 
 
The mutations as indicated were introduced into the full length p62 sequence, 
and the GST-tagged proteins used in pull-down assays at 37oC. Bacterial 
lysates containing the GST-p62 fusions were precipitated with glutathione-
Sepharose (G), control-Sepharose (C) and ubiquitin-Sepharose (U) beads. 
Precipitated proteins were detected by western blotting (anti-p62 antibodies). 
Proteins in the (G) lanes are precipitated via the GST-glutathione interaction, 
and (U) lanes via the UBA-ubiquitin interaction. At pH7.5 the A381V mutant 
did not show any reproducible loss of binding compared to the wild type 
protein, whereas at lower pH (pH6.5) the A381V mutant exhibited a slightly 
reduced ubiquitin-binding ability, relative to wild type. The control G425R 
mutant showed complete loss of ubiquitin-binding at both pHs. 
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3.5.2 Effects of the PDB-DVVRFLDWHG¨-388 mutation on the 
ubiquitin-binding function of p62 
 
With the exception of the P387L missense mutation which has already been 
shown to cause a partial loss of p62 ubiquitin-binding function in vitro at 
pH7.5 (Cavey et al., 2006), the only other (non-truncating) non-UBA domain 
mutants are that equivalent to a predicted product of the G1205C splice-site 
mutation, which lacks amino acids 351±388 (Beyens et al., 2006), and a 
D335E missense mutation (see 3.2 and 3.5.3). The former retains the region 
of p62 that was previously defined as the minimum (poly)ubiquitin-binding 
sequence, namely residues 392±436 (Cavey et al., 2006) but loses A381. The 
deleted 38 amino acids also include the first two amino acids of the UBA 
domain and a large part of the second PEST domain of p62, as well as the 
flexible linker region between UBA domain and second PEST domain (the PEST 
domain being encoded by amino acids 345-377 of p62; Figure 3.1). 
 
Residues 351±388 were deleted from the GST-p62 (wild type) sequence and 
the effects of this gross change on ubiquitin-binding function were assessed. 
As for the A381V mutation, these ubiquitin-binding assays were performed at 
37oC and at two different pHs (7.5 and 6.5). In this case, it was noted that the 
mutant protein showed significantly reduced binding to ubiquitin-Sepharose at 
pH7.5 (for a representative example see Figure 3.6). In addition, the effects of 
this mutation on ubiquitin-binding function of p62 were even more pronounced 
at pH6.5 (Figure 3.6). 
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Figure 3.6: Effects of the PDB-associated ¨-388 p62 mutation on 
ubiquitin-binding in vitro; at two different pHs (pH7.5, pH6.5) 
 
The mutations as indicated were introduced into the full length p62 sequence, 
and the GST-tagged proteins used in pull-down assays at 37oC. Bacterial 
lysates containing the GST-p62 fusions were precipitated with glutathione-
Sepharose (G), control-Sepharose (C) and ubiquitin-Sepharose (U) beads. 
Precipitated proteins were detected by western blotting (anti-p62 antibodies). 
Proteins in the (G) lanes are precipitated via the GST-glutathione interaction, 
and (U) lanes via the UBA-ubiquitin interaction. At both pHs (7.5, 6.5) the 
¨-388 mutant showed reduced ubiquitin-binding compared to the wild type 
protein. The control G425R mutant also showed loss of binding at both pHs. 
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3.5.3 Effects of the PDB-associated D335E mutation on ubiquitin-
binding function of p62 
 
This mutation was found in a single PDB patient in Italy with mild phenotype 
compared to other p62 common mutations, and it is the final example (in 
adGLWLRQWR3/$9DQG¨-388) of a non-UBA domain mutation of 
p62. Notably, this mutation does however map to an unstructured region of 
p62 involved in the direct interaction with LC3 (Pankiv et al., 2007) which is 
UHTXLUHGWRPHGLDWHS¶VUROHLQthe regulation of autophagy. 
 
The ubiquitin-binding properties of GST-p62 (D335E) compared to GST-p62 
(wild type) and GST-p62 (G425R) was assessed at 37oC and at pH7.5 and 
S+,QFRQWUDVWWRWKH$9DQG¨-388 mutants, under both conditions 
the D335E mutation retained ubiquitin-binding function comparable to the wild 
type sequence (for a representative example see Figure 3.7), indicating 
potentially a different disease mechanism for this mutation. 
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Figure 3.7: Effects of the PDB-associated D335E p62 mutation on 
ubiquitin-binding in vitro; at two different pHs (pH7.5, pH6.5) 
 
The mutations as indicated were introduced into the full length p62 sequence, 
and the GST-tagged proteins used in pull-down assays at 37oC. Bacterial 
lysates containing the GST-p62 fusions were precipitated with glutathione-
Sepharose (G), control-Sepharose (C) and ubiquitin-Sepharose (U) beads. 
Precipitated proteins were detected by western blotting (anti-p62 antibodies). 
Proteins in the (G) lanes are precipitated via the GST-glutathione interaction, 
and (U) lanes via the UBA-ubiquitin interaction. At both pHs (7.5, 6.5) the 
D335E retained ubiquitin-binding similar to the wild type protein. The control 
G425R mutant showed loss of binding at both pHs. 
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3.5.4 Effects of the PDB-associated P392L/S399P mutation on the 
ubiquitin-binding function of p62 
 
The effects of the individual P392L and S399P missense mutations on the 
ubiquitin-binding function of p62 have been analysed previously using the in 
vitro mono ubiquitin-binding assay at 37oC, pH7.5 (Cavey et al. 2005; Cavey 
et al. 2006). Both of the mutations showed complete loss of binding under 
these conditions. Interestingly, when assays were performed at a lower 
temperature (room temperature; ~21oC) it was noted that P392L retained its 
ubiquitin-binding function, whilst S399P showed only reduced binding relative 
to wild type. Hence, since neither of the mutations showed a complete loss of 
binding under these conditions, any additive effects of the mutations on 
ubiquitin-binding by p62 could be assessed. 
 
From assessments of representative western blots (Figure 3.8) the relative 
effects of the double mutation on the p62-ubiquitin interaction with ubiquitin 
were estimated; indeed it was concluded that the P392L/S399P double 
mutation causes a complete loss of ubiquitin-binding under conditions (~21oC) 
where the individual mutants retained at least some ubiquitin-binding function. 
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Figure 3.8: Effects of the PDB-associated double P392L/S399P p62 
mutation on ubiquitin-binding in vitro; at room temperature (~21oC) 
 
The mutations as indicated were introduced into the full length p62 sequence, 
and the GST-tagged proteins used in pull-down assays at room temperature 
(~21oC). Bacterial lysates containing the GST-p62 fusions were precipitated 
with glutathione-Sepharose (G), control-Sepharose (C) and ubiquitin-
Sepharose (U) beads. Precipitated proteins were detected by western blotting 
(anti-p62 antibody). Proteins in the (G) lanes are precipitated via the GST-
glutathione interaction, and (U) lanes via the UBA-ubiquitin interaction. As 
indicated the S399P/P392L double mutation caused a complete loss in 
ubiquitin-binding function. Both individual S399P and P392L mutations 
retained at least partial binding function under the same experimental 
conditions. Thus, effects of the mutations on protein function appear to be 
additive, and the double mutation has a more severe effect than the individual 
mutations. 
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3.6 Investigation of the interaction of p62 and ubiquitin using 2D 
protein NMR 
 
3.6.1 Introduction 
 
Analysis of the PDB-DVVRFLDWHGµGRXEOH¶3/638%$GRPDLQPLVVHQVH
mutation using in vitro binding assays (3.5.4) further supported the 
hypothesis that the ubiquitin-binding function of p62 may in some cases 
correlate with disease severity in patients. In addition, we noted a small but 
reduced ubiquitin-binding function of A381V mutant p62 (3.5.1), relative to 
wild type, but only under certain in vitro conditions. These observations 
highlight the need for more quantitative measures of p62 ubiquitin-binding 
function; not least because the in vitro pull-down assays described in the 
earlier part of this chapter are at best only semi-quantitative in nature. 
 
Consequently, we sought to investigate if a more quantitative biophysical 
approach, two dimensional Heteronuclear Single Quantum Coherence (2D-
HSQC) protein NMR, might be applied to investigate the effects of PDB-
associated mutations on protein (ubiquitin-binding) function. Indeed this 
technique has previously been used to estimate the dissociation constant (Kd) 
for the interaction of the p62-UBA (residues 387-436) with monoubiquitin at 
298K as 540 ± 45µM (Long et al., 2008), although the effects of PDB 
mutations were not reported, and more recent analyses (in house) indicated a 
refined value for this Kd of this interaction of 710 ± 10µM (Tom Gallagher, 
School of chemistry, University of Nottingham, personal communication). 
 
This particular NMR technique involves measuring chemical shift perturbations 
(CSP) of unbound and UBA-bound isotopically-labelled ubiquitin; these CSP 
changes are used as a sensitive tool to monitor the weak interactions between 
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ubiquitin and p62. With this approach one can quantify interactions by 
determining a Kd, or alternatively an association constant (Ka), where Ka can 
be defined as an equilibrium constant of a reversible reaction, which measures 
the affinity of two molecules to each other at equilibrium state, and Kd is an 
equilibrium constant defining the tendency of the products of a reversible 
reaction to dissociate to its reactants. These two constants are used to show 
how tight two proteins bind to each other, as the smaller the Kd (the higher 
the Ka) the tighter the proteins are binding. 
 
Prior to this work, the interaction of a longer p62 construct containing the UBA 
domain and additional N-terminal residues (341-440) with ubiquitin was also 
investigated using 2D-HSQC NMR (by Tom Gallagher, personal 
communication). In this case 15N-ubiquitin (prepared by growing E coli 
expressing the protein in a medium in which the only source for nitrogen was 
its isotope 15N) was titrated with unlabelled p62 (341-440) up to a 1:6 molar 
ratio (ubiquitin:UBA). The Kd for the p62 (341-440) binding to ubiquitin was 
estimated as 501µM ± 34µM, notably indicating that the longer p62 protein is 
associated with a tighter binding, and supporting the idea that non-UBA 
sequences (and by extension mutations) can influence ubiquitin-binding 
affinity.  
 
One of the downsides of the method is difficulty in studying full-length p62, 
which is 440 amino acids in total, because full-length p62 exhibits relatively 
low protein expression levels and the NMR technique requires a large amount 
of protein (typically >40mg). Therefore, a compromise of using the shorter 
p62 (341-440) construct was accepted; notably however this sequence does 
FRQWDLQ$WKHVLWHRIRQHRIWKHµQHZ¶3'%PXWDWLRQVDQDO\VHGLQWKLV
study. 
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Initially we sought to make quantitative analyses of the effects of the well 
characterised P392L mutation, associated with complete loss of ubiquitin-
binding function in full-length p62 in pull-down assays at 37oC, pH7.5 (Cavey 
et al., 2005) ± with the intention of extending these analyses to other PDB-
associated mutations. In particular it would be desirable to investigate more 
fully the A381V mutation which we noted appeared to be associated with a 
minor reduction in ubiquitin-binding function (3.5.1). 
 
3.6.2 Basic theoretical background of NMR 
 
NMR depends on the magnetic moment of nuclei, in other words their spin, 
which is a characteristic of atoms with a total odd number of protons and 
QHXWURQV$OEHUW\¶V3K\VLFDO&KHPLVWU\2th Ed.). When a strong magnetic field 
is applied to atoms the nucleus spin can exist at two energy states: E1 (which 
is the lower (ground) energy state and the magnetic spin is in alignment with 
the applied field), or the nucleus can be excited to a higher energy state E2 (in 
which the magnetic spin is in opposite direction of the applied field); the 
amount of energy needed to excite the nucleus from E1 to E2 is called 
resonance (Figure 3.12). The energy needed to cause the resonance is in the 
radio frequency range. As the nucleus return to the ground state it emits 
energy which is recorded by the NMR spectrometer as chemical shift, which is 
measured in Parts Per Million (PPM). Notably the amount of energy needed to 
cause the resonance and hence the chemical shift depends on the chemical 
(magnetic) environment around each nuclus. The reason that chemical shift is 
affected by the environment is that each nuclus and electron are moving 
charges, so they tend to have their own local magnetic field, which will reduce 
the applied field  by the amount of the local magnetic field of the atoms; this 
leads to a distinct chemical shift for every nuclus. In practice a reference 
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compound will be regarded as zero PPM chemical shift and the chemical shift 
of other compounds will be measured relative to this reference compound. 
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Figure 3.12: Energy level diagram of spin states of a nucleus. 
 
(LVWKHORZHUHQHUJ\VWDWH(LVWKHKLJKHUHQHUJ\VWDWH¨(UHSUHVHQWVWKH
energy difference between the two states, which is proportional to the radio 
frequency necessary to excite the nucleus from the lower energy state to the 
higher energy state. 
 
   :  Denotes to the spin state of the nucleus when it is in alignment to the     
direction of applied field. 
   :  Denotes to the spin state of the nucleus when it is aligned in the opposite 
direction of the applied field. 
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To study the interactions between p62 and ubiquitin, a two dimensional NMR 
approach was used. In our study we used 15N-1H HSQC, in which  the chemical 
shift of 15N is directly correlated to the chemical shift of 1H, and the correlated 
chemical shift is detected as a cross peak on the resulting spectrum (Vaynberg 
et al., 2006). This technique facilitates the detection of a chemical shift for 
every N-H bond across a protein. Since every residue of a protein (except 
proline) has an N-H derived from the Į-amino group of the amino acid, the 
number of peaks on the 2D spectrum represents number of the residues of the 
proteins (Branden and Tooze 2nd Ed.) and since the N-H of each amino acid 
has a different environment when contained in different proteins, each protein 
produces a characteristic cross-peak fingerprint. In addition, N-H of side chain 
residues (Asn, Gln) can be distinguished from the back bone N-H as an 
additional cross peak on the spectrum (Figure 3.13).  
 
In our experiment, first a separate 15N-1H HSQC spectrum is collected for the 
15N labelled protein (in this case ubiquitin), then another spectrum is collected 
after adding an unlabelled protein (p62 (341-440 containing the P392L 
mutation)) to the 15N labelled ubiquitin using a range of molar ratios. Since the 
chemical shifts of both N and H are sensitive to the chemical environment 
around them, the effects of protein binding on the chemical shifts can be used 
to study the interaction of the two proteins. 
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Figure 3.13: A polypeptide chain of a 15N-labelled protein, showing the 
15N and 1H at the back bone and selected side chains 
 
R represents amino acids side chain, blue groups are representative side 
chains (Gln, Asn). These two side chains have an NH2 group which has two 
hydrogen atoms attached to the same 15N, therefore there will be two 1H 
signals for each 15N signal. These two hydrogen atoms are denoted as a, b. 
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3.7 Generation of a prokaryotic expression constructs for GST-p62 
(341-440) containing the P392L mutation 
 
Previously in the lab, a pGEX-4T-1 plasmid which allows p62 residues (341-
440) to be expressed as a GST-fusion protein in E. coli was generated. The 
P392L mutation was introduced in to this sequence by site-directed 
mutagenesis following the instructions of QuikChange® Site-Directed 
Mutagenesis kit (Stratagene) (Materials and Methods). The resulting protein 
will be denoted GST-p62 (P392L; 341-440). 
 
The GST-p62 (P392L; 341-440) plasmid was analysed by DNA sequencing and 
the resulting chromatogram was viewed using ChromasLite2 software (Figure 
3.14). The mutation was confirmed by sequence alignment with the wild type 
sequence using ClustalW2. 
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2 
                                   
Figure 3.14: DNA sequencing of p62 (P392L; 341-440); the main chromatogram shows part of the wild type 
sequence of p62 (the arrow indicates mutation site). The smaller chromatogram highlights the PDB mutation 
introduced into p62 by site-directed mutagenesis. 
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3.8 Large scale purification p62 (P392L; 341-440) for protein NMR 
 
Bacterial lysates obtained from multiple one litre cultures of E. coli expressing 
GST-p62 (P392L; 341-440) were incubated at 4oC for 6 hours with 
glutathione-Sepharose beads in chromatography columns, producing a 
complex between GST tagged proteins with the glutathione-Sepharose beads. 
As the GST tagged p62 (P392L; 341-440) includes a thrombin enzyme 
recognition site, LeuValProArgGlySer, between the GST and p62 sequences, 
the beads were incubated with thrombin enzyme overnight, at room 
temperature resulting in proteolysis between Arg and Gly residues, eluting the 
p62 (P392L; 341-440) protein with additional Gly and Ser residues at the N-
terminus. The beads retain the GST tag (Figure 3.15). Fractions were analysed 
with SDS-PAGE followed by staining the gel with Coomassie brilliant blue dye 
(Figure 3.16). In total ~40 separate 1 litre cultures were processed in this 
way. The eluted p62 (P392L; 341-440) protein was stored at 4oC and 
subjected to further purification step by gel filtration. Final protein 
concentration was measured using Bradford assay (See Materials and 
Methods) and was equivalent to ~40mg of total recombinant protein. 
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Figure 3.15: Large scale purification of the recombinant p62 (P392L; 
341-440) 
 
Bacterial lysates containing GST-p62 (P392L; 341-440) were incubated with 
glutathione-Sepharose beads, which leads to formation of a complex between 
the GST-p62 (P392L; 341-440) and glutathione beads. Beads are incubated 
with thrombin enzyme, which proteolyses GST-p62 (P392L; 341-440) at its 
thrombin cleavage sequence, thus eluting p62 (P392L; 341-440) protein and 
leaving the rest of the tag sequence on the beads. 
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Figure 3.16: Large scale purification of GST-p62 (P392L; 341-440) 
 
GST-p62 (P392L; 341-440) was expressed in E. coli, and the bacterial lysates 
were bound to glutathione-Sepharose beads at 4oC for 6 hours, followed by 
incubating the resulting complex (lanes 1, 2) overnight and at room 
temperature with thrombin enzyme. Thrombin enzyme cleaves the complex 
and p62 (P392L; 341-440) is eluted (lanes 3, 4) leaving GST bound to the 
beads (lanes 5, 6). Aliquots of protein fractions were subjected to SDS PAGE 
and the gel stained with Coomassie blue. 
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3.9 NMR analysis of the interaction of 15N-ubiquitin with p62 (P392L; 
341-440) 
 
After purifying p62 (P392L; 341-440), NMR titration experiments were 
performed between the purified protein and 15N-ubiquitin (in collaboration with 
Tom Gallagher, School of Chemistry). A fixed concentration of 15N-ubiquitin 
(1mM) was titrated with a range of concentrations of unlabelled p62 (P392L; 
341-440) (Table 3.1), both prepared in NMR buffer pH7 at 298K, with analysis 
using a Bruker Avance 600MHz NMR spectrometer. The NMR spectra were 
collected at each titration step. The CSP was recorded for each 15N and 1H of 
ubiquitin as it interacted with p62 (P392L; 341-440). The same analyses were 
previously performed for p62 (WT; 341-440) by Tom Gallagher. 
 
Sample 
number 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
15N-
Ubiquitin 
(mM) 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 
p62 
(P392L; 
341-
440) 
(mM) 
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.8 1.0 1.2 1.5 2 4 6 
 
Table 3.1: Molar ratios of p62 (P392L; 341-440) and 15N-Ubiquitin 
 
 
Changes in the chemical VKLIWVRIVRPHRIXELTXLWLQ¶VUHVLGXHVREWDLQHGIURP
the analyses were used to calculate the Kd for the interaction between p62 
(P392L; 341-440) and ubiquitin.  
 
To illustrate how the Kds were obtained from the chemical shift data, we first 
need to consider basic theoretical concepts for Kd calculations: the interaction 
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between ubiquitin and p62 (P392L; 341-440) can be represented by reaction 
1, in which the reactants bind in a 1:1 model to form a complex; at 
equilibrium the reaction follows equation (1), in which Ka defines the 
association constant of the interactions, or alternatively Kd can be used to 
define the binding equilibrium. Ka or Kd (Ka=1/Kd) are calculated from equation 
(3). Equation (3) is derived from equations (1), (2) and the state of bound and 
unbound proteins in the solution; this equation is applied  to draw a graph 
(Figure 3.17) by assigning p62 (P392L; 341-440) concentration to the X axis 
and the CSP of a ubiquitin residue (CSP is measured from the NMR 
spectrometer) to the Y axis; a curve will form which shows that the complex 
will form a steady state, i.e. addition of more p62 (P392L; 341-440) will no 
longer lead to any observable CSP and this state is represented by the 
plateau. CSPmax is calculated from the point when the interactions reach the 
plateau. At this stage, 1/Ka (Kd) is the only unknown in equation (3), and by 
applying the equation using Igor Pro 5.0.5.7 software the Kds can be 
FDOFXODWHGIRUHDFKRIXELTXLWLQ¶VUHVLGXHV 
 
 
 
Ub + UBA        UBA:Ub 
 
 
UBA:Ub        Ub + UBA                                                               
 
[UBA:Ub] is the concentration of the complex between ubiquitin and p62 
(P392L; 341-440) at equilibrium 
[Ub] is the concentration of ubiquitin at equilibrium 
[UBA] is the concentration of p62 (P392L; 341-440) at equilibrium 
 
Kd= [UBA:Ub]          
                        
[Ub]x[UBA] 
                       
[Ub]x[UBA] Ka=  
 
[UBA:Ub]      (1) 
(2) 
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CSP = CSPMax * ([UBA] / ((1/Ka) + [UBA]))                                    (3) 
 
CSP: chemical shift perturbation measured by the NMR spectrometer. 
CSPMax is CSP at saturation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 3.18-3.21 demonstrate the necessary steps for Kd calculations; the 
chemical shift of one residue of ubiquitin (K11) is shown in Figure 3.18. The 
chemical shifts of each residue of ubiquitin were first recorded without addition 
of p62 (P392L; 341-440) and marked as red, while the CSPs of ubiquitin after 
addition of p62 (P392L; 341-440) were marked as black. The cross peak of 
K11 changes its position, indicating changes in the chemical environment of 
K11 after the addition of p62 (P392L; 341-440), which indicates possible direct 
interaction between K11 of ubiquitin and p62 (P392L; 341-440). 
 
The chemical shifts of all of ubiTXLWLQ¶VUHVLGXHVDUHVKRZQLQ)LJXUH, and 
to obtain a clearer graph the crosses on the residues were deleted (Figure 
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Figure 3.17: A typical rectangular hyperbola, plotted from CSP of ubiquitin 
as a function of p62 (P392L; 341-440) (denoted UBA) concentration. 
concentration.  
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3.20). From the CSP values obtained from Figure 3.19, binding curves for each 
ubiquitin residue were produced (Figure 3.21), and from these curves the Kds 
were calculated by applying equation (3) using the Igor Pro 5.0.5.7 computer 
software. 
 
Table 3.2 shows the CSP values of p62 (P392L; 341-440) compared to CSP 
values of p62 (WT; 341-440), the latter data provided by Tom Gallagher. The 
table shows that not all residues in ubiquitin undergo large variations in their 
CSPs, indicating that the binding surface between p62 (P392L; 341-440) and 
ubiquitin is a defined region. The CSP values were used as an indicator to 
gauge the areas in the UBA domain were most changes occur, and the CSP 
values indicated broadly that the changes in the CSP are roughly similar in 
both constructs with some variation at occasional residues. Based on the 
results obtained from this table the Kd values were measured for those 
residues which had detectable CSP variations. Table 3.3 shows individual Kds 
for each residue of ubiquitin and, the average Kd between ubiquitin and p62 
(P392L; 341-440) was compared to the Kd between p62 (WT; 341-440) and 
ubiquitin.   
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Figure 3.18: Detailed (15N ,1H) 2D HSQC NMR spectra for K11 of 
ubiquitin 
 
This spectrum shows a detailed illustration of chemical shift dynamics for one 
ubiquitin residue. The chemical shift for K11 of 15N-ubiquitin was measured in 
the absence (red) and after titration with different concentrations of p62 
(P392L; 341-440) (black) using an NMR spectrometer. Using a constant 
concentration of ubiquitin (1mM) the chemical shifts were measured after the 
addition of different concentrations of p62 (P392L; 341-440) up to a 1:6 molar 
ratio. The spectrum was collected at 298K (25oC), pH7 using a Bruker Avance 
600MHz NMR spectrometer. In the absence of p62 (P392L; 341-440), the N-H 
shift from K11 of ubiquitin is at 7.21 PPM/1H and 121.95 PPM/15N. As the 
concentration of p62 (P392L; 341-440) increases the residue shifts from its 
starting position to 7.30 PPM/1H and ~122.375 PPM/15N, indicating changes in 
the chemical environment of ubiquitin at that residue. 
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Figure 3.19: (15N, 1H) '+64&105VSHFWUDRIXELTXLWLQ¶VLQWHUDFWLRQ
with p62 (P392L; 341-440) labelling shifts from each residue of 
ubiquitin 
 
Chemical shifts for 151ODEHOOHGXELTXLWLQ¶VUHVLdues were measured in the 
absence (red) and after titration with p62 (P392L; 341-440) (black) using a 
constant concentration of ubiquitin (1mM). The chemical shifts were measured 
after the addition of p62 (P392L; 341-440) using a range of molar ratios 
(Table 3.3). The resultant chemical shifts of some of the residues show slight 
changes in their PPM, while the majority of the residues were superimposed 
indicating slight change in the chemical environment around the residues i.e. 
weak interaction. A Bruker Avance 600MHz NMR spectrometer was used and 
the spectra was collected at 298K (25oC), pH7. CSP values were fitted to 
Equation (3) using Igor Pro 5.0.5.7 software (Figure 3.21). A clearer graph is 
illustrated next page to show degree of CSP of bound and unbound residues. 
The chemical shifts are displayed at saturation. 
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Figure 3.20: (15N, 1H) 2D HSQC NMR spectra of 15N-XELTXLWLQ¶V
interaction with p62 (P392L; 341-440)  
 
Chemical shifts for 151ODEHOOHGXELTXLWLQ¶VUHVLGXHVZHUHPHDVXUHGLQWKH
absence (red) and after titration with p62 (P392L; 341-440) (black) using a 
constant concentration of ubiquitin (1mM). The chemical shifts were measured 
after the addition of different concentrations of p62 (P392L; 341-440). The 
resultant CSPs of some of the residues showed slight changes in their PPM, 
while the majority of the residues are superimposed indicating minor changes 
in the chemical environment around the residues i.e. weak interaction. A 
Bruker Avance 600MHz NMR spectrometer was used and the spectra was 
collected at 298K (25oC), pH7. The chemical shifts are displayed at saturation. 
CSP values were fitted to Equation (3) using Igor Pro 5.0.5.7 software (Figure 
3.21). 
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Figure 3.21: Binding curves for p62 (P392L; 341-440) and ubiquitin 
Each curve represents the chemical shift of different residues of ubiquitin as 
they were titrated with different concentration of p62 (P392L; 341-440). 
Based on Equation (3) the curves were plotted using Igor Pro 5.0.5.7 software 
which calculates the Ka between ubiquitin and p62 (P392L; 341-440), the 
plateau represents the saturation of the interactions between the proteins, and 
CSPmax was obtained from the concentration where the chemical shifts start 
to plateau. 
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Table 3.2: CSP values for selected ubiquitin residues as they interact 
with p62 (WT; 341-440) and p62 (P392L; 341-440)  
 
The table shows that similar residues of p62 (P392L; 341-440) and p62 (WT; 
341-440) undergo chemical shifts as they interact with 15N-XELTXLWLQ7KH³&63
YDOXHV´DUHXVHGDVDJXLGHWRGHWHFWWKRVHUHVLGXHVZKLFKXQGHUJRKLJKHVW
CPS variations and are used for subsequent analyses. SC indicatHVµVLGH
FKDLQV¶DDQGEUHSUHVHQWVWZRGLIIHUHQW1H atoms attached to the 15N of the 
same group (Figure 3.13). Italics are for minimum CSP predicted values for 
broadened residues from CSP at 0.1. 
 
 
 
 
 
 
 
 
CSP 
Value 
 
P62 (P392L; 341-
440)  
 
p62 (WT; 341-440)  
0.05-
0.1 
2,5,6,9,10,15,24,29
,34,41,45,51,52,67,
68,73 
2,5,6,9,10,15,24,29,33,41,
45,39,51,52,64,66,67,68,7
3 
0.1-
0.15 
8,11,14,32,43,47,50
,41b 
32,34,43,50, 
0.15-
0.2 
13,49,69, 72, 40a, 
40b, 
8,69,72,SC40a,SC40b,SC4
1b, 13,53 
0.2-
0.25 
46, SC49a 48 46, 49, SC49a,48 
>0.25 44, 70, SC49b ,42, 
71 
44, SC49b, 70, 42 ,71 
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Table 3.3: Comparison of Ka between 
15N-ubiquitin interaction with p62 
(P392L; 341-440) versus p62 (WT; 341-440)   The Ka values were calculated 
from the CSP of selected residues measured by NMR spectroscopy (Figure 3.19) with 
each value calculated from the binding curves (Figure 3.21) and an average Ka (Kd) 
was caOFXODWHGDQGLVKLJKOLJKWHGµ-µ represents disappearing residues on the 
spectrum, ± represents average difference between the calculated fit line and the 
experimental data point. *The binding curve for residue 49 of ubiquitin is shown in 
(Figure 3.22). ** After fitting the data to global fitting curves the average Kds for p62 
(P392L; 341-440) and p62 (WT; 341-440) was ǋ0 and 501±34µM 
respectively. 
 
 
 
Ubiquitin 
Residue 
Number 
Ka 
(P392L) 
Ka  
(WT) 
Ubiquitin 
Residue 
Number 
Ka  
(P392L) 
Ka  
(WT) 
5 
1444.4± 
53.5 
2183.5± 
147 
46 
1529.5± 
54.5 
1859.4±112 
6 
1804.9± 
149 
2183.4± 
232 
47 
1739.9 ± 
131 
- 
8 
1737.1 ± 
73 
2247.5± 
173 
*49 
1459.7± 
44.8 
2267.8 ± 
133 
10 
1482.9± 
66.5 
1863.8± 
198 
50 
1758.2 ± 
104 
2210.6 ± 
201 
11 
1658.3± 
82.7 
2243.4± 
176 
51 
1638.6± 
80.4 
2328.5 ± 
183 
13 
1516.8± 
72.4 
- 52 
1472 ± 
61.5 
1983.1 ± 
122 
14 
1383.4± 
40.1 
- 68 
1388.1± 
41.6 
2066.3 ± 
130 
15 
1285.6± 
138 
2294.2± 
185 
69 
1434.6± 
59.8 
1703.1 ± 
140 
24 
1580.8± 
106 
1608.5± 
144 
70 
1573.1± 
59.9 
- 
29 
1441.6± 
62.3 
2046.6± 
120 
72 
1628.3± 
79.1 
2125.5 ± 
173 
32 
1524.8± 
52.9 
2545.1± 
189 
SC40a 
1465 ± 
28.2 
2278.6 ± 
114 
34 
1520.4± 
93.3 
2631.9± 
197 
SC40b 
1465.7± 
28.7 
2279.4 ± 
121 
41 
1797.4± 
139 
1745.5± 
115 
SC41a 
1385.5 ± 
133 
1731.2 ± 
142 
43 
1572.3± 
33.5 
2165.2± 
145 
SC49a 
1521.2± 
55.1 
1639.8 ± 
154 
44 
1411.8± 
88.8 
1896.2± 
176 
SC49b 
1488.4± 
58.6 
1626.1 ± 
173 
45 
1539.5± 
184 
2646.2± 
254 
**Average 
Ka(Kd) 
1537.09M-1 
Kd(654µM)
 
2088.904M-1 
Kd(479µM)
 
126 
 
The average calculated Kds were 501±34 µM for p62 (WT; 341-440) and 658± 
ǋ0IRUS3/-440). These values indicate that p62 (WT; 341-
440) may bind slightly more strongly to ubiquitin than p62 (P392L; 341-440), 
although the difference was marginal and in terms of NMR analyses is 
negligible and unlikely to be significant. Indeed to emphasise the similarity of 
the values, the CSP of residue number 49 of ubiquitin as it interacts with both 
p62 constructs is illustrated in Figure 3.22; at different concentrations of p62 
protein, the changes in CSP values are virtually indistinguishable (and in fact 
overlay) for titrations with p62 (P392L; 341-440) and p62 (WT; 341-440). 
Thus, we conclude that this approach cannot reliably detect significant 
differences in binding affinity between p62 (WT; 341-440) and p62 (P392L; 
341-440). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
127 
 
 
 
 
 
 
Figure 3.22: Comparison of the chemical shift for residue number 49 of 
15N- ubiquitin (side chain NH2) resultant from titration of ubiquitin 
with p62 (WT; 341-440) and p62 (P392L; 341-440)  
 
Each curve represents the chemical shift of residue 49 of ubiquitin upon 
titration with different concentration of WT and p62 (P392L; 341-440). Based 
on Equation (3) the curves were plotted using Igor Pro 5.0.5.7 software. Note 
the curves virtually overlay and differences in chemical shifts appear 
negligible, consistent with identical binding affinities. 
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3.10 Discussion 
 
The majority of PDB-associated p62 mutations investigated to date are located 
within the UBA domain and result in impairment of the ubiquitin-binding 
properties of the p62 protein. Here we investigated a new hypothesis that 
non-8%$GRPDLQPXWDWLRQV$9'(DQG¨-388) might similarly 
affect the ubiquitin-binding properties of p62. 
  
The A381V mutant p62 retained its ubiquitin-binding function at pH7.5 in pull-
down assays, but interestingly showed reduced ubiquitin-binding in a mildly 
acidic environment. This pH-dependent variation of the ubiquitin-binding 
properties of the A381V mutant cannot be rationalised simply, but it is notable 
that an acidic environment exists inside autophagosomes in which p62 and 
ubiquitinated proteins are degraded by the autophagy machinery (Biørkøy et 
al., 2005; Pankiv et al., 2007). The effects of PDB mutations on p62-mediated 
autophagy have not been assessed to date. 
 
7KHSGHOHWLRQPXWDQW¨-388, which notably removes A381, also 
reduced ubiquitin-binding relative to wild type p62 and consistent with original 
findings of Vadlamudi and co-workers related to the function of p62 
(Vadlamudi et al., 1996), which noted two p62 internal deletion constructs 
¨-DQG¨-440) exhibited partial loss of ubiquitin-binding.  Based 
on these observations it was proposed that p62 might have two ubiquitin-
binding regions, or that ubiquitin has more than one binding site with p62 
(Vadlamudi et al., 1996). Interestingly, our own co-workers also noted a 
correlation between the length of UBA domain constructs with increasingly 
extended N-terminal sequences and ubiquitin-binding ability in pull-down 
assays; as the N-terminus of the UBA domain was progressively extended the 
binding affinity of p62 to ubiquitin increased, indicating that multiple regions of 
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p62 affect the interaction with ubiquitin (Najat et al., 2009). Further, 
quantitative analyses showed that the longer (341-440) UBA construct bound 
ubiquitin more tightly than the UBA domain alone (387-436), with respective 
.G¶VRI0-436) and 501µM ± 34µM (341-440) (Tom Gallagher, 
School of chemistry, University of Nottingham, personal communication). 
 
Previous structural analyses give few clues to rationalise the effects of A381V 
DQG¨-388 non-UBA domain mutations on the ubiquitin-binding affinity of 
the UBA domain, nor how non-UBA sequences contribute to binding affinity.  
The A381V mutation is located within a region of p62 (341-386) which 
precedes the UBA domain and through a combination of NMR spectroscopy 
and circular dichroism (CD) analysis it was shown that this region is 
unstructured (Figure 3.23) (Najat et al., 2009). P387L, a missense mutation 
previously shown to result in a partial loss of ubiquitin-binding function is 
located on a potential hinge region of p62 immediately before the UBA domain 
and it was initially suggested that this region adopts a flexible Į-helix 
conformation and might be recruited to form a stable structure that binds 
ubiquitin (Cavey et al., 2006). However, a structural investigation of the 
longer p62 UBA construct (341-440) using NMR did not support this 
hypothesis, providing no evidence for additional secondary structure with the 
UBA domain (Najat et al., 2009). Collectively, these results indicate that 
although our observations support the important role of non-UBA domain 
sequences in regulating binding affinity, more research is needed to 
understand the mechanism of ubiquitin recognition by p62. 
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Figure 3.23: Proposed tertiary structure of the p62 protein. 
 
The A381V mutation affects a region of p62 predicted to be unstructured and 
some eleven residues from the start (P392) of the structured UBA domain. The 
N-terminal PB1 domain which adopts ubiquitin-like fold is shown (in this case 
the PB1 and ZZ domains of other proteins are presented). Numbering relates 
to the positions of specific residues in the 440 amino acid sequence. Residues 
351-388 are removed in a predicted product of the G1205C splice-site 
mutation. From (Najat et al., 2009) 
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In contrast to the other non-UBA domain mutants, the D335E mutant p62 
protein retained ubiquitin-binding function at both pH7.5 and pH6.5. This is 
perhaps not surprising as D335E is a conservative mutation involving a 
substitution of an acidic side chain with another acidic side chain; 
alternatively, D335E may simply represent a rare polymorphism. Further, a 
recent study noted that P364S, DQRWKHUµQHZ¶QRQ-UBA domain mutation, also 
had no effect on ubiquitin-binding properties of p62 at both pH7.5 and pH 6.5 
(Rea et al., 2009). Together, these data suggest that as the p62 mutations are 
located further from the UBA domain, their effects on ubiquitin-binding (at 
least in our in vitro pull-down assays) become less pronounced. One 
LQWHUSUHWDWLRQRIWKHVHREVHUYDWLRQVLVWKDWORVVRIS¶VXELTXLWLQ-binding 
function may not be important in PDB aetiology. Alternatively, non-UBA 
domain regions of p62 may be involved in additional interactions with its 
ubiquitinated substrates (most likely other components of the RANK-NF-Ȓ%
signalling pathway). In other words non-UBA domain mutations might cause 
reduced binding to ubiquitinated substrates of p62 but, in contrast to UBA 
domain mutations, might specifically impair interaction with the substrate 
proteins rather than the ubiquitin modification. Such effects would not be 
evident in our in vitro assays. To further investigate the effects of the D335E 
mutation on then biological functions of p62, we went on to use 
immunofluorescence confocal microscopy to study the interaction between the 
D335E mutant and LC3 (see section 4.6.1). LC3 is an autophagic marker and 
notably the D335E change is located within the middle of LC3-interacting 
region (LIR) of p62 (321-342).  
 
There remains ongoing debate as to whether PDB is caused by viral infections 
or genetic factors, whilst a few groups have suggested that combination of 
these two factors may be important. Since some SQSTM1 mutations appear to 
have an incomplete penetrance, it is difficult to conclude whether genetic 
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variants play a causal role in PDB or simply increase the susceptibility to the 
disease. Correlations between disease severity in patients with SQSTM1 
mutations, and ubiquitin-binding properties of corresponding mutant p62 
proteins, would provide strong evidence that the mutations play a central role 
in PDB aetiology. In 2004 Hocking et al. proposed that in some cases PDB 
disease severity might be correlated to the ubiquitin-binding properties of p62, 
based on the notion that a p62 truncating mutation (E396X) lost its ubiquitin-
binding function completely in in vitro pull-down assay and the patient carriers 
of this mutation had the most extensive disease phenotypes compared to 
other PDB mutations (Table 3.4).  
We also attempted to correlate the ubiquitin-binding properties of p62 carrying 
the double UBA domain mutation S399P/P392L, and individual P392L or S399P 
mutants, to disease phenotype. P392L/S399P mutant p62 showed complete 
loss of ubiquitin-binding function in our in vitro pull-down binding assay at 
room temperature, and was associated with a particularly severe disease 
phenotype (Eekhoff et al., 2004) (Table 3.4). In contrast individual P392L and 
S399P mutations had less obvious effects on the ubiquitin-binding function of 
p62, and are reported to be associated with milder disease phenotypes than 
the double mutation S399P/P392L (Eekhoff et al., 2004). This indicates that 
the double mutation appeared to have an additive effect both on protein 
function and disease phenotype, providing support for the relationship 
between disease severity and the ubiquitin-binding properties of PDB-mutant 
p62 proteins. However, as these proposals are based on phenotypic 
descriptions of only single S399P and P392L/S399P carriers, in the future more 
investigations are needed to derive robust conclusions about this relationship. 
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Table 3.4: Selected PDB-associated p62 mutations and their phenotypes; 
some of the mutations have limited data therefore the corresponding fields are 
denoted as N.A. (not available). Reference 1: (Hocking et al., 2004), 
Reference 2: (Eekhoff et al., 2004).  
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In our study, we initially assessed the ubiquitin-binding properties of p62 
proteins mutations by subjective visual assessments of western blots of the in 
vitro pull-down assays. Although attempts were made to generate semi-
quantitative binding data by densitometric analyses of blots, this was on the 
whole found to be unreliable. In addition, within the binding assays 
themselves some limitations were noted; for example, difficulty arose in 
pipetting equal amounts of the Sepharose beads, which varied slightly 
between the experiments or within the same experiment, because Sepharose 
beads tend to stick to pipette tips. Further, maintaining constant temperatures 
(especially 37oC) throughout the binding/washing stages of the pull-down 
assay was difficult. Consequently, better methods to quantify the ubiquitin-
binding properties of p62 were sought; specifically, we decided to measure the 
dissociation constant (Kd) for interactions between p62 (residues 341-440) and 
ubiquitin using 2D-HSQC NMR, as such measurements represent a more 
accurate quantitative assessment of protein binding affinities. 
 
The ultimate goal of our experiments was to measure Kd values for the 
interactions between wild type/A381V mutant p62 and ubiquitin using 2D-
HSQC NMR, in order to try to confirm subtle effects of the A381V mutation on 
the ubiquitin-binding properties of p62 noted in our pull-down assays. In an 
extension, it would also have been desirable to collect Kd values for all PDB 
mutations. However, we concluded that this approach is not optimal to study 
the interaction between ubiquitin and p62 for several reasons. Firstly, we 
began by analysing a well characterised PDB mutation known to be associated 
with loss of ubiquitin-binding function in pull down assays (P392L), but noted 
that the Kd value for the interaction of p62 (P392L; 341-440) with ubiquitin 
was not significantly different than that of p62 (WT; 341-440). This indicates 
that the Kd values were broadly inconsistent with the in vitro ubiquitin-binding 
results, and that protein NMR would not be able to detect the even more 
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subtle changes in protein function exerted by other PDB-associated p62 
mutations. However, the experimental parameters were unavoidably different 
between the two methods (pull-down and protein NMR). A pH of 7.5 and 37oC 
was used in the in vitro pull-down assays, whilst the NMR experiments were 
performed at a pH7 and 25oC, as raising the temperature to greater than 25oC 
can lead to protein denaturation over the time scale of the NMR analyses; 
protein chemical shifts are also very sensitive to slight changes in the pH, 
temperature or environmental changes (Vaynberg et al., 2008). In hindsight a 
PDB-associated mutation which was not associated with significant increases 
in ubiquitin-binding affinity in pull-down assays at temperatures below 37oC 
(e.g. G425R) may also have been a better choice of mutation to initially 
analyse by protein NMR. A further limitation we noted is that the protein NMR 
technique required expression of >40 litres of culture of E. coli expressing the 
GST-p62 (341-440) proteins to obtain sufficient (~40mg) protein for analysis; 
hence this method of protein preparation was labour intensive, time 
consuming, and costly. In the future other biophysical approaches, such as ITC 
(isothermal titration calorimetry) and SPR (surface plasmon resonance) which 
rely on less sample should be considered to quantify p62-ubiquitin interaction. 
 
,QVXPPDU\ZRUNLQWKLVFKDSWHUVKRZHGWKDWVRPH$9¨-388) but 
not all (D335E) non-UBA domain PDB-associated mutations are associated 
with reduced p62 ubiquitin-binding function in pull-down assays; provided 
support for the proposed relationship between (mutant) p62 ubiquitin-binding 
function and disease severity in patients; and indicated that protein NMR was 
not optimal to quantitatively assess the interaction between p62 and ubiquitin 
in vitro.  
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Subsequent chapters describe work to develop approaches to investigate 
interactions between wild type and PDB-mutant p62 and ubiquitin in a more 
physiologically relevant and functional context. 
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Cellular phenotypes of PDB mutant p62 proteins 
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Chapter 4: Cellular phenotypes of PDB mutant p62 proteins 
 
4.1 Introduction 
 
Following our initial analyses of the ubiquitin-binding properties of p62 
proteins using in vitro binding assays and protein NMR (Chapter 3), we 
extended our study to examine the interaction of p62 and certain PDB mutants 
with ubiquitin in a cellular context. In particular, it was hoped that these 
experiments could provide further support for the partial loss of ubiquitin-
binding function associated with the A381V mutation suggested from the pull-
down assays (Chapter 3).  
 
For these studies, we took advantage of earlier published work which showed 
that when transfected into mammalian cells, p62 forms cytoplasmic bodies 
contDLQLQJXELTXLWLQDQGWKDWDµIXQFWLRQDO¶8%$GRPDLQRISLVUHTXLUHGIRU
the formation of these structures (Biørkøy et al., 2005) consistent with the 
p62-ubiquitin interaction being central to their biogenesis. Although not fully 
characterised, some of these structures are presumed to represent 
membrane-confined autophagosomes and a role for p62 in autophagic protein 
clearance (as well as turnover of p62 via autophagy) of ubiquitinated proteins 
has recently been suggested (Pankiv et al., 2007; Komatsu et al., 2007). 
Another group previously investigated the subcellular localisation of two PDB-
associated missense p62 mutants (P392L, P387L) in HEK293 cells (Biørkøy et 
al., 2005). Their study concluded that both mutant proteins formed larger 
cytoplasmic bodies (possibly also equivalent to non-membrane-confined p62 
protein aggregates as well as autophagosomes) than wild type p62, although 
co-localisation of ubiquitin with these mutant proteins was not investigated 
(Leach et al., 2006).  
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In addition, studies have shown that transfected p62 exhibits similar cellular 
phenotypes in a wide range of cell lines, including human HEK293 and U2OS 
cells (Biørkøy et al., 2005), and since U2OS cells are osteosarcoma-derived  
(i.e. bone-derived) we selected this line for our studies. 
 
Specifically, we used indirect immunofluorescence staining and confocal 
microscopy to study the effects of selected PDB mutations on (i) p62 
subcellular localisation and (ii) co-localisation of p62 with ubiquitin, with the 
assumption being that WKHODWWHUPD\DFWDVDµVXUURJDWH¶RIWKHXELTXLWLQ-
binding function of p62. The experiments were performed by transfecting 
polyHis-FLAG-tagged p62 constructs both without and with HA-tagged 
ubiquitin, followed by immunofluorescence staining and protein visualisation 
using 2D confocal laser scanning microscopy. In these experiments, image 
analysis software was used to quantify the sizes of p62 cytoplasmic bodies and 
the degree of co-localisation between p62 and ubiquitin. This is because often 
co-localisation measurements depend on visual assessment of a digital image 
with a mixed colour resultant from overlaying two different colours, and such 
an assessment is subjective and qualitative with a high degree of variability 
(French et al., 2008). 
 
In addition, we went on to further characterise the nature of p62 cytoplasmic 
bodies and noted like others (Biørkøy et al., 2005; Pankiv et al., 2007) co-
localisation of transfected p62 with transfected LC3. LC3 (Light Chain 3) is a 
mammalian homologue to Atg8 in yeast (Kabeya et al., 2000). Cleavage of 
LC3 at its C-terminus forms cytosolic LC3 (LC3-I). LC3-I is converted to LC3-II 
through conjugation of phosphatidylethanolamine (PE) to an exposed glycine 
residue of LC3-I. LC3-II is the autophagosome membrane-associated type of 
LC3 (Pankiv et al., 2007) and since bound LC3-II on the inner membrane of 
autophagosomes together with the sequestered materials will be degraded at 
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the late stages of autophagy, LC3-II is commonly used as an autophagic 
marker (Kabeya et al., 2000; Koamtsu et al., 2007). As the p62-LC3 
interaction is central to autophagosome formation (Biørkøy et al., 2005; 
Pankiv et al., 2007), we also tested the hypothesis that the PDB-associated 
D335E mutant of p62 which is located within the LC3-binding region of p62 
(Pankiv et al., 2007), may manifest its effects by disrupting this interaction 
and colocalisation. 
 
 
4.2 Generation of eukaryotic expression constructs for PDB mutant 
p62 proteins  
 
Previously in the lab, a construct allowing expression of polyHis-FLAG tagged 
wild type human p62 in mammalian cells was prepared by introducing the p62 
cDNA sequence into the pcDNA3.1 plasmid (Invitrogen). The D335E and 
A381V mutations were introduced separately into the wild type pcDNA3.1-p62 
sequence by site-directed mutagenesis following the instructions of 
QuikChange® Site-Directed Mutagenesis kit (Stratagene; see Materials and 
Methods). Each mutant plasmid was analysed by DNA sequencing and 
resulting chromatograms were viewed using ChromasLite2 software (Figures 
4.1). The mutations were confirmed by sequence alignment with the wild type 
p62 sequence using ClustalW2. 
 
Since three well characterised PDB-associated p62 mutants (E396X, G425R 
and P392L), each associated with significant impairment of ubiquitin-binding 
function, were used as controls for the in vitro ubiquitin-binding assays 
(Chapter 3), these same mutants were used as controls in our cellular studies. 
These mutants were generated from the wild type pcDNA3.1-p62 construct, 
SUHYLRXVO\LQWKHODEWKH3/63GRXEOHPXWDQWDQG¨-388 splice 
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site mutant (Chapter 3) were not analysed further in these experiments. The 
HA-ubiquitin expression vector (kindly provided by T. Hagen, University of 
Nottingham) was generated by PCR amplification from the human ubiquitin C 
IMAGE clone 4076286, including an XhoI VLWHDQ+$WDJLQWKH¶3&5SULPHU
and a KpnI VLWHLQWKH¶SULPHUDQGOLJDWLRQLQWRWKHSF'1$P\FKLV (2) 
plasmid (Invitrogen). The pcDNA3.1 construct for expression of LC3 as a 
fusion with tdTomato (tdTomato-LC3), a red fluorescent protein (Biørkøy et 
al., 2005), was kindly provided by T. Johansen, University of Tromsø, Norway. 
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Figure 4.1: DNA sequencing of polyHis-FLAG-p62 expression constructs containing PDB 
mutations D335E or A381V.  
Each of the mutations was introduced to the wild type polyHis-FLAG-p62 sequence by site-directed 
mutagenesis. Arrows indicate the sites of each mutation, with the bases changes shown above. 
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4.3 Method development  
 
The principle of indirect immunofluorescence staining depends on laser 
excitation of a fluorescent dye linked to specific secondary antibodies (in 
complex with primary antibodies bound to antigens within the sample under 
investigation), followed by detecting the emitted light by confocal microscopy. 
In this case, a wavelength of 568nm (green-yellow) is used for the excitation 
of the fluorescent secondary antibody directed against one of the protein 
targets to be detected, resulting in the emission of red light. At the same time, 
a wavelength of 488nm (red) is used for the excitation of the fluorescent 
secondary antibody directed against the other target, resulting in the emission 
of green light. In addition, to facilitate efficient location and shape of the cells, 
the nucleus is stained with another fluorescent dye, in this case Hoescht 
32258, which emits a blue light upon UV-excitation (Suzuki et al., 1992; 
Kuroiwa et al., 1982). This approach is sensitive to several experimental 
variables, which can result in poor image quality and non-reproducible results; 
therefore, we first optimised the detection protocols prior to detailed co-
localisation studies. Some of the experimental variables investigated as part of 
method development are described below. 
 
4.3.1 Localisation of endogenous p62 and ubiquitin in U2OS cells 
 
Prior to detailed analyses of the co-localisation of transfected polyHis-FLAG-
tagged p62 and HA-tagged ubiquitin in U20S cells, the expression and 
subcellular localisation of endogenous proteins (i.e. at normal physiological 
expression levels) was first investigated. This was important to ensure that the 
subsequent expression of transfected proteins was associated with cellular 
phenotypes that were physiologically relevant. U2OS cells without ectopic 
expression of p62/ubiquitin were fixed (in this case using formaldehyde) and 
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immunoprobed with anti±ubiquitin and anti-p62 antibodies, to detect 
endogenous ubiquitin and p62 proteins, respectively. Endogenous ubiquitin 
staining was diffuse throughout the cytoplasm and nucleus, whilst endogenous 
p62 staining was noted as small cytoplasmic bodies (as previously reported 
(Biørkøy et al., 2005)); limited overlap of staining of the endogenous p62 and 
ubiquitin proteins was noted (Figure 4.2). 
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Figure 4.2: Localisation of endogenous p62 and ubiquitin in U2OS cells 
  
U2OS cells fixed with formaldehyde were probed using mouse anti-p62 as 
primary antibody and stained green using anti-mouse Alexafluor 488 as 
secondary antibody. Rabbit anti±ubiquitin was used as primary antibody to 
detect endogenous ubiquitin and anti-rabbit Alexafluor 568 is used as 
secondary antibody (red). Hoescht 32258 was used for nuclear staining. On 
analysis by confocal microscopy, endogenous ubiquitin showed a diffuse 
pattern in the cytoplasm and the nucleus, whilst endogenous p62 staining was 
localised to small cytoplasmic vesicle-like structures (a higher magnification 
and staining intensity image of p62 is included). All images were collected with 
a 63X objective lens, with scale bar as indicated.  
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4.3.2 Comparison between different chemical fixatives 
 
Processing of samples for analysis by indirect immunofluorescence staining 
and confocal microscopy begins with fixation. A fixation method must balance 
the preservation of cellular morphology with access to antigenic sites. Initially 
methanol-acetone (50:50) was used to fix the U2OS cells singly transfected 
with polyHis-FLAG-tagged wild type p62 prior to immunostaining, however 
later the cells were fixed with formaldehyde. In both cases p62 staining was 
found to be similar (Figure 4.3), with cellular phenotypes that appeared to be 
exaggerated forms of those noted for the endogenous protein i.e. distinct 
cytoplasmic bodies; in some cases these were noted to be perinuclear. 
Although the methanol-acetone mixture gave encouraging initial results, 
overall formaldehyde gave more reproducible and higher quality images upon 
confocal microscopic analysis (Figure 4.3). Therefore, formaldehyde fixative 
was chosen to fix U2OS cells for subsequent experiments. 
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Figure 4.3: Comparison between different chemical fixatives 
 
Wild type polyHis-FLAG-p62 was transfected in to U2OS cells which after ~40 
hours were fixed as indicated. Detection of p62 was using mouse anti-p62 as 
primary antibody and anti-mouse Alexafluor 488 as secondary antibody. 
Hoescht 32258 was used for staining of nuclei. Confocal microscopy images 
were collected at 63X objective lens, with scale bar as indicated. Overall 
formaldehyde fixation was judged to produce more reproducible and higher 
quality images. 
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4.3.3 Optimisation of polyHis-FLAG-tagged p62 plasmid concentration 
for transfections 
 
To determine the optimum concentration of plasmids to use in subsequent 
experiments, two different concentrations of wild type polyHis-FLAG-tagged 
p62 plasmid were selected and transfected into U20S cells.  Approximately 40 
hours after transfection, cells were fixed and transfected. p62 was detected by 
immunoprobing with anti-p62 antibodies and visualisation by confocal 
microscopy analysis. At the two different plasmid concentrations used 
(0.15µg/ml and 0.5µg/ml) p62 staining was similar (Figure 4.4), with cellular 
phenotypes that again appeared to be exaggerated forms of those noted for 
the endogenous protein i.e. cytoplasmic bodies. These observations indicate 
that formation of p62 cytoplasmic bodies was not plasmid concentration-
dependent in our cells, opposing previous reports which suggested that p62 
µDJJUHJDWH¶IRUPDWLRQZDVSURSRUWLRQDOWRSODVPLGFRQFHQWUDWLRQLQWUDQVIHFWLRQ
experiments (Paine et al., 2005). However, it should be noted that we used a 
different experimental method to investigate the optimum plasmid 
concentration; we used confocal microscopy whilst Paine et al. used SDS-PAGE 
analysis. 
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Figure 4.4: Optimisation of polyHis-FLAG-tagged p62 plasmid 
concentration for transfections 
 
Two different concentrations of wild type polyHis-FLAG-tagged p62 plasmid, 
0.15µg/ml and 0.5µg/ml, were transfected in to U2OS cells, which after ~40 
hours were fixed with formaldehyde. p62 was detected using mouse anti-p62 
as primary antibody and stained green using anti-mouse Alexafluor 488 as 
secondary antibody. Hoescht 32258 was used for nucleus staining. All images 
were collected at 63X objective lens. Transfected p62 showed broadly similar 
localization and staining in U2OS cells at the two different plasmid 
concentrations. 
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4.3.4 Optimisation of time of transfection   
 
Previous studies reported that the formation of p62 cytoplasmic 
bodies/aggregates is proportional to incubation time of the plasmids after 
transfection (Paine al., 2005). To test this in our U20S cells, we transfected 
cells with polyHis-FLAG tagged p62 for different time intervals prior to 
immunostaining and confocal microscopy analysis (Figure 4.5). After 56 hours 
of transfection, cells showed a significant proportion of large p62-positive 
cytoplasmic bodies. At approximately 36-40 hours transfection, p62 still 
formed cytoplasmic bodies, but in general these were judged to be smaller 
than at the longer incubation times with a cellular phenotype closer to that of 
non-transfected cells, consistent with the earlier observations of Paine et al. 
Consequently, 36-40 hours was chosen as the optimum transfection time for 
subsequent experiments. 
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 Figure 4.5: Optimisation of time of transfection   
U20S cells were transfected with polyHis-FLAG tagged p62 for different time 
intervals prior to fixing the cells with formaldehyde. p62 was detected using 
mouse anti-p62 as primary antibody and stained green using anti-mouse 
Alexafluor 488 as secondary antibody. Hoescht 32258 was used for nucleus 
staining. All images were collected at 63X objective lens. After 56 hours of 
transfection, cells showed a significant proportion of large p62-positive 
cytoplasmic bodies. At approximately 36-40 hours transfection, p62 still 
formed cytoplasmic bodies, but in general these were judged to be smaller 
than at the than longer incubation times with a cellular phenotype closer to 
that of non-transfected cells, as a result we chose approximately 36 hours as 
optimum transfection time. 
 
 
 
 
 
 
152 
 
4.3.5 Co-transfection of polyHis-FLAG-p62 and HA-ubiquitin, and 
comparison of staining of different primary antibodies 
 
To begin to investigate interactions between p62 and ubiquitin in transfected 
cells, U20S were co-transfected with wild type polyHis-FLAG-tagged p62 and 
HA-ubiquitin plasmids, using conditions established in 4.3.2 and 4.3.4 (cell 
fixation with formaldehyde; transfection for ~36-40 hours). As p62 
cytoplasmic body formation did not seem to be sensitive to amount of p62 
plasmid in the range we tested (4.3.3), a concentration of 0.5µg/ml was 
selected for the transfected plasmids (both polyHis-FLAG-p62 and HA-
ubiquitin). In addition, two different primary antibodies were assessed for 
detecting p62 and ubiquitin after transfection. p62 was detected with anti-
FLAG and anti-p62, the latter of which was judged to show more robust and 
clearer staining upon confocal microscopy analysis. For ubiquitin detection, 
anti-ubiquitin and anti-HA was compared and again the latter was judged to 
show better staining (Figure 4.6). Upon co-transfection with ubiquitin, p62 
staining was broadly similar to that noted in single transfections of p62 only, 
with cytoplasmic bodies still clearly visible, and significant co-localisation of 
wild type poly-His-FLAG-p62 and HA-ubiquitin was noted (see 4.3.8 for a more 
detailed analysis). 
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Figure 4.6: Co-transfection of polyHis-FLAG-p62 and HA-ubiquitin, and 
comparison of staining of different primary antibodies  
 
Wild type polyHis-FLAG-tagged p62 plasmid and HA-ubiquitin were co-
transfected in to U2OS cells, which after ~40 hours were fixed with 
formaldehyde. p62 was detected using two different primary antibodies as 
indicated and stained green using anti-mouse Alexafluor 488 as secondary 
antibody. Ubiquitin was also detected with two different primary antibodies as 
indicated and stained red using anti-rabbit Alexaflour 568 as secondary 
antibody. Hoescht 32258 was used for nuclear staining. Confocal microscopy 
images were collected at 63X objective lens, with scale bar as indicated. 
Overall anti-p62 and anti-HA primary antibodies were assessed to produce 
clearer staining and more reproducible results. 
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4.3.6 Comparison of different staining colours for p62 and ubiquitin  
 
Two different colours (secondary antibodies) were tested to stain for co-
transfected wild type polyHis-FLAG-p62 and HA-ubiquitin in U20S cells. After 
immunoprobing for p62 with mouse anti-p62 and for ubiquitin with rabbit anti-
HA (as established in 4.3.5), p62 was stained green with anti-mouse 
Alexafluor 488 and ubiquitin stained red with anti-rabbit Alexafluor 568; 
alternatively, p62 was stained red with anti-mouse Alexafluor 568 and 
ubiquitin stained green with anti-rabbit Alexafluor 488. The staining patterns 
of the interchanged antibodies were similar. However, since ubiquitin has a 
wider distribution in the cytoplasm and the nucleus of the cells than p62, and 
based on our visual preferences, we subsequently stained ubiquitin as red and 
p62 as green (Figure 4.7). 
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Figure 4.7: Comparison of different staining colours for p62 and 
ubiquitin 
 
Wild type polyHis-FLAG-tagged p62 plasmid and HA-ubiquitin were co-
transfected in to U2OS cells, which after ~40 hours were fixed with 
formaldehyde. p62 was detected using  mouse anti-p62 as primary antibody 
and ubiquitin was detected using rabbit anti-HA as primary antibody. The 
secondary antibodies (anti-mouse Alexafluor 488 and anti-rabbit Alexafluor 
568) were used to stain p62 and ubiquitin interchangeably. Hoescht 32258 
was used for nuclear staining. Confocal microscopy images were collected at 
63X objective lens, with scale bar as indicated. Based on visual preference we 
decided to subsequently stain p62 as green and ubiquitin as red. 
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4.3.7 Specificity of secondary antibodies  
 
As a final control, the specificity of the secondary antibodies was investigated 
after co-transfection of U2OS cells with wild type polyHis-FLAG-p62 and HA-
ubiquitin for ~40 hours. Transfected cells were treated with a mixture of 
secondary antibodies (anti-mouse Alexafluor 488 and anti-rabbit Alexafluor 
568), whilst primary antibodies were omitted. Both red and green channels of 
the collected images showed no evidence of non-specific binding of secondary 
antibodies (Figure 4.8). 
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Figure 4.8: Specificity of secondary antibodies 
 
U2OS cells co-transfected with wild type polyHis-FLAG-tagged p62 plasmid 
and HA-ubiquitin for ~40 hours were fixed with formaldehyde. Cells were 
treated with a mixture of secondary antibodies (anti-mouse Alexafluor 488 and 
anti-rabbit Alexafluor 568), whilst primary antibodies were omitted.  Hoescht 
32258 was used for nuclear staining. All images were collected with a 63X 
objective lens, with scale bar as indicated. Both red and green channels of the 
collected images showed no evidence of non-specific binding of secondary 
antibodies. 
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4.3.8 Cellular phenotypes of transfected wild type polyHis-FLAG-p62 
and selected PDB mutants in U2OS cells  
 
Prior to the detailed co-localisation studies between wild type and PDB mutant 
p62 and ubiquitin, p62 localisation (in the absence of transfected HA-ubiquitin) 
in U2OS cells was investigated to evaluate any effects of selected PDB 
mutations (A381V, D335E, E396X) on cellular phenotype. U2OS cells were 
transiently transfected with polyHis-FLAG-p62 for ~40 hours and fixed with 
formaldehyde. Mouse anti-p62 was used as a primary antibody for probing p62 
and then anti-mouse Alexafluor 488 was used as a secondary antibody. Wild 
type p62 and the missense mutations showed cytoplasmic bodies varying in 
their size and shape (investigated in detail in sections 4.4; 4.5), whilst in 
contrast the E396X mutant showed diffuse staining throughout the cytoplasm 
(Figure 4.9). 
 
To confirm that the observed phenotypes (in particular that of the E396X 
mutant) were not resultant from variable expression levels of the ectopic 
proteins, the expression levels of each p62 construct in U2OS cells were 
detected with western-blotting after ~40 hours transfection (using anti-p62). 
The blots confirmed similar p62 expression levels for the wild type protein and 
its mutants (Figure 4.10). 
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160 
 
Figure 4.9: Representative examples of wild type and PDB mutant 
polyHis-FLAG-p62 localisation in U2OS cells (previous page) 
 
Wild type or PDB mutant (as indicated) polyHis-FLAG-p62 was transfected in 
to U2OS cells, which after ~40 hours were fixed with formaldehyde. Detection 
of p62 was using mouse anti-p62 as primary antibody and anti-mouse 
Alexafluor 488 as secondary antibody. Hoescht 32258 was used for staining of 
nuclei. Confocal microscopy images were collected at 63X objective lens, with 
scale bars as indicated. Wild type p62 and the A381V or D335E missense 
mutants formed cytoplasmic bodies, however the E396X mutant exhibited 
diffuse staining throughout the cytoplasm. 
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Figure 4.10: Immunoblot of ectopic expression levels of polyHis-FLAG-
p62 constructs in U2OS cells 
 
Equal numbers of U2OS cells were transiently transfected with polyHis-FLAG-
p62 constructs as indicated. After ~40 hours cells were washed and then 
solubilised with gel loading buffer; equal volumes of resulting lysates were 
resolved by SDS PAGE and analysed by western blotting (anti-p62). The blot 
shows approximately equal expression levels of transfected wild type and 
A381V or E396X mutant p62. The D335E mutant similarly showed comparable 
expression levels to the wild type (data not shown).  
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4.3.9 Cellular phenotypes of transfected HA-ubiquitin in U2OS cells 
 
Prior to the detailed co-localisation studies between wild type and PDB mutant 
p62 and ubiquitin, transfected HA-ubiquitin cellular localisation (in the absence 
of transfected polyHis-FLAG-p62) in U2OS cells was also first investigated.  
 
U2OS cells were transiently transfected with HA-ubiquitin for ~40 hours and 
fixed with formaldehyde. Rabbit anti-HA was used as a primary antibody to 
detect ubiquitin and then anti-rabbit Alexafluor 568 was used as a secondary 
antibody. Transfected HA-ubiquitin showed a diffuse distribution in the 
cytoplasm as well as in the nucleus (Figure 4.11), comparable with the 
staining pattern of the endogenous protein (Figure 4.2). 
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Figure 4.11: Localisation of transfected HA-ubiquitin in U2OS cells 
HA-ubiquitin was transfected into U2OS cells, which after ~40 hours were 
fixed with formaldehyde. Detection of ubiquitin was using rabbit anti-HA as 
primary antibody and anti-rabbit Alexafluor 568 as secondary antibody. 
Hoescht 32258 was used for staining of nuclei. Confocal microscopy images 
were collected at 63X objective lens, with scale bar as indicated. Transfected 
ubiquitin exhibited a diffused staining pattern, and was distributed evenly in 
the cytoplasm or in the nucleus. 
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4.4 Co-localisation of wild type and PDB mutant polyHis-FLAG-p62 
with HA-ubiquitin  
 
Previous studies showed strong co-localisation between wild type p62 and 
ubiquitin co-transfected in mammalian cells (Biørkøy et al., 2005). Therefore, 
we decided to assess the effects of PDB-associated mutations on the 
interaction of p62 with ubiquitin by examining co-localisation patterns in U20S 
cells. In particular, it was hoped that these experiments may provide support 
for the marginal loss of ubiquitin-binding function associated with the A381V 
mutant noted in the pull-down assays, and would provide an alternative 
method to 2D-HSQC NMR for examining p62-ubiquitin interactions (Chapter 
3). 
 
U2OS cells were transiently co-transfected with p62 and ubiquitin for ~40 
hours and the cells were fixed with formaldehyde. p62 was detected with anti-
p62 and ubiquitin with anti-HA. The secondary antibodies were a mixture of 
Alexafluor 488 and Alexafluor 568. 
 
To obtain accurate co-localisation measurements, the confocal microscope was 
adjusted to its optimum settings, as confocal microscopes have several 
tecKQLFDOOLPLWDWLRQV2QHRIWKHOLPLWDWLRQVRIFRQIRFDOPLFURVFRSHVLV³FURVV
WDON´SKHQRPHQRQZKLFKLVFDXVHGE\WKHRYHUODSRIWKHHPLVVLRQDQG
excitation spectra of the fluorophores of the secondary antibodies. The 
fluorophores usually have emission or excitation spectra that are close 
together or partially overlapping, thereby the wavelength selected to excite 
the first fluorophore might excite the second fluorophore at the same time, 
causing false co-localisation intensities (French et al., 2008). To avoid the 
cross talk phenomenon, the spectra of the fluorophores must be separated as 
far as possible, and a narrow detection band for the emitted light should be 
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used (French et al., 2008). Also, collecting the images with sequential 
scanning decreases background and cross talk emission by reducing the 
overlap between the two emission spectra of the fluorophores. 
 
After setting the microscope to its optimum setting, the slides were scanned. 
Wild type polyHis-FLAG-p62 co-localised strongly with HA-ubiquitin (Figure 
4.12, 4.13). Notably, upon co-transfection with HA-ubiquitin wild type polyHis-
FLAG-p62 showed similar cellular phenotypes to singly transfected p62 
protein. In contrast, transfected HA-ubiquitin changed its morphology from a 
diffuse pattern and became incorporated within cytoplasmic bodies, which 
mimicked the cytoplasmic bodies of polyHis-FLAG-p62. As a result, it was 
concluded that transfected polyHis-FLAG-p62 appears to recruit HA-ubiquitin 
in to the cytoplasmic bodies, which were later shown to contain an 
autophagosome marker (see section 4.6). 
 
The E396X mutant did not co-localise when co-transfected with HA-ubiquitin 
(Figure 4.14). Each of the p62 missense mutants A381V, P392L and D335E 
retained their co-localisation with ubiquitin and on first inspection their co-
localisation patterns were subjectively indistinguishable from those of wild 
type polyHis-FLAG-p62 with HA-ubiquitin (Figures 4.17-4.20). Hence, minor 
defects in the ubiquitin-binding function associated with the A381V mutant 
noted in the pull-down assays (Chapter 3) did not appear to manifest as 
obvious differences in co-localisation of transfected proteins, nor did more 
severe effects on ubiquitin-binding function previously noted for the P392L 
mutant (Cavey et al., 2005). Notably, the G425R mutant was the only 
missense mutant that occasionally showed reduced co-localisation with 
ubiquitin (Figure 4.16); this mutant was associated with significant impairment 
of ubiquitin-binding in vitro (Cavey et al., 2005).  
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Assessing the images visually, we noted that transfected wild type polyHis-
FLAG-p62 appeared to form two distinct major cellular phenotypes, based on 
their morphology. The first group was denoted common rounded and semi-
rounded cytoplasmic bodies, and was further subdivided to three types (Figure 
4.12):  
A - Small rounded cytoplasmic bodies.  
B - Medium rounded cytoplasmic bodies. 
C - Large semi-rounded cytoplasmic bodies. 
 
The second group was denoted rarer irregular cytoplasmic structures, and was 
also further subdivided to three types (Figure 4.13):  
D - Perinuclear structures. 
E - Multiple connected bodies.  
F - Diffuse structures. 
To ensure the results were consistent, the experiment was repeated several 
times and on each occasion, all of the above cellular phenotypes were noted.  
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Figure 4.12: Co-localisation of wild type polyHis-FLAG-p62 and HA-
ubiquitin in U20S cells and their cellular phenotypes (part 1) 
 
Wild type polyHis-FLAG-p62 and HA-ubiquitin were co-transfected into U2OS 
cells, which after ~40 hours were fixed with formaldehyde. p62 was detected 
using mouse anti-p62 as primary antibody and stained green using anti-mouse 
Alexafluor 488 as secondary antibody. Ubiquitin was detected using rabbit 
anti-HA primary antibody and stained red using anti-rabbit Alexaflour 568 as 
secondary antibody. Hoescht 32258 was used for staining nuclei. Confocal 
microscopy images were collected at 63X objective lens, with scale bars as 
indicated. Wild type polyHis-FLAG-p62 co-localised strongly with HA-ubiquitin. 
 
Three major cellular phenotypes, common rounded and semi-rounded 
cytoplasmic bodies, were observed to be associated wild type polyHis-FLAG-
p62: 
 
A) Small rounded cytoplasmic bodies. 
B) Medium rounded cytoplasmic bodies. 
C) Large semi-rounded cytoplasmic bodies. 
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Figure 4.13: Co-localisation of wild type polyHis-FLAG-p62 and HA-
ubiquitin in U20S cells and their cellular phenotypes (part 2) 
 
Wild type polyHis-FLAG-p62 and HA-ubiquitin were co-transfected into U2OS 
cells, which after ~40 hours were fixed with formaldehyde. p62 was detected 
using mouse anti-p62 as primary antibody and stained green using anti-mouse 
Alexafluor 488 as secondary antibody. Ubiquitin was detected using rabbit 
anti-HA primary antibody and stained red using anti-rabbit Alexaflour 568 as 
secondary antibody. Hoescht 32258 was used for staining nuclei. Confocal 
microscopy images were collected at 63X objective lens, with scale bars as 
indicated. Wild type polyHis-FLAG-p62 co-localised strongly with HA-ubiquitin. 
 
Three rarer irregular cytoplasmic structures observed for wild type polyHis-
FLAG-p62 were: 
 
D) Perinuclear structures. 
E) Multiple connected bodies. 
F) Diffuse staining (similar to E396X diffuse staining phenotype). 
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The cellular phenotypes of cells co-transfected with E396X mutant polyHis-
FLAG-p62 and HA-ubiquitin were not comparable to the rest of the p62 
constructs, as this mutant commonly showed diffuse staining as opposed to 
cellular bodies/perinuclear staining. Very rarely miniature cytoplasmic bodies 
were also noted for this mutant (Figure 4.14, 4.15). The G425R mutant 
exhibited similarities to the cellular phenotypes of wild type polyHis-FLAG-p62, 
DOWKRXJKRFFDVLRQDOO\WKLVPXWDQWDOVRVKRZHGGLVWLQFWµVHPL-GLIIXVH¶
structures, which were not observed to be associated with other PDB-
associated mutants (Figure 4.16). The P392L mutant also exhibited very 
similar cytoplasmic bodies to wild type polyHis-FLAG-p62 (Figure 4.17). 
Figures 4.16 and 4.17 show some common cellular phenotypes associated with 
the G425R and P392L mutants, although other cellular phenotypes equivalent 
to those noted for wild type polyHis-FLAG-p62 were also evident for these 
mutants (data not shown). 
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Figure 4.14: Co-localisation of E396X mutant polyHis-FLAG-p62 and 
HA-ubiquitin in U20S cells and their cellular phenotypes (part 1) 
 
E396X mutant polyHis-FLAG-p62 and HA-ubiquitin were co-transfected into 
U2OS cells, which after ~40 hours were fixed with formaldehyde. p62 was 
detected using mouse anti-p62 as primary antibody and stained green using 
anti-mouse Alexafluor 488 as secondary antibody. Ubiquitin was detected 
using rabbit anti-HA primary antibody and stained red using anti-rabbit 
Alexaflour 568 as secondary antibody. Hoescht 32258 was used for staining 
nuclei. Confocal microscopy images were collected at 63X objective lens, with 
scale bars as indicated. Transfected E396X mutant commonly showed a diffuse 
staining pattern which did not co-localise with ubiquitin. Rarely cytoplasmic 
bodies were also observed for E396X mutant polyHis-FLAG-p62, as shown in 
Figure 4.15. 
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Figure 4.15: Co-localisation of E396X mutant polyHis-FLAG-p62 and 
HA-ubiquitin in U20S cells and their cellular phenotypes (part 2) 
 
E396X mutant polyHis-FLAG-p62 and HA-ubiquitin were co-transfected into 
U2OS cells, which after ~40 hours were fixed with formaldehyde. p62 was 
detected using mouse anti-p62 as primary antibody and stained green using 
anti-mouse Alexafluor 488 as secondary antibody. Ubiquitin was detected 
using rabbit anti-HA primary antibody and stained red using anti-rabbit 
Alexaflour 568 as secondary antibody. Hoescht 32258 was used for staining 
nuclei. Confocal microscopy images were collected at 63X objective lens, with 
scale bars as indicated. This rare cellular phenotype involved miniature 
cytoplasmic bodies but only very occasionally, which did not co-localise with 
ubiquitin. 
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Figure 4.16: Co-localisation of G425R mutant polyHis-FLAG-p62 and 
HA-ubiquitin in U20S cells and their cellular phenotypes 
 
G425R mutant polyHis-FLAG-p62 and HA-ubiquitin were co-transfected into 
U2OS cells, which after ~40 hours were fixed with formaldehyde. p62 was 
detected using mouse anti-p62 as primary antibody and stained green using 
anti-mouse Alexafluor 488 as secondary antibody. Ubiquitin was detected 
using rabbit anti-HA primary antibody and stained red using anti-rabbit 
Alexaflour 568 as secondary antibody. Hoescht 32258 was used for staining 
nuclei. Confocal microscopy images were collected at 63X objective lens, with 
scale bars as indicated. The G425R mutant showed co-localisation with 
ubiquitin in some cells, although reduced co-localised with ubiquitin (relative 
to wild type) was also sometimes noted as indicated by the arrows of the first 
row of the images. In general G425R mutant polyHis-FLAG-p62 exhibited 
similar cellular phenotypes to wild type p62 (in this figure medium and large 
cytoplasmic bodies are shown but the other cellular phenotypes were also 
evident). This mutant also exhibited a semi-diffuse staining pattern in a few 
cells as evident from the images of the first and third rows. 
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Figure 4.17: Co-localisation of P392L mutant polyHis-FLAG-p62 and 
HA-ubiquitin in U20S cells and their cellular phenotypes 
 
P392L mutant polyHis-FLAG-p62 and HA-ubiquitin were co-transfected into 
U2OS cells, which after ~40 hours were fixed with formaldehyde. p62 was 
detected using mouse anti-p62 as primary antibody and stained green using 
anti-mouse Alexafluor 488 as secondary antibody. Ubiquitin was detected 
using rabbit anti-HA primary antibody and stained red using anti-rabbit 
Alexaflour 568 as secondary antibody. Hoescht 32258 was used for staining 
nuclei. Confocal microscopy images were collected at 63X objective lens, with 
scale bars as indicated. P392L mutant polyHis-FLAG-p62 strongly co-localised 
with HA-ubiquitin. This mutant exhibited very similar cellular phenotypes to 
wild type p62 (in this figure, medium and large cytoplasmic bodies are shown, 
but the other cellular phenotypes were also evident). 
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The various cellular phenotypes of cells co-transfected with A381V mutant 
polyHis-FLAG-p62 and HA-ubiquitin were very similar to those associated with 
wild type p62 (Figures 4.18 and 4.19), with strong co-localisation of staining. 
However, more detailed visual assessments suggested that larger cytoplasmic 
bodies may be more commonly associated with the A381V mutant than the 
wild type sequence, which would be consistent with earlier investigations 
which concluded that P392L and P387L mutants formed larger cytoplasmic 
bodies than wild type p62 (Leach et al., 2006); this is investigated further in 
Section 4.5. 
 
The D335E mutant also showed similar cellular phenotypes to those of wild 
type p62, although notably few very large cytoplasmic bodies were observed, 
with infrequent observation of the rare phenotypes associated with the wild 
type sequence (Figure 4.20). Again, strong co-localisation of p62 and ubiquitin 
staining was noted. 
  
Notably, all transfected cells that contained smaller cytoplasmic bodies 
P2), regardless of p62 sequence, were noted to contain more rounded 
bodies than cells with larger cytoplasmic bodies. 
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Figure 4.18: Co-localisation of A381V mutant polyHis-FLAG-p62 and 
HA-ubiquitin in U20S cells and their cellular phenotypes (part 1) 
 
A381V mutant polyHis-FLAG-p62 and HA-ubiquitin were transfected into U2OS 
cells, which after ~40 hours were fixed with formaldehyde. p62 was detected 
using mouse anti-p62 as primary antibody and stained green using anti-mouse 
Alexafluor 488 as secondary antibody. Ubiquitin was detected using rabbit 
anti-HA primary antibody and stained red using anti-rabbit Alexaflour 568 as 
secondary antibody. Hoescht 32258 was used for staining nuclei. Confocal 
microscopy images were collected at 63X objective lens, with scale bars as 
indicated. A381V mutant polyHis-FLAG-p62 co-localised strongly with HA-
ubiquitin. 
 
Similar to the wild type sequence, three major cellular phenotypes were 
observed to be associated A381V mutant polyHis-FLAG-p62: 
 
A) Small rounded cytoplasmic bodies. 
B) Medium rounded cytoplasmic bodies. 
C) Large semi-rounded cytoplasmic bodies. 
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Figure 4.19: Co-localisation of A381V mutant polyHis-FLAG-p62 and 
HA-ubiquitin in U20S cells and their cellular phenotypes (part 2) 
 
A381V mutant polyHis-FLAG-p62 and HA-ubiquitin were transfected into U2OS 
cells, which after ~40 hours were fixed with formaldehyde. p62 was detected 
using mouse anti-p62 as primary antibody and stained green using anti-mouse 
Alexafluor 488 as secondary antibody. Ubiquitin was detected using rabbit 
anti-HA primary antibody and stained red using anti-rabbit Alexaflour 568 as 
secondary antibody. Hoescht 32258 was used for staining nuclei. Confocal 
microscopy images were collected at 63X objective lens, with scale bars as 
indicated. A381V mutant polyHis-FLAG-p62 co-localised strongly with HA-
ubiquitin.  
 
 
Similar to the wild type sequence, three rarer irregular cytoplasmic structures 
observed for A381V mutant polyHis-FLAG-p62 were: 
 
D) Perinuclear structures. 
E) Multiple connected bodies. 
F) Diffuse staining. 
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Figure 4.20: Co-localisation of D335E mutant polyHis-FLAG-p62 and 
HA-ubiquitin in U20S cells and their cellular phenotypes 
 
D335E mutant polyHis-FLAG-p62 and HA-ubiquitin were co-transfected into 
U2OS cells, which after ~40 hours were fixed with formaldehyde. p62 was 
detected using mouse anti-p62 as primary antibody and stained red using 
anti-mouse Alexafluor 568 as secondary antibody. Ubiquitin was detected 
using rabbit anti-HA primary antibody and stained green using anti-rabbit 
Alexaflour 488 as secondary antibody. Hoescht 32258 was used for staining 
nuclei. Confocal microscopy images were collected at 63X objective lens, with 
scale bars as indicated. D335E mutant polyHis-FLAG-p62 strongly co-localised 
with HA-ubiquitin. This mutant displayed a similar range of cellular phenotypes 
to the wild type protein (in this figure medium and large cytoplasmic bodies 
are shown, but the other cellular phenotypes were also evident). Although the 
D355E mutant showed both the common and rarer p62 cellular phenotypes 
associated with wild type sequence, medium rounded cytoplasmic bodies were 
the predominant phenotype. 
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Finally, co-transfected HA-Ubiquitin with polyHis-FLAG-p62 in U2OS cells was 
also analysed using western blotting. Following transfection of cells for ~40 
hours, HA-ubiquitin was detected by western blotting with rabbit anti-HA. The 
immunoreactivity was associated with high molecular weight smears, 
consistent with covalent conjugation of HA-ubiquitin to other cellular proteins 
(Figure 4.21). 
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Figure 4.21: Immunoblot of HA-
ubiquitin in U2OS cells 
U2OS cells were transiently co-transfected 
with polyHis-FLAG-p62 and HA-Ubiquitin. 
After ~40 hours incubation cells were 
washed and then solubilised with gel 
loading buffer; resulting lysate was resolved 
by SDS PAGE and analysed by western 
blotting (anti-HA). The immunoreactivity is 
associated with high molecular weight 
smears, consistent with covalent 
conjugation of HA-ubiquitin to other cellular 
proteins. 
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4.5 Quantification of the size of p62-positive and ubiquitin-positive 
cytoplasmic bodies 
 
Co-localisation analyses of proteins using confocal microscopy involves 
selection of two different coloured fluorescent probes and detection of the 
emission spectra of these probes in two different channels of a digital imager. 
Then a merged image, which forms a mixed colour, is used to assess the 
degree of the co-localisation by evaluating the brightness of the resultant 
mixed colour.  
 
In confocal microscopy, visual assessment is used commonly to compare the 
degree of co-localisation between proteins (French et al., 2008) but, visual 
assessment is highly subjective. Random co-localisation of two proteins in the 
same compartment does not imply actual co-localisation, because the 
compartments are not well separated spatially (Costes et al., 2004), which is 
caused by the limitation of the microscopes resolution and zooming levels. In 
addition, sometimes the signals might originate from outside the plane of 
interest (French et al., 2008), causing false co-localisation intensities.  
 
Considering these caveats, we initially tried to objectively quantify co-
localisation of polyHis-FLAG-p62 and HA-ubiquitin, using Volocity confocal 
imaging software from Improvision (version 4.2.0). However, we noted that 
the co-localisation measurements also resulted in considerable variation using 
this approach (the same images, analysed on different occasions, resulted in 
differing results). Subsequently, we sought alternative ways to analyse the 
polyHis-FLAG-p62 cytoplasmic bodies without considering the intensity of the 
co-localised fluorophores. This was best achieved using Leica confocal 
microscopy software to simply measure the area of p62 cytoplasmic bodies in 
confocal images of cells transfected with wild type or mutant polyHis-FLAG-
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p62. The areas of p62 structures were measured by drawing a polygram 
around a selected structure, which is defined as ROI: region of interest. These 
area measurements gave reproducible results (not shown) and allowed us to 
accurately determine if any of the p62 mutants were associated with more 
extensive cytoplasmic bodies than wild type p62, as indicated in other studies 
(Leach et al., 2006). 
 
The common rounded and semi-rounded cytoplasmic bodies (section 4.4) 
could now be classified based on their areas, as follows: 
A) Small rounded cytoplasmic bodies, having an area ranging from detection 
limit of the microscope to 5µm2. 
B) Medium rounded cytoplasmic bodies, having an average area from 5-
40µm2.  
C) Large semi-rounded cytoplasmic bodies, having an average area of 40µm2 
or greater. 
 
The rarer irregular cytoplasmic structures had more irregular shapes, therefore 
it was difficult to calculate their areas accurately, as calculations require 
drawing a continuous line around the area to be measured. Therefore, we 
omitted calculating the areas of these cellular phenotypes. 
 
Figure 4.22 is a representative example of area measurements of cytoplasmic 
bodies of wild type polyHis-FLAG-p62 and a selected PDB-associated mutant 
(A381V). Similar analyses were performed on the rest of the selected PDB-
associated mutants (P392L, G425R, D335E), in which they showed similar 
ranges of cellular phenotypes to the wild type sequence (not shown). Each of 
the missense mutations also previously noted to show similar ranges of 
cellular phenotypes to the wild type sequence (section 4.4). 
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In summary, our analyses confirmed that the polyHis-FLAG-p62 cytoplasmic 
bodies representing common cellular phenotypes associated with the selected 
PDB-associated missense mutations (A381V, P392L, G425R, D335E) had 
comparable areas to the cytoplasmic bodies formed by the wild type p62 
sequence. 
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Figure 4.22:  Area calculations of cytoplasmic bodies associated with 
wild type and A381V polyHis-FLAG-p62 
 
Leica confocal software was used to calculate the areas of wild type and 
A381V polyHis-FLAG-p62 cytoplasmic bodies in U20S cells co-transfected with 
HA-ubiquitin by drawing polygons matching the shapes of the p62 structures 
using a mouse and cursor (although the images were taken from cells co-
transfected with polyHis-FLAG-p62 with HA-ubiquitin, ubiquitin is omitted in 
the images, because the red colour of ubiquitin obscured the borders of the 
cytoplasmic bodies). All the images were taken at a fixed scanning zoom 
(2.3). Calculated areas for different regions of interest (ROI; separate 
medium rounded bodies) as indicated are presented, along with average 
areas. A, B and C represents small, medium and large p62 cytoplasmic bodies 
respectively as described in page 178. 
10µm 
1.11 
3.15 
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4.6 Further analysis of polyHis-FLAG-p62 cytoplasmic bodies  
 
 
As all of the polyHis-FLAG-p62 constructs (except the E396X mutant) formed 
various cytoplasmic bodies when transfected in U2OS cells, attempts were 
made to further characterise these structures inroder to understand their 
physiological significance. 
Earlier investigations of transfected p62 proteins showed that ectopic 
expression of p62 resulted in numerous rounded cytoplasmic bodies in the 
perinuclear region of human HeLa cells (Lamark et al., 2003; Biørkøy et al., 
2005). These p62 cytoplasmic bodies were classified to two populations: large 
immobile cytoplasmic bodies (>0.5µm) that were membrane-free structures 
and not related to endocytic vesicles (Biørkøy et al., 2005); and small rounded 
highly mobile cytoplasmic bodies (<0.3 µm), which were suggested to be late 
endosomes or lysosomes. In addition, the larger p62 bodies were also rarely 
observed in the nucleus (Biørkøy et al., 2005). Notably, all these p62 bodies 
were ubiquitin-positive, consistent with the interaction of ubiquitin and p62 
through its UBA domain (Biørkøy et al., 2005).  
 
Both PB1 and UBA domains of p62 were reported to be required for the 
formation of these cytoplasmic bodies (Biørkøy et al., 2005) and absence of 
either of the domains resulted in diffuse p62 localisation. Interestingly, a p62 
construct containing a fusion of only the two domains (PB1 and UBA) was still 
able to form the regular cytoplasmic bodies, which were indistinguishable from 
the cytoplasmic bodies formed by full length p62 constructs (Biørkøy et al., 
)XUWKHUDVLJQLILFDQWSRUWLRQRIS¶VF\WRSODVPLFVWUXFWXUHVWKH
smaller rounded highly mobile cytoplasmic bodies) were shown to represent 
autophagosomes or autolysosomes (Biørkøy et al., 2005). Aggregates 
containing ubiquitin and p62 (e.g. the large immobile membrane-free 
D335E p62 
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cytoplasmic bodies) might also occasionally be engulfed in autophagosomes 
without delivery to the lysosomes, indicating a possible protective role of 
autophagy for these aggregates (Shvets et al., 2008).   
 
Indeed more detailed analyses revealed that cytoplasmic p62 might be either 
part of membrane-IUHHDJJUHJDWHVFDOOHG³VHTXHVWRVRPHV´RUGRXEOH
membrane structures, which were indicative of autophagosomes (Biørkøy et 
al., 2005). Interestingly, p62 is also itself degraded by autophagy (Biørkøy et 
al., 2005) and autophagic degradation of polyubiquitylated proteins is 
dependent on  p62 interaction with polyubiquitylated proteins via the UBA 
domain of p62, self oligomerisation of p62 through its PB1 domain and further 
interaction of p62 with LC3 (Biørkøy et al., 2005; Pankiv et al., 2007). 
Notably, the interaction between p62 and LC3 is direct, involving the LC3-
interaction region (LIR), and although a conservative change, the D335E 
missense mutation is located within the LIR. 
 
$VDQH[WHQVLRQRI%L¡UN¡\¶VVWXG\ZHDOVRLQYHVWLJDWHGWKHUROHRISRO\+LV-
FLAG-p62-containing cytoplasmic bodies in autophagy and studied the 
interaction of transfected proteins with co-transfceted tdTomato-LC3 using 
confocal microscopy. Here, tdTomato-LC3 is used as an autophagic marker: 
this autophagic marker is the LC3-II form, which is tightly associated with the 
autophagosomal membrane (Biørkøy et al., 2005) and detection is achieved 
with the red fluorescent tdTomato protein. These co-localisation studies also 
allowed us to investigate effects of the D335E mutation on the recruitment of 
p62 to LC3-positive autophagosomes. 
 
Before investigating the co-localisation between wild type polyHis-FLAG-p62 
and tdTomato-LC3, subcellular localisation of the latter alone was first 
investigated in U2OS cells. tdTomato-LC3 was transiently transfected into 
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U2OS cells, which were fixed after ~40 hours with formaldehyde, then the 
cells were visualised using a Leica confocal microscope. Singly transfected 
tdTomato-LC3 showed a diffuse phenotype in U2OS cells and distributed 
evenly in the cytoplasm and the nucleus (Figure 4.23). 
 
Later, we investigated the co-localisation of wild type polyHis-FLAG-p62 and 
tdTomato-LC3. U2OS cells were transiently co-transfected with wild type 
polyHis-FLAG-p62 and tdTomato-LC3 and fixed after ~40 hours with 
formaldehyde. Mouse anti-p62 was used as a primary antibody for probing p62 
and anti-mouse Alexafluor 488 was used as a secondary antibody. 
Endogenous fluorescence of tdTomato was directly detected. Wild type 
polyHis-FLAG-p62 co-localised strongly with tdTomato-LC3 (Figure 4.24) and 
co-transfection of polyHis-FLAG-p62 with tdTomato-/&FKDQJHGWKH/&¶V
cellular phenotype from a diffuse pattern to rounded cytoplasmic bodies, 
suggesting that the p62 and ubiquitin-positive structures previously noted 
(Section 4.4) are likely to represent autophagosomes. Occasionally, wild type 
polyHis-FLAG-p62 formed a shell surrounding tdTomato-LC3 structures, 
consistent with previous reports (Pankive et al., 2007) DQGZLWKS¶VUROHLQ
autophagosome formation. 
 
Another possibility to explain the formation of p62/LC3-containing cytoplasmic 
bodies is that p62 polymerisation, through its PB1 domain, with other p62 
monomers (or with other proteins containing PB1 domain), produces polymers 
VWUXFWXUHGLQDµEDFNWRIURQW¶PDQQHU:LOVRQet al., 2003). Therefore, we 
checked that the observed p62 cytoplasmic bodies were not simply aggregates 
of p62 polymers. Interestingly, although the UBA domain of p62 is not 
required for p62 polymerisation (Leach et al., 2006) the E396X deletion 
mutant (which lacks the whole UBA domain but contains the LIR) was still 
unable to form p62/LC3-containing cytoplasmic bodies, thereby confirming 
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that the observed polyHis-FLAG-p62 cytoplasmic bodies were not simply p62 
polymers. 
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Figure 4.23: tdTomato-LC3 localisation in U2OS cells 
 
tdTomato-LC3 was transfected into U2OS cells, which after ~40 hours were 
fixed with formaldehyde. tdTomato is a red fluorescent protein and 
endogenous fluorescence was detected directly. Hoescht 32258 was used for 
staining nuclei. Confocal microscopy images were collected at 63X objective 
lens, with scale bars as indicated. tdTomato-LC3 showed a diffuse staining 
pattern with even distribution in the cytoplasm as well as in the nucleus.  
Small rounded dot-like structures are likely to represent autophagosomes. 
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Figure 4.24: Co-localisation of tdTomato-LC3 and with wild type 
polyHis-FLAG-p62 in U20S cells  
 
Wild type polyHis-FLAG-p62 and tdTomato-LC3 were co-transfected into U2OS 
cells, which after ~40 hours were fixed with formaldehyde. p62 was detected 
using mouse anti-p62 as primary antibody and stained green using anti-mouse 
Alexafluor 488 as secondary antibody. Endogenous fluorescence of tdTomato 
was detected directly. Hoescht 32258 was used for staining nuclei. Confocal 
microscopy images were collected at 63X objective lens, with scale bars as 
indicated. Wild type polyHis-FLAG-p62 co-localised strongly with tdTomato-
LC3. Occasionally, wild type polyHis-FLAG-p62 formed a shell surrounding 
tdTomato-LC3-containing structures. The embedded square of the last image 
is presented without nuclear staining for improved visualisation.  
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4.6.1 Co-localisation studies of D335E mutant polyHis-FLAG-p62 with 
tdTomato-LC3 in U20S cells 
 
In our in vitro ubiquitin-binding assays (Chapter 3), the PDB-associated D335E 
mutant of p62 retained its full ubiquitin-binding activity at both pH7.5 and 
pH6.5. Studying the effects of this mutation on other cellular functions of p62 
may provide further clues to whether the D335E substitution is a bona fide 
mutation or a rare polymorphism. Since D335 is located within the LIR of p62 
(residues 321-342) (Pankiv et al., 2007), we speculated that the D335E 
change may affect the interaction between p62 and LC3.  
 
Accordingly, we studied the co-localisation patterns between D335E mutant 
polyHis-FLAG-p62 and tdTomato-LC3. U2OS cells were transiently co-
transfected with D335E mutant polyHis-FLAG-p62 and tdTomato-LC3, and 
fixed with formaldehyde. Mouse anti-p62 was used as a primary antibody for 
probing p62 and then anti-mouse Alexafluor 488 was used as a secondary 
antibody; tdTomato fluorescence was detected directly. 
 
D335E mutant polyHis-FLAG-p62 co-localised with tdTomato-LC3 and 
exhibited similar co-localisation patterns to wild type polyHis-FLAG-p62 and 
tdTomato-LC3. Both p62 constructs (wild type and D335E) co-localised with 
LC3, suggesting that the D335E variant was still able to produce 
autophagosomes, and the change did not affect the normal co-localisation 
patterns between p62 and LC3. Occasionally the D335E mutant, like wild type 
p62, formed a shell around the LC3-containing structures (Figure 4.25).  
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Figure 4.25 Co-localisation of tdTomato-LC3 and with D335E mutant 
polyHis-FLAG-p62 in U20S cells 
 
D335E mutant polyHis-FLAG-p62 and tdTomato-LC3 were co-transfected into 
U2OS cells, which after ~40 hours were fixed with formaldehyde. p62 was 
detected using mouse anti-p62 as primary antibody and stained green using 
anti-mouse Alexafluor 488 as secondary antibody. Endogenous fluorescence of 
tdTomato was detected directly. Hoescht 32258 was used for staining nuclei. 
Confocal microscopy images were collected at 63X objective lens, with scale 
bars as indicated. D335E mutant polyHis-FLAG-p62 co-localised strongly with 
tdTomato-LC3, showing a similar co-localisation pattern to wild type p62 and 
tdTomato-LC3. Occasionally, D335E mutant polyHis-FLAG-p62 formed a shell 
surrounding tdTomato-LC3-containing structures.  
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4.7 Discussion 
  
Earlier studies showed that transfected wild type p62 co-localised strongly with 
ubiquitin in HEK293 cells (Biørkøy et al., 2005); therefore, we sought to 
extend these studies and investigate the co-localisation of selected PDB-
associated p62 mutants and ubiquitin. In addition, we hoped to develop a 
more physiologically relevant (cell-based) model to study p62-ubiquitin 
interactions, in improvement to our in vitro ubiquitin-binding assays (Chapter 
3). 
  
In our study, wild type polyHis-FLAG- p62 was found to co-localise with HA-
ubiquitin, consistent with the in vitro binding data, whilst the E396X truncating 
mutant showed little or no co-localisation with ubiquitin, consistent with earlier 
studies that showed a requirement for the UBA domain to achieve co-
localisation in cells (Biørkøy et al., 2005). The remainder of the PDB-
associated p62 mutations analysed - P392L, A381V, D335E - also showed 
strong co-localisation with ubiquitin, with the exception of the G425R mutant, 
which showed reduced co-localisation with ubiquitin.  
 
These co-localisation patterns between the various p62 constructs and 
ubiquitin indicate that there is no simple correlation between the in vitro 
ubiquitin-binding assay and co-localisation of p62/ubiquitin in transiently 
transfected cells. For example, in contrast to our in vitro ubiquitin-binding 
assay, in which the G425R, P392L and A381V mutants all showed impaired 
ubiquitin-binding function (albeit only partial loss at pH6.5 for the A381V 
mutant), these selected mutants retained strong co-localisation with ubiquitin 
in transfected cells. In contrast, the co-localisation patterns of the D335E and 
E396X PDB-associated p62 mutants and ubiquitin were consistent with their 
ubiquitin-binding properties obtained from in vitro ubiquitin-binding assay, in 
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which the former retained full ubiquitin-binding, whilst the latter showed 
complete loss of ubiquitin-binding. This inconsistency between the two assays 
may in part be caused by experimental limitations associated with the confocal 
microscopy studies (see Section 4.7.1). To remove bias from subjective visual 
assessment in confocal microscopy, we attempted to quantify co-localisation of 
the fluorophores of p62 and ubiquitin, but these results were also variable 
probably due to uncontrollable factors within the confocal analysis (see section 
4.7.1).  
  
Following our failure to quantify the co-localisation intensities between p62 
and ubiquitin staining, we further investigated the various cellular phenotypes 
associated by both wild type polyHis-FLAG-p62 and the selected PDB-
associated mutants. In summary, the PDB-associated mutants showed a 
similar subcellular localisation to the wild type sequence, with the exception of 
the E396X mutant which had a diffuse staining pattern, indicating that the 
presence of a UBA domain (be it functional or defective with respect to 
ubiquitin-binding) is required for the formation of p62-containing cytoplasmic 
bodies.  
 
We went on to classify the different phenotypes of these p62 cellular bodies 
into two types: first, common rounded and semi-rounded cytoplasmic bodies, 
which in turn were subdivided to three subgroups ranging in their average 
area from the detection limit of the microscope to 40µm2 or greater; and 
second, rarer irregular cytoplasmic structures, which again could be divided to 
three subgroups (perinuclear structures, multiple connected bodies and diffuse 
structures). 
 
In contrast to a study by Leach et al., we could not confirm that the A381V 
mutant nor the selected PDB-associated p62 missense mutants analysed 
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formed larger cytoplasmic bodies than the wild type sequence. Several 
experimental differences might account for the discrepancies between our 
results and those of the Leach study, as they used a different cell line 
(HEK293), and an EGFP-tagged protein. In addition, certain experimental 
conditions, which are important in the formation of p62-containing cytoplasmic 
bodies, such as time of transfection, plasmid concentration, relative protein 
expression levels, and method of quantification of the cytoplasmic bodies were 
disregarded or not reported in their study. 
  
Interestingly, our results were also in opposition to the observation that 
ubiquitin-binding of p62 is required for the formation of its cytoplasmic bodies 
(Biørkøy et al., 2005), as the P392L and G425R mutants impaired ubiquitin-
binding in vitro ((Cavey et al., 2005) and confirmed in Chapter 3) however, 
these two missense mutants still formed various cytoplasmic bodies; notably, 
only the truncated UBA domain mutant of p62 (E396X) did not form 
cytoplasmic bodies in our experiments. However, it should be noted that 
although the P392L and G425R mutants present as complete loss of binding 
function in in vitro pull-down assays, in fact in reality they do retain some 
ubiquitin-binding activity (including in vivo) at a level (Kd) that is undetectable 
in the assays. Overall these results indicate the requirement of UBA domain, 
but not necessarily ubiquitin-binding, for the formation of p62-containing 
cytoplasmic bodies. In addition, it should be considered that p62, through its 
UBA domain, would interact with non-ubiquitin partners, which might be 
UHTXLUHGIRUWKHIRUPDWLRQRIS¶VF\WRSODVPLFERGLHVDQGWKHVHLQWHUDFWLRQV
could be maintained in G425R and P392L mutants (Najat et al., 2009). 
  
We presume that some of the p62-containing cytoplasmic bodies observed in 
our cells represent autophagosomes, as wild type polyHis-FLAG-p62 co-
localised with LC3, consistent with autophagic clearance of p62 along with 
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polyubiquitylated proteins (Biørkøy et al., 2005). Notably, other studies using 
live cell imaging indicate these cytoplasmic bodies appear to grow by fusion, 
and the various sizes of p62-containing cytoplasmic bodies might represent 
accumulated proteins associated with different components/stages of 
autophagy machinery (Waters et al., 2009). Although the exact relationship 
between autophagy and bone remodelling has not been investigated yet, these 
results indicate a possible role of autophagy in PDB, obviously, further 
research is needed in this area (Najat et al., 2009).  
  
The PDB-associated D335E variant of p62, which is located within the LIR, did 
not appear to disturb the interaction between p62 and LC3 (at least in 
transfected cells), as this mutant showed strong co-localisation with LC3. 
Using the in vitro ubiquitin-binding assay (Chapter 3), the D335E mutant 
retained its ubiquitin-binding function. Collectively these data suggest that the 
D335E variant did not affect two functionally-relevant cellular interactions of 
p62, which might be because the D335E change is conservative, substituting 
one acidic side chain for another, thereby only causing weak effects on the 
overall binding between p62 and LC3. Another possibility is that D335E may 
represent a rare polymorphism rather than disease-associated mutations, as 
this change was found only in one Italian patient. 
 
In summary, the selected PDB-associated p62 mutants (except E396X) were 
indistinguishable from wild type p62 in our co-transfection experiments, as 
they in general co-localised with ubiquitin in a similar manner to the wild type 
protein, and also formed various cytoplasmic bodies with similar cellular 
phenotypes/sizes to wild type p62. Interestingly, the p62 cytoplasmic bodies 
were presumed to be autophagosomes, which was supported by the co-
localisation of wild type p62 with LC3. 
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Since the confocal analyses did not provide further support for the partial loss 
of ubiquitin-binding function associated with the A381V mutation suggested 
from the in vitro pull down assays (Chapter 3), we moved on to study the 
functional effects of this mutation on NF-Ȓ%VLJQDOOLQJ&KDSWHU 
  
4.7.1 Limitations of indirect immunofluorescence and 2D confocal 
laser scanning microscopy 
 
This approach has several limitations, because it depends on measuring the 
intensity of the emitted light from a fluorescent source, which in turn is 
dependent on several factors such as: labelling methods, sample preparation, 
washing stages, laser stability and the way the samples and the images were 
collected. These factors are difficult to control, especially between independent 
experiments, even with samples prepared in the same day (Alan R.Hibbs 1st 
Ed.). 
 
Technical limitations within the confocal microscope can also cause false co-
localisation results. For example, if the zoom level and the resolution of the 
scanning images are decreased the fluorescence might appear falsely co-
localised, because the imaging systems of the microscope cannot resolve small 
distances between very closely co-localised proteins (French et al., 2008). 
Another limitation is if the fluorophore is exposed to the laser for too long, 
bleaching can occur, although the exposure time can be decreased by 
collecting the images with less optical slices, or with a single optical slice. 
However, a single optical slice is thin and causes false labelling levels, 
therefore it is advisable to collect confocal images by comparing areas of a 
specimen as quickly as possible with smallest number of optical slices (Alan 
R.Hibbs 1st Ed.).  
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Obviously, co-localisation analyses of fluorophores using this approach can be 
misleading, and it was suggested that quantification of the fluorophore signals 
could give better estimation of the intensity of the co-localised fluorophores 
using commercial (Volocity) image analysis software. Unfortunately the 
intensity of the co-localised fluorophores was also found to be inconsistent in 
this case, consistent with previous studies on the quantification software 
(French et al., 2008). It is possible that the variability observed was caused by 
the software design, as Volocity depends on producing a scatter plot for a 
merged image composed of red, green and yellow pixels. Volocity calculates 
the co-localisation intensities by defining a colour threshold manually with a 
regular computer mouse, and this technique inevitably causes pixel loss. 
Despite these limitations and caveats, a semi-quantitative analysis was 
achieved, and work is still ongoing to improve the available quantification 
software (French et al., 2008) (Alan R.Hibbs 1st Ed.). 
  
In the future, other protein interaction methods should be used to obtain 
definitive measurements of the ubiquitin-binding properties of p62. For 
example, studying protein interaction with Fluorescence resonance energy 
transfer (FRET) might overcome the limitations of confocal microscopes, as 
FRET investigates two molecules within several nanometres, which is sufficient 
to evaluate physical molecular interactions. 
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CHAPTER 5 
 
 
Effects of PDB-mutant p62 proteins on NF-Ȓ%
signalling 
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Chapter 5: Effects of PDB-mutant p62 proteins on NF-Ȓ%VLJQDOOLQJ 
 
5.1 Overview 
 
Earlier attempts in our study to investigate the changes exerted by the non-
UBA domain A381V mutation on the ubiquitin-binding properties of p62 were 
inconclusive. For example, using in vitro ubiquitin-binding assays the A381V 
mutation was found to be associated with RQO\YHU\VXEWOHFKDQJHVLQS¶V
ubiquitin-binding properties (Chapter 3), and the co-localisation pattern of 
transfected A381V mutant p62 with ubiquitin was indistinguishable to that of 
wild type p62 in U20S cells (Chapter 4). A further sensitive method for 
studying protein-protein interactions, 2D-HSQC NMR, proved to have limited 
utility for studying the effects of the A381V mutation on protein function 
(Chapter 3). 
 
As investigations have shown that other PDB-associated p62 mutations known 
to be associated with loss of ubiquitin-binding function result in increased 
(relative to wild type sequence) NF-ǉ%DFWLYDWLRQDQGRVWHRFODVWDFWLYLW\in 
vitro (Yip et al., 2006; Rea et al., 2006), and that selective inhibition of NF-Ȓ%
signalling inhibits osteoclastogenesis (Jimi et al., 2004), we sought to study 
the effects of the A381V mutation (and other selected PDB-associated 
mutations) on NF-ǉ%VLJQDOOLQJDVDVXUURJDWHRISURWHLQIXQFWLRQ6SHFLILFDOO\
we used three different approaches to investigate the effects of p62 (and its 
mutation) on NF-ǉ%VLJQDOOLQJ,QLWLDOO\OXFLIHUDVHUHSRUWHUDVVD\VZHUHFKRVHQ
to investigate the gross functional effects of the A381V mutation on basal and 
induced p62-dependent NF-Ȓ%VLJQDOOLQJLQ+(.FHOOV 
p62 has been reported to negatively regulate NF-ǉ%VLJQDOOLQJWKURXJKLWV8%$
domain-dependent interaction with TRAF6 (Xu et al., 2008) and wild type p62 
repressed NF-Ȓ%DFWLYDWLRQUHODWLYHWRHPSW\YHFWRUFRQWUROVLQUHSRUWHUDVVD\V
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(Rea et al., 2006). However, the precise mechanism by which p62 exerts its 
effects on NF-ǉ%SDWKZD\LVVWLOOQRWFOHDUDQGLQWHUDFWLRQRISZLWKRWKHU
elements of the RANK/NF-ǉ%SDWKZD\PLJKWFRQWULEXWHWRWKLVQHJDWLYH
regulatory function (Figure 5.1). Indeed, another protein (CYLD), which is a 
deubiquitinating (DUB) enzyme, negatively regulates NF-ǉ%VLJQDOOLQJWKURXJK
deubiquitylation of TRAF6 (Jin et al., 2008) (Figure 5.1.1). Interestingly, p62 
mediates the interaction of CYLD with TRAF6 and notably, a p62 construct 
lacking the UBA domain failed to interact with CYLD (Wei et al., 2008). 
Therefore, we used indirect immunofluorescence staining and confocal 
microscopy to study the effects of the A381V mutation (and other PDB-
associated mutations) on the p62-CYLD interaction in transfected cells. 
 
Finally, since p62 has been shown to form a complex with IKK (Zhang et al. 
2005) a downstream effector of RANK, and may also regulate the 
XELTXLWLQDWLRQRI,..Ǆ1(02DFRPSRQHQWRIWKH,..FRPSOH[0DUWLQet al., 
2006), we also investigated the effects of p62 (and its mutation) on the p62-
NEMO interaction. Here, we tested the speculative hypothesis that PDB-
associated p62 mutations might disturb autophagic degradation of NEMO, as 
NEMO is degraded by autophagy (Li et al., 2006), and p62 mediates 
autophagic degradation of ubiquitylated proteins (Biørkøy et al., 2005) (Figure 
5.1.2). Specifically the hypothesis was tested by assessing the effects of 
ectopic p62 expression in U2OS cells on the expression levels of endogenous 
NEMO. 
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Figure 5.1: Overview of the RANK-NF-Ȓ%VLJQDOOLQJSDWKZD\ 
In osteoclasts NF-ǉ%VLJQDOOLQJLVDFWLYDWHGE\5$1.-L and antagonised by 
OPG. Normally, I-ǉ%VHTXHVWHUV1)-ǉ%LQWKHF\WRSODVPDQGXSRQ
phosphorylation (and degradation of I-ǉ%1)-ǉ%LVUHOHDVHGWRWKHQXFOHXVWR
activate gene expression. I-ǉ%GHJUDGDWLRQLVWULJJHUHGE\WKHDFWLYDWHG,..
complex (composed of IKKĮ,..ǃDQG,..Ǆ>1(02@ZKLFKLQWXUQLV
activated by two different complexes, the first of which is composed of TAB1-
TAB2-TAK1 and the second composed of p62-aPKC-TRAF6. Ubiquitylation is 
required at various stages for NF-ǉ%DFWLYDWLRQ&</'GHXELTXLW\ODWHV.-
linked polyubiquitylated proteins in the pathway (e.g. TRAF6, NEMO) and 
hence negatively regulates NF-ǉ%VLJQDOOLQJ$DQG%UHSUHVHQWHFWRSLFSDV
in reporter assays) expression, which might cause competition for ubiquitin 
and hence inhibiting the NF-Ȓ%SDWKZD\7KH,..FRPSOH[LQFOXGLQJ1(02LV
selectively degraded by autophagy (Qing et al., 2006). LC3 (light chain 3) is 
an autophagic marker.  
 
*1 and 2 are illustrated in more detail in Figures 5.1.1 and 5.1.2 respectively. 
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Figure 5.1.1: Negative regulation of NF-ǉ%VLJQDOOLQJE\&</' 
Interaction of RANK-L with RANK induces K63-linked polyubiquitylation of 
TRAF6, causing induction of NF-ǉ%DQGH[SUHVVLRQRIJHQHVUHTXLUHGIRU
osteoclastogenesis/osteoclast activity. p62 and CYLD also regulate RANK-L 
signalling as they control ubiquitylation of TRAF6. CYLD deubiquitylates TRAF6 
and p62 scaffolds this process, hence CYLD negatively regulate RANK-NF-ǉ%
signalling. CYLD expression is also induced by NF-ǉ%LQDIHHGEDFNORRS 
   
 
 
Reproduced from Jin et al., 2008 
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Figure 5.1.2: p62-dependent autophagic degradation of ubiquitylated 
proteins 
 
Autophagy starts with isolation and formation of a double membrane structure 
(autophagosome) which engulfs the materials for degradation. Ubiquitylated 
proteins (such as NEMO) may be delivered to the autophagy machinery by p62 
to be degraded at the later steps of autophagy, through fusion of the 
autophagosomes with lysosomes.  p62 interacts with LC3-PE through its LIR 
(residues 321-342).  
PE: Phosphatidylethanolamine (lipid modification of LC3 which anchors the 
protein to the autophagosome) 
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Chapter 5 - Part I 
 
 
Investigation of regulation of NF-ǉ%DFWLYDWLRQE\
PDB-mutant p62 proteins using luciferase 
reporter assays 
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5.2 Investigation of regulation of NF-ǉ%DFWLYDWLRQE\3'%-mutant p62 
proteins using luciferase reporter assays 
 
5.2.1 Introduction 
 
Several previous studies investigated the effects of transfecting different p62 
constructs on NF-ǉ%DFWLYDWLRQXVing cell-based luciferase reporter assays (e.g. 
Rea et al., 2006) and concluded that certain PDB-associated p62 mutations 
(all associated with loss of ubiquitin-binding function) increased NF-ǉ%
activation relative to wild type p62, and wild type p62 repressed NF-ǉ%
activation relative to empty vector controls. We extended these reporter assay 
studies to determine the effect of the A381V non-UBA domain mutation (and 
other PDB mutations) on NF-Ȓ%DFWLYDWLRQ 
 
Reporter assays have been used widely to monitor transcriptional activities, 
because they are relatively easy to perform and give accurate results. A 
reporter gene is a recombinant gene, which is placed downstream of the 
promoter region of an expression vector. An ideal reporter gene is not 
expressed endogenously by the selected cell type of the study. 
 
In our study the expression vector was pGL2 (Promega), the promoter was 
composed of a consensuses sequence (IL8) which is recognized by NF-ǉ%
transcription factors. The structural gene region of the pGL2 expression vector 
encodes the firefly luciferase enzyme and hence expression of luciferase is 
regulated by the IL8 promoter; therefore, the amount of luciferase enzyme is 
proportional to the activity of the IL8 promoter in the fused gene. Upon over-
expression of p62 constructs along with the reporter gene in HEK293 cells, NF-
ǉ%ZLOOEHGH-activated and prevented from interacting with the IL8 promoter 
in the reporter gene, which in turn leads to reduced expression of luciferase; 
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this technique serves as an indirect method to measure the activation levels of 
NF-ǉ%E\SYDULDQWV 
 
In the luciferase reporter assay, a chemiluminescent reaction results from 
mixing a luciferase substrate (Luciferin) with cell extracts containing luciferase 
expressed from the reporter. The amount of the emitted light is measured 
quantitatively with a luminometer (Reaction 1). The amount of the light 
produced from the reaction is directly proportional to the amount of luciferase 
enzyme produced by the cells, which in turn is regulated by the transcriptional 
activity of the gene of interest. 
 
 
Reaction 1: Monooxygenation of Luciferin (provided within the assay kit) is 
catalyzed by the enzyme (firefly) luciferase, which is expressed from HEK293 
cell lysates, and in the presence of magnesium ions, oxygen and excess ATP. 
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5.2.2 Measurements of basal NF-ǉ%DFWLYDWLRQXVLQJOXFLIHUDVH
reporter assays 
 
HEK293 cells were cultured in 12-well plates and co-transfected with 0.3µg per 
well of NF-ǉ%ILUHIO\OXFLIHUDVHUHSRUWHUFRQVWUXFWDQGJRIZLOGW\SHRU
various PDB mutant polyHis-FLAG-p62 pCDNA3.1 constructs (produced in 
Chapter 4), or empty pCDNA3.1 vector control. Luciferase activity was 
measured ~30 hours after co-transfection of the plasmids, using the Steady-
*OROXFLIHUDVHDVVD\V\VWHP3URPHJDDQGDFFRUGLQJWRWKHPDQXIDFWXUHU¶V
instructions. 
 
In this study, the E396X and P392L mutants were used as controls for the 
A381V mutant, as they both showed significant loss of ubiquitin-binding 
function when investigated with in vitro ubiquitin-binding assays (Chapter 3 
and (Cavey et al., 2005)). In addition, the P392L mutant was investigated in 
similar reporter assays in a previous study (Rea et al., 2006) 
 
Because the absolute luminescent signal is variable between independent 
experiments (although maximum care is taken to replicate the experiments 
with the same conditions small changes were inevitable such as in cell growth 
rate and temperature) an empty vector is used for the assay as a control, to 
normalise the results obtained from different experiments. In addition, to 
determine the transfection efficiency, in some experiments, cells were co-
WUDQVIHFWHGZLWKǋJRI5HQLOODOXFLIHUDVHFRQWUROSODVPLGS5/-CMV; 
Promega) and the firefly and Renilla luciferase activities were measured using 
the dual luciferase reporter assay system. There was no significant difference 
in the Renilla luciferase activity with the various p62 constructs; therefore, all 
results were expressed as percentage firefly luciferase activity compared with 
the empty vector control. 
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The A381V, P392L and E396X mutants were all found to be associated with 
increased basal NF-ǉ%DFWLYDWLRQUHODWLYHWRZLOGW\SHSDOWKRXJKDOO
constructs decreased NF-Ȓ%DFWLYDWLRQFRPSDUHGWRWKHHPSW\YHFWRUFRQWURO
(consistent with previous findings). The E396X truncating mutation was 
associated with the greatest level of NF-ǉ%DFWLYDWLRQDOWKRXJKERWKPLVVHQVH
mutations (P392L and A381V) also appeared to be associated with a greater 
signalling potential than wild type p62. Each experiment was performed in 
duplicate and the assay was repeated in three different occasions; the values 
obtained from the luminometer were expressed as percentage firefly luciferase 
activity compared to the empty vector control, then the data were transformed 
to [log10 %] data (as % data is not normally distributed). To determine if 
there was a statistical significance in the differences in NF-ǉ%DFWLYDWLRQ
between wild type p62 and PDB mutants, statistical tests was performed using 
DRQHZD\$129$ZLWK'XQQHWW¶VWHVWXVLQJ3ULVPVRIWZDUHYHUVLRQThe 
statistical analysis was performed by selecting a 95% confidence limit. Data 
for the E396X mutant showed P<0.01, and for the A381V and P392L mutants 
P<0.05, confirming the difference between the activation of basal NF-ǉB 
signalling for each mutant relative to wild type p62 was statistically significant 
(Figure 5.2). 
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Figure 5.2: Effects of PDB-mutant p62 proteins on basal NF-Ȓ%
signalling 
The effects of transfection of different polyHis-FLAG-p62 constructs with 
indicated PDB mutations on basal NF-ǉ%VLJQDOOLQJLQ+(.FHOOVZHUH
assessed using luciferase reporter assays. Note that although PDB mutant p62 
constructs (including the A381V mutant) activated NF-ǉ%VLJQDOOLQJPRUH
efficiently than wild type (WT), compared with empty vector control all p62 
constructs showed reduced activation, suggesting the mutations may be 
diminishing a repressive function of p62 with respect to NF-Ȓ%VLJQDOOLQJ
Experiments were performed in duplicate, and assays were repeated on three 
independent occasions. Data are presented as mean values ± SE, with p 
values indicating significance difference compared with WT. 
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5.2.3 Measurements of TNF-Į induced NF-ǉ%DFWLYDWLRQXVLQJ
luciferase reporter assays 
 
Effects of the p62 constructs on induced NF-ǉ%DFWLYDWLRQZDVPHDVXUHGXVLQJ
the same protocol for basal NF-ǉ%DFWLYDWLRQVHHEXWZLWKDGGLWLRQRI
25ng/ml of TNF-Į to the HEK293 cells 7 hours after co-transfection of the cells 
for 23 hours (again 0.3µg NF-ǉ%ILUHIO\OXFLIHUDVHUHSRUWHUFRQVWUXFWDQGJ
of wild type or PDB-mutant p62 pCDNA3.1 construct, or empty pCDNA3.1 
control, was used). As for basal signalling, transfection of wild type p62 and 
the PDB mutants (A381V, P392L, E396X) suppressed NF-ǉ%DFWLYDWLRQUHODWLYH
to the empty vector control. To compare the statistical significance of the 
changes exerted by each mutation relative to wild type p62, the results were 
DQDO\VHGZLWKRQHZD\$129$E\FKRRVLQJ'XQQHWW¶VVWDWLVWLFDOWHVWDQd using 
Prism software (version4). The statistical analysis was performed by selecting 
a 95% confidence limit (Figure 5.3). 
Data for the P392L and E396X mutants showed P values were <0.05, 
confirming the difference between the activation of induced NF-ǉB signalling 
for each of these mutant (relative to wild type p62) was statistically 
significant. However, data for the A381V mutant showed a P value >0.05, 
indicating in this case the increase in NF-ǉ%DFWLYDWLRQUHODWLYHWRZLOGW\SH
was not statistically significant.  
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Figure 5.3: Effects of PDB-mutant p62 proteins on TNF-Į induced NF-
Ȓ%VLJQDOOLQJ 
 
The effects of transfection of different polyHis-FLAG-p62 constructs with 
indicated PDB mutations on TNF-Į induced NF-ǉ%VLJQDOOLQJLQ+(K293 cells 
were assessed using luciferase reporter assays. The P392L and E396X mutants 
showed a statistically significant increase in their efficiency of activating NF-ǉ%
signalling, relative to wild type (WT), although the increase for the A381V 
mutant was not statistically significant. Experiments were performed in 
duplicate, and assays were repeated on three independent occasions. Data are 
presented as mean values ± SE, with p values indicating significance 
difference compared with WT. 
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5.2.4 polyHis-FLAG-p62 expression levels in luciferase reporter assays 
 
To confirm that changes in NF-ǉ%DFWLYDWLRQDVVRFLDWHGZLWKGLIIHUHQWS
constructs noted in the luciferase reporter assays was not caused by variations 
in ectopic p62 expression levels, lysates of HEK293 cells (used in the reporter 
assays) were analysed with western blotting (anti-FLAG), which confirmed 
relatively equal expression levels for the p62 variants (Figure 5.4). 
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Figure 5.4: Ectopic expression levels of polyHis-FLAG-p62 in HEK293 
cell lysates analysed in luciferase reporter assays  
 
HEK293 cells were co-transfected with polyHis-FLAG-p62 and NF-ǉ%ILUHIO\
luciferase reporter constructs for ~24 hours, then the cells were lysed 
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQVLQWKH6WHDG\-Glo luciferase assay 
system. Equal volumes of cell lysate were then analysed by western blotting 
(anti-FLAG). Representative blot (in this case from a basal signalling assay) 
indicates that the cell lysates show relatively similar expression levels of 
different p62 variants. 
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Interaction of PDB-mutant p62 proteins and CYLD 
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5.3 Interaction of PDB-mutant p62 proteins and CYLD 
 
5.3.1 Introduction  
 
In certain contexts, p62 also appear to function as a positive regulator of 
RANK-NF-ǉ%VLJQDOOLQJWKURXJKUHJXODWLRQRIDFDVFDGHWKDWOHDGs to 
phosphorylation and degradation of I-ǉ%WKHUHE\UHOHDVLQJ1)-ǉ%IURPWhe 
cytoplasm to the nucleus (Scheidereit, et al., 2006). However, in addition to 
its positive role, p62 also appears to have a negative role in regulating RANK-
NF-ǉ%VLJQDOOLQJGHPRQVWUDWHGLQHDUOLHUZRUNRQWKHIXQFWLRQRIS5HDet 
al., 2006). In addition, we confirmed in the previous section (see 5.2) that 
although transfected PDB-associated p62 mutants (A381V, P392L, E396X) 
activated basal NF-ǉ%VLJQDOOLQJUHODWLYHWRWKHZLOGW\SHVHTXHQFHLQIDFWDOO
constructs analysed repressed signaling relative to empty vector controls. 
Although the mechanism of this negative regulation is poorly understood, it 
may involve interaction of p62 with negative regulators of NF-ǉ%VLJQDOOLQJ
(Wei et al., 2008). One of these negative regulators of NF-ǉ%VLJQDOOLQJLVa 
DUB enzyme, CYLD, which appears to exert its effects through interactions 
with TRAF6, TRAF2 and NEMO (Kovalenco et al., 2003). Interestingly, p62 
through its C-terminal mediates the interaction between CYLD and TRAF6 (Wei 
et al., 2008); indeed co-immunoprecipitation assays showed that p62 deletion 
mutants lacking the UBA domain could not physically interact with CYLD (Wei 
et al., 2008). CYLD might specifically mediate the negative signalling function 
of p62 in the RANK-NF-ǉ%SDWKZD\E\GHXELTXLW\ODWLQJ.-polyubiquitylated 
TRAF6 (Wei et al., 2008) (Figure 5.1.1), thereby causing deactivation of 
signaling (Trompouki et al., 2003). Notably, the interaction between p62 and 
TRAF6 is not affected by expression levels of CYLD, and CYLD itself seems to 
be induced by NF-ǉ%H[SUHVVLRQDVSDUWRIDIHHGEDFNORRS-RQRet al., 2004) 
(Figure 5.1.1).  
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Based on these observations we attempted to assess the impact of PDB-
associated mutations on the p62-CYLD interaction using indirect 
immunofluorescence staining and confocal microscopy, with the rationale that 
mutant p62 may be less able to recruit CYLD to (ubiquitylated) TRAF6 and 
thus may account for its reduced ability to repress NF-ǉ%VLJQDOOLQJLQUHSRUWHU
assays.  
 
5.3.2 Co-localisation studies of wild type and PDB mutant polyHis-
FLAG-p62 with HA-CYLD 
 
To assess the effects of PDB-associated mutations on the interaction of p62 
and CYLD, co-localisation of co-transfected proteins in U20S cells was 
investigated using indirect immunofluorescence staining and confocal 
microscopy (in a similar manner to Chapter 4 where p62-ubiquitin interactions 
in transfected cells were investigated). For these experiments, polyHis-FLAG-
p62 and HA-CYLD constructs (the latter kindly provided by Dr. SC Sun, 
Houston) were used. Prior to the detailed co-localisation studies between p62 
and CYLD, transfected CYLD localisation alone (in the absence of transfected 
FLAG-p62) in U2OS cells was investigated to evaluate any effects of the 
selected PDB mutations on cellular phenotype. U2OS cells were transiently 
transfected with HA-CYLD for ~48 hours and fixed with formaldehyde. Rabbit 
anti-HA was used as a primary antibody for probing CYLD and then anti-rabbit 
Alexafluor 568 was used as a secondary antibody. Transfected HA-CYLD 
showed a diffuse distribution pattern in U2OS cells, and localised mainly in the 
cytoplasm, perinuclear area and occasionally in the nucleus (Figure 5.5).  
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Figure 5.5: Subcellular localisation of transfected HA-CYLD in U2OS 
cells 
 
U2OS cells were transiently transfected with a plasmid encoding HA-CYLD. 
After ~48 hours incubation the cells were fixed with formaldehyde. 
Transfected CYLD was probed using rabbit anti-HA as primary antibody and 
stained red using anti-rabbit Alexaflour568 as secondary antibody. Hoescht 
32258 was used for staining nuclei. The images were collected at 40X 
objective lens with scale bar as indicated. HA-CYLD showed a diffuse staining 
pattern in the cytoplasm and perinuclear region, and occasionally the nucleus 
(as in this representative image). 
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Next, HA-CYLD and polyHis-FLAG-p62 constructs were transiently co-
transfected in U2OS cells. p62 was probed with mouse anti-p62 as primary 
antibody and stained green using anti-mouse Alexafluor 488 as secondary 
antibody. CYLD was probed using rabbit anti-HA as primary antibody and 
stained red using anti-rabbit Alexafluor 568 as secondary antibody. 
Transfected CYLD showed some overlap of staining with each of the different 
p62 constructs tested (wild type, A381V, P392L and E396X mutants). 
However, in complete contrast to the findings in Chapter 4, when co-
transfected with CYLD all of the regular cytoplasmic p62 bodies were lost and 
instead p62 staining was consistently of a diffuse nature (Figure 5.6). Thus, 
these experiments revealed that CYLD expression appears to abrogate the 
formation of p62 cytoplasmic bodies, and therefore interaction of p62 with 
CYLD could not be compared to the common p62 cytoplasmic bodies. 
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Figure 5.6: Co-localisation of HA-CYLD with polyHis-FLAG-p62 in U20S 
cells 
 
polyHis-FLAG-p62 constructs as indicated were transiently co-transfected with 
HA-CYLD in U2OS cells. After ~48 hours cells were fixed with formaldehyde; 
p62 were probed using mouse anti-p62 as primary antibody and stained green 
using anti-mouse Alexafluor488 as secondary antibody. CYLD was probed 
using rabbit anti-HA as primary antibody and stained red using anti-rabbit 
Alexaflour568 as secondary antibody. Hoescht 32258 was used for staining 
nuclei. The images were collected at 40X objective lens with scale bars as 
indicated. In all transfected cells both p62 and CYLD had a diffuse staining 
pattern, CYLD was distributed in the cytoplasm and the nucleus, and p62 
cytoplasmic bodies were not evident. 
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Since CYLD expression appeared to abrogate the formation of p62 cytoplasmic 
bodies, structures that were commonly found to be ubiquitin-positive (Chapter 
4), we reasoned that protein ubiquitination may be required for the formation 
of these cytoplasmic bodies and that changes in cellular ubiquitination 
following CYLD transfection may be sufficient to prevent cytoplasmic body 
formation. To investigate this idea further, whole cell lysates of U2OS cells 
which have been transiently co-transfected with HA-CYLD and polyHis-FLAG-
p62 constructs were western blotted with anti-ubiquitin antibodies (Figure 
5.7). Endogenous ubiquitin showed a conjugated staining pattern (Figure 5.7) 
even when CYLD was expressed, suggesting that CYLD does not exert its 
effects on p62 cytoplasmic body formation by grossly affecting protein 
ubiquitination, but instead must manifest more subtle effects. The same blot 
was re-probed with anti-ǃ-actin, (Figure 5.7), in order to confirm equal loading 
of the U2OS cell lysates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
222 
 
 
 
 
Figure 5.7: Detection of endogenous conjugated ubiquitin in U20S 
cells co-transfected with polyHis-FLAG p62 and HA-CYLD  
 
U2OS cells were transiently co-transfected with polyHis-FLAG-p62 constructs 
as indicated (WT = wild type and A381V, P392L and E396X mutants) and HA-
CYLD for ~48hours, followed by subjecting whole cells lysates to SDS-PAGE 
and immunoblotting with anti-ubiquitin antibodies. Ubiquitin showed a 
characteristic conjugated staining pattern which was not significantly affected 
by CYLD expression. 
The bottom blot shows dHWHFWLRQRIHQGRJHQRXVǃ-actin in U20S cells co-
transfected with polyHis-FLAG-p62 and HA-CYLD. The blot, used to detect 
conjugated ubiquitin in U20S cells co-transfected with polyHis-FLAG-p62 and 
HA-CYLD, was re-probed with mouse anti-ǃ-actin antibodies confirming 
approximately equal loading of cell lysates.  
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Chapter 5 - Part III 
 
Interaction of PDB-mutant p62 proteins and NEMO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
224 
 
5.4 Interaction of PDB-mutant p62 proteins and NEMO 
 
5.4.1 Introduction 
 
In part I of this Chapter, changes in NF-ǉ%DFWLYDWLRQDVVRFLDWHGZLWK3'%
mutants of p62 were studied using luciferase reporter assays. These 
experiments showed that wild type p62 suppressed the activation of NF-ǉ%
compared to empty vector controls indicating that p62 may function as a 
negative regulator of NF-ǉ%VLJQDOOLQJDQGWKDWFHUWDLQ3'%PXWDQWV$9
P392L, E396X) exerted less of a repressive effect on signalling than wild type 
p62. As CYLD is a negative regulator of NF-ǉ%VLJQDOOLQJDQGLQWHUDFWVZLWK
S¶V&-terminus (containing the UBA domain), we then studied the effects of 
PDB mutations on the CYLD-p62 interaction (Chapter 5, Part II). However, 
unexpectedly we found that CYLD expression altered the cellular phenotype of 
p62-transfected cells such that p62 cytoplasmic bodies were no longer formed; 
consequently interaction of p62 with CYLD could not be reliably assessed using 
confocal microscopy. 
 
Therefore, in a final attempt to investigate the molecular mechanism by which 
p62 (and its PDB mutants) exerts its effects on NF-ǉ%VLJQDOOLQJSDWKZD\VZH
examined interactions with another important regulator of NF-ǉ%VLJQDOOLQJ
1(021(02,..ǄLVSDUWRIWKH,NDSSD%NLQDVH,..FRPSOH[ZKLFKLV
composed of two catalytic subunits (IKKĮ,..ǃDQGRQHUHJXODWRU\VXEXQLW
NEMO. N(02ELQGVWR,..ǃZKLFKLVQHFHVVDU\WRDFWLYDWH1)-ǉ%6FKHLGHUHLW
et al., 2006).  
 
We selected  NEMO specifically for this study because previous work showed 
that p62 is part of a complex composed of TRAF6, aPKC and IKK (Zhang et al.,  
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2005) and p62 interacts with NEMO and mediates its K63-linked 
polyubiquitylation through TRAF6 (Figure 5.1) (Martin et al., 2005). 
In addition, CYLD also regulates the K63-linked polyubiquitylation of NEMO 
(Kovalenko et al., 2003) and also interacts with NEMO as well as p62 (Figure 
5.1) (Courtious et al., 2008; Trompouki et al., 2003). Hence, we sought to 
assess the effects of PDB-associated mutations on the interaction of p62 
constructs with endogenous NEMO, using co-localisation of co-transfected 
proteins in U20S cells with immunofluorescence staining and confocal 
microscopy. 
 
A further way to study the effects of PDB-associated p62 mutations on NEMO 
homeostasis relates to the autophagic degradation of NEMO. IKK (including 
NEMO) is selectively degraded by autophagy and not through the proteasome 
system (Li et al., 2006) and since p62 is part of the autophagy machinery 
(Biørkøy et al., 2005) we speculated that one role of p62 may be to recruit 
NEMO to the autophagic machinery mediating its degradation. Our proposal 
was that PDB mutant p62 may be less efficient than wild type at recruiting 
NEMO to autophagosomes, thereby resulting in defective autophagic 
degradation of NEMO and hence a net activation of the IKK complex and NF-
ǉ%VLJQDOOLQJ6SHFLILFDOO\ZHLQLWLDOO\VRXJKWWo examine any effects of ectopic 
p62 expression on levels of endogenous NEMO in U20S cells. 
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5.4.2 Effects of expression of polyHis-FLAG-p62 on levels of 
endogenous NEMO in U20S cells 
 
In these experiments ectopic expression of polyHis-FLAG-p62 in U2OS cells 
was used to test the hypothesis that NEMO is degraded by p62-mediated 
autophagy and that PDB mutant p62 is less efficient in promoting this process. 
U2OS cells were transfected with different p62 constructs (wild type p62, 
A381V and E396X mutants) and incubated for ~48 hours, then cell lysates 
ZHUHLPPXQREORWWHGIRUERWKWUDQVIHFWHGSDQGHQGRJHQRXV1(02,..Ǆ
The NEMO blots showed that U2OS cells expressing different p62 constructs 
contained equal levels of endogenous NEMO protein (Figure 5.8), suggesting 
that expression of PDB mutants did not alter rates of NEMO degradation. 
Approximately equal expression of p62 variants was confirmed by re-probing 
the blots with anti-FLAG antibodies (not shown). 
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)LJXUH1(02,..ǄSURWHLQOHYHOVLQ826FHOOVWUDQVIHFWHGZLWK
polyHis-FLAG-p62 constructs 
 
U2OS cells transiently transfected with polyHis-FLAG-p62 constructs as 
indicated were incubated for ~48 hours. The cells were lysed with SDS PAGE 
loading buffer and lysates were analysed by western blotting (anti-NEMO) to 
GHWHFWHQGRJHQRXV1(02,..Ǆ7KHUHSUHVHQWDWLYHEORWVKRZVDSSUR[LPDWHO\
equal levels of NEMO protein in cells transfected with different p62 constructs. 
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5.4.3 Co-localisation studies of wild type and PDB mutant polyHis-
FLAG-p62 with endogenous NEMO 
 
Prior to the detailed co-localisation studies between wild type and PDB mutant 
p62 and NEMO, endogenous NEMO localisation (in the absence of transfected 
polyHis-FLAG-p62) in U2OS cells was investigated to evaluate any effects of 
p62 expression on cellular phenotype.  
 
Non-transfected U2OS cells were incubated for ~40 hours after splitting into 
12-well plates. Cells were stained with anti-NEMO and analysed by confocal 
microscopy as described earlier. Endogenous NEMO was distributed in U2OS 
cells in a diffuse pattern, mainly around the nucleus and the cytoplasm (Figure 
5.9). 
 
U2OS cells were then transiently transfected with various polyHis-FLAG-p62 
constructs (wild type, and A381V, P392L, E396X mutants). Mouse anti-p62 
was used as a primary antibody to detect p62 and then anti-mouse Alexafluor 
488 used as a secondary antibody. Rabbit anti-NEMO was used as a primary 
antibody to detect endogenous NEMO and then anti-rabbit Alexafluor 568 is 
used as a secondary antibody. 
 
Ectopic expression of wild type p62 had an obvious effect on the phenotype of 
endogenous NEMO in U2OS cells, as NEMO was recruited to cytoplasmic bodies 
similar to the previously characterised p62 cytoplasmic bodies (Figure 5.10) 
presumed to represent autophagosomes. Indeed transfected wild type p62 and 
endogenous NEMO showed strong co-localisation. Although the E396X mutant 
of p62 again failed to form cytoplasmic bodies (and co-localise with NEMO), 
the A381V and P392L mutants retained this property and consistently 
recruited endogenous NEMO to these structures. Thus, PDB-associated 
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mutants of p62 did not appear to be associated with a generalised loss of co-
localisation (and presumably interaction) with NEMO. 
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Figure 5.9: Subcellular localisation of endogenous NEMO in U2OS cells 
 
U2OS cells were incubated for ~40 hours after splitting without ectopic protein 
expression. The cells were fixed with formaldehyde. Endogenous NEMO was 
probed using rabbit anti-NEMO as primary antibody and stained red using anti-
rabbit Alexaflour568 as secondary antibody. Hoescht 32258 was used for 
staining nuclei. All images were collected at 63X objective lens with scale bar 
as indicated. Endogenous NEMO showed a diffuse staining pattern and was not 
able to from cytoplasmic structures in the absence of ectopic p62 (compare to 
Figure 5.10). 
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Figure 5.10: Co-localisation of endogenous NEMO and polyHis-FLAG-
p62 in U20S cells 
 
polyHis-FLAG-p62 constructs as indicated were transiently transfected in U2OS 
cells. After ~48 hours incubation the cells were fixed with formaldehyde. p62 
was probed using mouse anti-p62 as primary antibody and stained green 
using anti-mouse Alexafluor488 as secondary antibody. Endogenous NEMO 
was probed using rabbit anti-NEMO as primary antibody and stained red using 
anti-rabbit Alexaflour568 as secondary antibody. Hoescht 32258 was used for 
staining nuclei staining. All images were collected at 63X objective lens with 
scale bars as indicated. p62 cytoplasmic bodies (wild type, A381V, P392L but 
not present in E396X) showed a general co-localisation with endogenous 
NEMO.  
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5.5 Discussion  
 
 
 
Earlier we used several protein interaction methods to study the ubiquitin-
binding properties of p62 and its PDB-associated mutants, including the non-
UBA domain A381V mutant. Using in vitro ubiquitin-binding assays, the A381V 
mutant showed subtle changes in its ubiquitin-binding properties compared to 
wild type p62 (Chapter 3) but confocal microscopy studies of transfected cells 
failed to distinguish the co-localisation of the mutant p62 and ubiquitin with 
that observed for the wild type. Therefore, in this chapter we went on to study 
the functional effects of the A381V mutation on NF-ǉ%VLJQDOOLQJLQLWLDOO\XVLQJ
cell-based luciferase reporter assays. 
 
The selected PDB-associated p62 mutants including A381V (as well as P392L 
and E396X) all increased basal NF-ǉ%VLJQDOOLQJUHODWLYHWRZLOGW\SHS
despite the fact that the A381V variant had only minimal effects on the 
ubiquitin-binding properties of p62. In contrast to basal NF-ǉ%DFWLYDWLRQWKH
A381V mutant did not significantly activate TNF-Į induced signalling, although 
the control mutants (P392L and E396X) were associated with a statistically 
significant increase (relative to wild type). The high P value for the A381V 
mutant (>0.05) may be due to the experimental limitations of the luciferase 
reporter assay (see Section 5.5.2). 
 
Compared with previous studies, our results were consistent with those 
observed by Rea et al., in which both E396X and (K378X) deletion mutants 
increased NF-ǉ%DFWLYDWLRQUHODWLYHWRZLOGW\SH,QFRQWUDVW:RRWHQet al. 
reported that a UBA-domain deletion construct of p62 ¨-440) decreased 
NF-ǉ%DFWLYDWLRQFRPSDUHGWRZLOGW\SH:RRWHQet al., 2005). This 
discrepancy might arise from different experimental conditions of the assays, 
as the luciferase reporter assay is sensitive to many experimental variables. 
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Nevertheless, in general experimental evidence from several different studies 
suggests that UBA domain deletion mutants are associated with increased 
rather than decreased NF-ǉ%DFWLYLW\UHODWLYHWRZLOGW\SHS)RUH[DPSOH
another p62 UBA-GRPDLQGHOHWLRQPXWDQW¨-442) was found to increase 
RANK-L induced NF-ǉ%DFWLYDWLRQUHODWLYHWRZLOGW\SH;Xet al., 2008). 
 
Our results were also consistent with a recent study of another novel non-UBA 
domain mutation, P364S, which was found to increase NF-ǉ%VLJQDOOLQJ
relative to wild type despite retaining its full ubiquitin-binding function at both 
pH7.5 and pH6.5 (Rea et al., 2009). Together these results imply that the 
ubiquitin-binding properties of p62 proteins do not simply correlate with the 
activation of NF-ǉ%VLJQDOOLQJDQGVXJJHVWRWKHUFRPSRQHQWVRIWKH1)-ǉ%
signalling axis might be involved in the regulation of this pathway (Rea et al., 
2009) (Najat et al., 2009). 
 
In conclusion, our data showed that in reporter assays wild type p62 inhibited 
NF-ǉ%VLJQDOOLQJDQGWKDW3'%-associated mutations increase NF-ǉ%DFWLYDWLRQ
relative to wild type. However, the precise physiological significance of the 
apparent repression of signalling by p62 is still unclear (Layfield et al., 2007) 
(see Section 5.5.1 for detailed discussion). 
 
To further examine the function of p62 in the regulation of NF-ǉ%VLJQDOOLQJZH
went on to determine possible effects of PDB-associated mutations on the 
p62-CYLD interaction. Interestingly, we were unable to conduct detailed co-
localisation studies (by confocal microscopy) because CYLD expression 
changed the sub-cellular localisation of p62 in U2OS cells, resulting in the loss 
of the common p62 cytoplasmic bodies (see Section 4.6) previously shown to 
be ubiquitin-positive and associated with wild type, A381V and P392L p62 
mutants. Notably, the diffuse p62 staining pattern observed for these 
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constructs when co-transfected with CYLD was very similar to the diffuse 
phenotype normally observed for the E396X mutant (when transfected both 
without and with ubiquitin). The cellular phenotype of the E396X mutant of 
p62, which lacks almost the entire UBA domain (and is unable to bind 
ubiquitin) may provide some clues to explain the diffuse staining pattern noted 
when the other p62 constructs were co-transfected with CYLD. One possibility 
is that full length p62, regardless of whether it is wild type or mutant, through 
its UBA domain interacts with transfected CYLD and this competes with other 
interactions required for the formation of p62 cytoplasmic 
bodies/autophagosomes (which cannot be formed by the E396X mutant). 
Another possible explanation is that since CYLD is a DUB, full length p62 
constructs could not form their regular phenotypes, because of a lack of 
cellular conjugated ubiquitin normally required for cytoplasmic 
body/autophagosome formation when CYLD is expressed at high levels. 
However, immunoblotting of U2OS cells transfected with CYLD could not 
demonstrate gross changes in cellular ubiquitylation. Moreover, it remains a 
possibility that CYLD selectively deubiquitylates only certain cellular proteins, 
the ubiquitylation of which regulates p62 cytoplasmic body/autophagosome 
formation. 
 
Finally, we went on to study the interaction of p62 (and its PDB mutants) with 
another important regulator of NF-ǉ%VLJQDOOLQJ,..Ǆ1(02:HFRQFOXGHG
that NEMO appeared to be recruited to p62-positive cytoplasmic bodies (as 
some of these cytoplasmic bodies interacted with the autophagic marker, LC3) 
regardless of the mutation status of p62, which may be indicative of its 
delivery to autophagosomes for degradation. However, despite the findings of 
earlier studies, which showed that the IKK complex (including NEMO) is 
selectively degraded by autophagy (Qing et al., 2006), ectopic expression of 
p62 (wild type or mutant) did not appear to accelerate the degradation of 
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NEMO, as assessed by western blotting. Nevertheless these contradicting 
results may be rationalised, as we speculate that NEMO might be stably 
recruited to p62-positive autophagosomes but only degraded in a signal 
induced manner (our transfected cells were unstimulated). Clearly further 
research is needed to understand the role of PDB-associated p62 mutations in 
the disruption of NEMO-mediated NF-ǉ%VLJQDOOLQJ$ILQDOSRVVLELOLW\LVWKDW
p62 might not recruit NEMO to the autophagy machinery at all and that the 
p62-positive structures in our cells might not all be autophagosomes, as p62 
and LC3 are able to interact within aggregates that are independent from 
autophagy pathway (Shvetz et al., 2008); again further studies in this area 
will be informative. 
 
In conclusion, our results show that the non-UBA domain A381V PDB-
associated mutation of p62, although having only minimal effects on ubiquitin-
binding in vitro, is (like other PDB mutations) associated with increased basal 
NF-ǉ%DFWLYDWLRQUHODWLYHWRZLOGW\SH:HFRQFOXGHGWKDWZLOGW\SHDQG3'%-
mutant p62 proteins are capable of recruiting NEMO to cytoplasmic bodies 
which may represent autophagosomes, but do not appear to accelerate its 
degradation. Finally, we found that CYLD expression appears to abrogate the 
formation of p62 cytoplasmic bodies, although not through gross changes in 
protein ubiquitination; mutations in CYLD might have subtle roles in PDB 
development and further work is clearly needed to investigate possible genetic 
abnormalities in other genes of the of RANK/NF-ǉ%VLJQDOOLQJD[LVLQ3'%
patients.  
5.5.1 p62 positively and negatively regulates RANK-NF-Ȓ%VLJQDOOLQJ 
 
Earlier studies demonstrated that p62 is central to RANK-NF-ǉ%VLJQDOOLQJDQG
osteoclastogenesis, but the exact role of p62 in vivo is still poorly 
characterised (Layfield et al., 2007). NF-ǉ%LVDWUDQVFULSWLRQIDFWRUZKLFKLs 
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normally sequestered by I-Ȓ%LQWKHF\WRSODVPDQGDVHULHVRIVLJQDOOLQJ
cascades mediated by p62-mediated ubiquitylation ultimately leads to 
degradation of I-ǉ%DQGVXEVHTXHQWUHOHDVHRI1)-ǉ%WRWKHQXFOHXV)LJXUH
5.1). Specifically p62 appears to regulate the K63-linked polyubiquitylation of 
NEMO (which is a regulatory subunit of the IKK complex) through TRAF6, and 
this process causes phosphorylation of NEMO and subsequent K48-linked 
polyubiquitylation of I-Ȓ%ZKLFKVHUYHVDVDWDJIRULWVGHJUDGDWLon by the 26S 
proteasome system causing the release of NF-ǉ%WRWKHQXFOHXV=KDQJet al., 
2005). One of the cascades that lead to NF-ǉ%DFWLYDWLRQLVWKURXJKDFWLYDWLRQ
of IKK complex, the activation of which is regulated by two different signalling 
complexes, which both depend on ubiquitylation (Figure 5.1). The first 
complex comprises TAB1-TAB2-TAK1, and K63-linked polyubiquitylation of 
TRAF6 mediates its recruitment to TAB2-TAK1 through binding of K63-
polyubiquitin chains to TAB2 (TRAF6 may also bind to TAB2 without the 
involvement of K63-polyubiquitin chains). The interaction between TRAF6 and 
7$%DFWLYDWHV7$.ZKLFKWKHQSKRVSKRU\ODWHV,..ǃZKLFKLQWXUQDFWLYDWHV
the IKK complex and ultimately NF-ǉ%&KHQet al., 2005).  
 
The second complex, which results in IKK activation, is composed of p62-
aPKC-TRAF6 (Duran et al., 2004), and functions in a similar manner to the 
TAB2-TAK1 complex (Chen et al., 2005). Upon various stimuli (including RANK 
activation by RANK-L) the complex will form, in which p62 bridges aPKCs to 
TRAF6; this complex activates IKK and subsequently causes activation of NF-
ǉ%-LQet al., 2008). This signalling system illustrates a positive role of p62 in 
NF-ǉ%DFWLYDWLRQH[SHULPHQWDOPRGHOVDOVRVXSSRUWWKHLPSRUWDQFHRISLQ
osteoclast NF-ǉ%DFWLYDWLRQDVSNQRFNRXWPLFHVKRZGHIHFWLYH1)-ǉ%
signalling and osteoclastogenesis upon stimulation with parathyroid hormone 
related protein, although basal osteoclastogenesis was not affected in these 
animals (Duran et al., 2004). 
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Based on these data one might expect that ectopic expression of wild type p62 
in U2OS cells would activate NF-ǉ%VLJQDOOLQJZKLOVWWKH3'%PXWDQWVPLJKW
decrease NF-ǉ%DFWLYDWLRQUHODWLYHWRZLOGW\SHDVWKH\LQJHQHUDOELQGPRUH
weakly to ubiquitin than the wild type protein. However, despite this notion, 
differences in p62 expression levels appear to be associated with different 
effects on NF-ǉ%DFWLYLW\)RUH[DPSOHLQRXUUHSRUWHUDVVD\VDQGSUHYLRXV
studies) where p62 is expressed at relatively high levels, wild type and mutant 
constructs in fact repress NF-ǉ%DFWLYDWLRQFRPSDUHGWRHPSW\YHFWRUFRQWUROV
and PDB mutants are associated with increased signalling compared to wild 
type (Figure 5.2). These results indicate that at these expression levels wild 
type p62 has a repressive function with respect to NF-ǉ%VLJQDOOLQJDQGWKDW
PDB-associated mutants diminish this repressive function (Rea et al., 2006). 
Previously such results were interpreted that p62 is in fact normally a negative 
regulator of NF-ǉ%signalling but of course this proposal contradicts the 
defective NF-ǉ%VLJQDOOLQJQRWHGLQWKHSNQRFNRXWPLFH7KHPRVWIHDVLEOH
explanation for the repressive effects of ectopic p62 expression on NF-ǉ%
activation is that since p62 is an ubiquitin-binding protein, over-expression of 
the protein may lead to competition with other ubiquitin-binding proteins in 
the NF-ǉ%SDWKZD\GLVWXUELQJWKHLUXELTXLWLQ-dependent functions. Hence, we 
speculate that in our luciferase reporter assay, the repression of signalling 
REVHUYHGPLJKWUHSUHVHQWDQµDUWHIDFW¶RIKLJKSH[SUHVVLRQOHYHOVDERYH
normal physiological levels of p62 in cells. For example, ectopic p62 might 
compete with TAB2 for binding polyubiquitin, hence deactivating the TAB1-
TAB2-TAK1 complex and causing subsequent deactivation of IKK and NF-ǉ%
(Figure 5.1 (A)). Further, p62 might also compete ubiquitylated I-ǉ%ELQGLQJ
to the 26S proteasome, thus inhibiting I-ǉ%GHJUDGDWLRQDQGSUHVHQWLQJDVD
repression of NF-ǉ%DFWLYDWLRQ)LJXUH%In this regard, it could be 
argued that in the reporter assays the effects of PDB-associated p62 mutants 
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that do not repress signalling to the level of wild type p62, simply result from 
differences in the ability of the transfected proteins to compete in these 
ubiquitin-dependent interactions. 
 
Interestingly, this competition mechanism of p62 binding to ubiquitin can be 
compared to a parallel signalling system, which involves another polyubiquitin-
binding protein, AWP1, which also normally positively regulates NF-ǉ%
signalling. Over expression of AWP1 repressed NF-ǉ%VLJQDOOLQJLQUHSRUWHU
assays, and it was suggested that ectopic AWP1 would compete with NEMO for 
K63-polyubiquitin chains, thereby repressing NF-ǉ%)HQQHUet al., 2009).  
 
Another possible explanation for the negative regulation of NF-ǉ%VLJQDOOLQJE\
p62 over-expression in reporter assays is as a result of interactions with the 
DUB enzyme CYLD.  CYLD interacts with p62 through the UBA domain and 
specifically negatively regulates NF-ǉ%VLJQDOOLQJE\WKHGHXELTXLW\ODWLRQRI
K63-linked polyubiquitylated chains assembled by TRAF6 (Jin et al., 2008). In 
addition, CYLD might deubiquitylate several other proteins in the NF-ǉ%
pathway, as previous reports showed that CYLD suppresses NF-ǉ%DFWLYDWLRQ
upstream of IKK (Chen et al., 2005); since IKK activation requires 
ubiquitylation, a reversible covalent process, it was suggested that IKK also is 
regulated by deubiquitylation (Chen et al., 2005). These studies collectively 
confirm that proteins modified with or that can bind to K63-linked 
polyubiquitin play important roles in the regulation of NF-ǉ%VLJQDOOLQJ 
 
Following on from the proposed theories of p62s role in the regulation of NF-
ǉ%VLJQDOOLQJPDQ\TXHVWLRQVUHPDLQXQDQVZHUHGDQGREYLRXVO\PRUH
research is required. One of these questions is why the E396X truncating 
mutant, which loses most of its UBA domain and has no ubiquitin-binding 
ability in vitro, still appears to activate the NF-ǉ% activity relative to wild type 
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p62 in vitro (in fact this could equally be viewed as repression of signalling, 
relative to the empty vector control) (Figures 5.2 and 5.3). This observation 
suggests that other domains of p62 must also contribute to the regulation of 
NF-ǉ%VLJQDOOLQJ 
 
In summary, all the data available to date suggests that p62 may be able to 
both positively and negatively regulate NF-ǉ%VLJQDOOLQJDQGIXUWKHUUHVHDUFK
is necessary to understand how defective p62-mediated signalling contributes 
to the pagetic phenotype.  
 
5.5.2 Limitations of the luciferase reporter assay  
 
The luciferase reporter assays were repeated at least three times and although 
care was taken to use the same experimental conditions, such as temperature 
and media composition, variability was still observed for this assay. Of note, 
the P392L mutant gave a great degree of variability in results when compared 
to the other p62 seqeunces, and this variation was even apparent for the 
duplicates of the same experiment performed in the same day with the same 
transfected cell samples.  
Interestingly, another group noted the same variability associated with the 
P392L mutant in luciferase reporter assays (S Rea, personal communication). 
One possibility is that this variation may arise because P392L is a 
temperature-sensitive mutation (Cavey et al., 2005) and small differences in 
temperature when incubating the cultured cells could translate to differences 
in ubiquitin-binding affinities of the transfected P392L-p62 protein. 
 
The statistical analyses also contribute to the limitation of the reporter assay, 
because the high standard deviation of P392L data affected the individual P 
YDOXHVIRUWKHRWKHUPXWDWLRQVIRUH[DPSOHE\UXQQLQJWKH$129$'XQQHW¶V
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test) without considering P392L data, the P value associated with the data for 
the A381V mutant (relative to wild type) changed from non-significant to 
significant in the TNF-Į induced signalling assays. These results show the 
importance of precision in statistical analyses. Obviously, a more robust result 
requires more than three repeats, which is the minimum number of replicates 
UHTXLUHGWRUXQD'XQQHWW¶VWHVW 
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Chapter 6: General Discussion 
 
6.1 General Discussion 
 
In recent years there has been substantial research and conflicting theories 
related to the pathogenesis of PDB (Roodman et al., 2005). The most 
important breakthrough in bone remodelling was the identification of the 
osteoclastic regulatory signalling axis comprising OPG/RANKL/RANK (Khosla et 
al., 2001). Several therapies of pathological bone conditions subsequently 
emerged based on the regulation of this axis, however direct and precise 
manipulation is difficult, as this may cause unwanted side effects (Boyle et al., 
2003). 
 
Several mutated genes were identified in PDB patients and those with related 
syndromes in recent years, many of which were found to be important 
regulators of osteoclastogenesis, therefore extensive recent research has 
focused on the role of genetic factors in osteoclastogenesis and their 
subsequent effects on bone remodelling in bone diseases (Roodman et al., 
2005). 
 
In this study we extended a proposal by Cavey et al. that all of the SQSTM1 
mutations associated with PDB manifest as loss of or impaired ubiquitin-
binding function of the p62 protein (Cavey et al., 2006). Specifically, we 
investigated newly identified and previously uncharacterised PDB-associated 
non-UBA domain mutations of p62, hoping to understand the effects of these 
mutations on ubiquitin-binding function of p62 and on RANKL-NF-ǉ% signalling. 
Two of the non-UBA domain PDB-associated mutations analysed in this study 
(A381V, ¨-388) resulted in subtle reductions in ubiquitin-binding function 
of p62 in pull-down assays, although notably the A381V mutant only showed 
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reductions in its ubiquitin-binding function in pull-down assays under acidic 
conditions; we correlated this finding with the notion that p62-bound 
ubiquitylated proteins are shuttled to autophagosomes, which themselves 
operate at an acidic pH. Our findings were consistent with a previously studied 
artificial deletion construct of p62 (368-391), which showed impaired 
ubiquitin-binding properties (Vadlamudi et al., 1996). Structural analyses of 
p62 may provide some clues to the role of the non-UBA domain mutations in 
regulating the ubiquitin-binding function of p62; indeed it was found through 
structural analysis that the region of p62 which immediately precedes the 
UBA-domain and contains A381V (residues 341-386) is not significantly 
structured. Further, this region contributes to a small enhancement of 
ubiquitin-binding affinity of the p62 UBA domain (Najat et al., 2009). Notably 
however, another novel non-UBA domain mutation tested in a parallel study 
(P364S) retained its ubiquitin-binding function at both pH7.5 and pH6.5 (Rea 
et al., 2009). Based on these data we speculated that missense mutations 
located further from the UBA domain have less pronounced effects on 
ubiquitin-binding function of p62. In combination, these observations can be 
rationalised by the notion that impaired ubiquitin-binding function of p62 per 
se is not directly required for PDB pathogenesis, or more likely that non-UBA 
domain regions of p62 contribute to additional interactions of p62 with 
ubiquitylated proteins (including protein members of the RANK signalling 
pathway). In other words, non-UBA domain mutations might cause reduced 
interaction with previously ubiquitylated substrates of p62, rather than directly 
with the ubiquitin modification as is the case for UBA domain mutations (Najat 
et al., 2009). In conclusion, our results indicate that non-UBA domain 
sequences play an important role in regulating binding affinity of p62, but their 
exact contribution to p62-ubiquitin recognition is still unclear. Further research 
is clearly needed in this area. 
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A previous study by Hocking et al. highlighted a possible correlation between 
the ubiquitin-binding properties of p62 and disease severity in PDB patients 
with the corresponding mutations. Most interestingly, patients with truncating 
UBA domain mutants had the most severe disease phenotypes, changes 
associated with a complete loss of ubiquitin-binding function of p62 in vitro. 
Therefore, we used a double p62 mutation (P392L/S399P on the same allele) 
to further test the hypothesis of a relationship between (mutant) protein 
function and disease phenotype. The P392L/S399P double mutation had an 
additive effect both on p62 protein function and disease phenotype, as the 
mutant p62 protein showed complete loss of ubiquitin-binding function in our 
in vitro pull-down binding assay at room temperature where individual 
mutations retained some binding. The ubiquitin-binding function of these 
mutations correlated with disease severity in patients with the double 
mutation, who were described to have particularly severe disease phenotypes, 
whilst carriers of the individual mutations had milder disease phenotypes 
(Eekhoff et al., 2004). These observations further support the original proposal 
of a possible correlation between disease severity and the ubiquitin-binding 
properties of mutant p62 (Hocking et al., 2004). However, the proposal has 
some limitations and extensive research is needed to draw robust conclusions, 
and in light of our other findings it should be considered that this proposal 
may only be relevant to UBA domain mutations (Najat et al., 2009).  
 
Based on these results, it was deemed necessary to quantify using biophysical 
approaches the interaction properties of p62 and ubiquitin, to more rigorously 
support the previous proposal. However using 2D-HSQC protein NMR we found 
that it is not feasible to easily study the interaction constants (Ka and Kd) 
between p62 and ubiquitin, and in the future using other quantitative methods 
such as surface plasmon resonance, may provide better quantitative results. 
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Following our failure to study the interaction constants between mutant p62 
and ubiquitin using protein NMR, we sought a more physiologically relevant 
(cell based) model to investigate the ubiquitin-binding properties of p62. Our 
cell based confocal microscopy analyses, involving co-transfection of p62 and 
ubiquitin proteins, provided no advantage over pull-down assays in 
distinguishing the function of wild type p62 from several PDB-associated 
mutants (except for the E396X truncating mutant), as all the missense 
mutations studied co-localised with ubiquitin in a similar manner to wild type 
p62. In addition, sizes of cytoplasmic bodies formed by the p62 mutants could 
not be used to distinguish them from wild type p62, contradicting earlier 
proposals that missense PDB-associated mutnats produce larger cytoplasmic 
bodies than the wild type p62 in transfected cells (Leach et al., 2006). The co-
localisation patterns between various p62 constructs (wild type and PDB-
mutant) and ubiquitin indicated that there is no simple correlation between the 
in vitro ubiquitin-binding assay and co-localisation of p62/ubiquitin in 
transiently transfected cells. Previous studies and some of our own 
observations showed that a functional UBA domain (with respect to ubiquitin-
binding) is required for the formation of ubiquitin-positive and p62-positive 
cytoplasmic bodies, however analyses of other mutations, such as P392L 
(which impaired ubiquitin-binding of p62 in vitro) contradicted this notion, as 
the P392L mutant readily formed regular p62/ubiquitin positive cytoplasmic 
bodies in transfected cells. In contrast, the E396X mutant did not form 
cytoplasmic bodies; these contradicting observations might be because the 
UBA domain interacts with other substrate proteins (in addition to ubiquitin), 
which are required for the formation of p62 bodies and that the A381V and 
P392L mutants maintain these interactions (Najat et al., 2009). 
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Interestingly, and similar to previous studies, we found that some of the p62-
posititve cytoplasmic bodies may be autophagosomes, as they co-localised 
with the autophagic marker LC3. Another non-UBA domain mutant, D335E, 
was investigated in this study and it did not affect two functionally-relevant 
cellular interactions of p62; the D335E mutant retained its ubiquitin-binding 
function in the in vitro ubiquitin-binding assays, and this mutant also co-
localised strongly with LC3 in transfected U2OS cells. These observations may 
be rationalised by the fact that the D335E change is conservative, substituting 
one acidic side chain for another, or since this change was found only in one 
Italian patient, D335E may represent a rare polymorphism rather than a 
disease-associated mutation. 
 
Since the partial loss of ubiquitin-binding function of the A381V mutant of p62 
could not be investigated further with confocal microscopy analyses, we 
studied the effects of this mutation on cellular functions of p62, first 
determining the functional effects of the mutation on NF-Ȓ%VLJQDOOLQJ2XU
results showed that this non-UBA domain PDB-associated mutation, although 
having only minimal effects on ubiquitin-binding in vitro, is (like other PDB 
mutations) associated with increased basal NF-ǉ%DFWLYDWLRQUHODWLYHWRZLOG
type in luciferase reporter assays. Interestingly another novel non-UBA 
domain, P364S, has also recently been reported to show increased NF-ǉ%
signalling potential relative to wild type p62, and this mutation retained its full 
ubiquitin-binding function at both pH7.5 and pH6.5 (Rea et al., 2009). 
Together these results imply that the ubiquitin-binding properties of p62 
proteins do not simply correlate with the activation of NF-ǉ%VLJQDOOLQJ 
although defective NF-ǉ%signalling may still be a major cause of disrupted 
bone remodelling. Further these results suggest that dysregulation of other 
components of the NF-ǉ%VLJQDOOLQJD[LVPLJKWEHLQYROYHGLQ3'%DHWLRORJ\
(Rea et al., 2009; Najat et al., 2009). 
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The NF-ǉ% luciferase reporter assays also showed that p62 mutants (like wild 
type sequence) have a repressive function in NF-ǉ%signalling relative to 
empty vector controls, which might indicate that p62 has a role in negative 
regulation of NF-ǉ%pathway (diminished when p62 is mutant). To further 
investigate this hypothesis, we examined the interaction properties of PDB-
associated p62 mutants with a negative regulator of the NF-ǉ%pathway, the 
DUB enzyme CYLD. CYLD co-transfection with p62 in U20S cells resulted in a 
loss of the formation of p62 cytoplasmic bodies, therefore we could not 
investigate the effects of p62 mutants on p62-CYLD interactions using this 
approach; however, this result does not exclude the possibility that the p62-
CYLD interaction might still have important roles in PDB pathogenesis and in 
NF-ǉ%UHJXODWLRQ 
  
Finally, we studied the effects of selected PDB mutations on the interaction 
properties of p62 and NEMO, which is an important regulator of NF-ǉ%
pathway. Our western blot analyses suggested that ectopic expression of p62 
(wild type or mutant) did not facilitate the degradation of NEMO, regardless of 
the confocal analyses results, which indicated that NEMO was recruited to p62-
positive cytoplasmic bodies (which we presumed were autophagosomes) 
formed by both wild type p62 and selected PDB-associated p62 mutants. 
Obviously more detailed investigation is needed to understand the potential 
role of PDB-associated p62 mutations in the disruption of NEMO-mediated NF-
ǉ%VLJQDOOLQJ 
 
Based on our results and current research on PDB pathogenesis, more detailed 
investigations are necessary to understand the molecular basis of PDB, in 
order to develop specific therapeutic targets for the disease. Previously, it was 
proposed that bisphosphonates can be used to control the extent of PDB; 
however a recent clinical trial of intensive bisphosphonate treatment versus 
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symptomatic management of PDB showed that no significant differences in the 
pain or quality of life between the two groups (Langston et al., 2009). In 
particular, extensive research is needed to understand the functional role of 
p62 and its mutations on RANKL-NF-Ȓ%SDWKZD\$OVRRWKHUJHQHVDVVRFLDWHG
with PDB might give important clues to the disease pathogenesis (Goode et 
al., 2009).  
 
Our results (together with previous studies) suggested that in reporter assays 
overexpressed p62 functions as a negative regulator of the NF-ǉ%pathway. 
But, based on the recent emerging links between autophagy and the ubiquitin-
proteasome system, in which autophagy inhibition resulted in delays in 
shuttling p62 ubiquitylated proteins to the proteasome system further causing 
aggregation of p62 (Korolchuk et al., 2009), it is more logical to speculate that 
p62 is not a normal physiological negative regulator of the NF-ǉ%pathway, but 
rather p62 accumulation (resulting from defective autophagy) causes defective 
degradation of ubiquitylated proteins (such as I-Ȓ%) by the proteasome 
systems (Goode et al., 2009). Obviously, defective autophagy may effect the 
signalling proteins downstream the RANKL-NF-ǉ%signalling pathway, but it 
should be considered that current investigations suggest that defective 
autophagy and dysregulated NF-ǉ%signalling in PDB may not necessarily be 
mutually exclusive (Goode et al., 2009). 
 
The role of p62 in autophagy might introduce another important cellular 
degradation system in bone remodelling and bone diseases, although there is 
not any investigation to date on the link between autophagy and osteoclasts. 
It would certainly be interesting to investigate the role of autophagy in PDB, 
as potentially autophagy could be used as an alternative therapeutic target for 
pathological bone conditions, because autophagy is relatively easily 
pharmacologically manipulated in vivo (Goode et al., 2009). 
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Finally, the role of viruses and other environmental factors in PDB should not 
be disregarded, in order to draw a combined theory for the disease aetiology, 
(Goode et al., 2009) as for example there is an emerging realisation that 
many viruses in fact target mammalian autophagic systems (Taylor et al., 
2009). 
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Appendix: vector maps 
 
 
 
 
 
 
 
Figure A.1: Empty pGEX-4T1 (Amersham Biosciences). pGEX-4T1-WT-
p62 was generated by introducing cDNA encoding the complete p62 protein 
(IMAGE clone 2906264) to the EcoRI/XhoI restriction sites of the pGEX-4T-1 
plasmid. 
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Figure A.2: Empty pDNA3.1 (+)(Invitrogen). pcDNA3.1 (+)-WT-p62 was 
generated by PCR amplification of the wildtype p62 cDNA, and ligation into the 
NotI restriction site of a pcDNA3.1.  
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Figure A.3: Empty pcDNA3.1(-) (Invitrogen). HA-Ub-pcDNA3.1(-) was 
generated by PCR amplification from the human ubiquitin C IMAGE clone 
4076286, including an XhoI site, an HA tag in the 5¶ PCR primer, and a KpnI 
site in the 3¶primer, and ligation into the pcDNA3.1 (-) plasmid.  
 
 
 
 
 
 
 
272 
 
 
 
 
 
 
 
Figure A.4: Empty pGL2 (Promega). The NF-Ȓ%UHSRUWHUFRQVWUXFW 
contained the -2415/-293 fragment of the human IL8 promoter cloned into the 
KpnI and HindIII restriction sites of the pGL2 plasmid.  
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Figure A.5: Empty pcDNA3.1(+)(Invitrogen). pcDNA3.1-HA-CYLD was 
generated by isolating human CYLD by RT-PCR using SCSH1122/1123 
primers, cut with ClaI/SpeI and ligated into the ClaI/XbaI sites in the pcDNA-
HA vector. 
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. 
Figure A.6: Empty pEGFP-C1 (Clontech Laboratories). tdtomato-LC3 was 
generated through two steps. First, to obtain pGFP-LC3 (pEGFP-C1-LC3) 
(Figure A.6.1), LC3 cDNA was inserted into the BgIII and EcoRI sites of 
pEGFP-C1, then ptdTomato-LC3 was made by inserting a 400-bp EcoRI±
BamHI fragment from pEGFP-C1-LC3 (Clontech Laboratories) into ptdTomato-
C1 (Figure A.6.2) (Clontech Laboratories) cut with the same enzymes. 
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Figure A.6.1: Empty pGFP-LC3 (pEGFP-C1-LC3) (Clontech Laboratories). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.6.2: Empty ptdTomato-C1 (Clontech Laboratories originally from 
7VLHQ¶VODE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